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Abstract 
Background Diabetes prevalence is increasing worldwide. Increased burden of diabetes 
and recent developments in treatment and prevention of diabetes and cardiovascular 
complications present opportunities for screening of people at risk of diabetes in order to 
implement disease-modifying intervention and prevent long-term complications.  
Aim The aim of this study was to develop a simple inexpensive score for identifying 
individuals with undiagnosed diabetes in the African context. 
Methods A population based sample of 5193 individuals aged 15 years and above from 
diabetes surveys in Tanzania, Senegal and Guinea was used to develop the score, the derived 
score was then validated in populations from South Africa, Guinea and Tanzania. New cases 
of diabetes were defined using fasting glucose measurements. Binary logistic regression 
model coefficients were used to assign individual scores for the predictor variables in the 
model.  
Results Age, hypertension and waist circumference were the variables included in the 
final model. The model has an area under the ROC curve (AUC) of 0.83 (95% CI 0.82 to 
0.84). A meta-analysis of applying the score at individual country data yielded a summary 
ROC curve with an AUC of 0.8 (95% CI 0.74-0.85) and an inconsistency score ( I
2
) of 0%. 
The performance of the newly derived risk score in the validation samples was comparable to 
the performance in derivation study population with Area under the ROC curve ranging from 
0.7 to 0.82. 
Conclusion Presented in this thesis is the first ever diabetes risk score derived from Africa. 
It is a simple inexpensive tool for identifying individuals with undiagnosed diabetes in 
African settings. Further work is needed to externally validate the score in other populations 
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Chapter 1. Introduction 
In most populations a substantial proportion of individuals with diabetes remain undiagnosed 
(Whiting et al., 2011). There is strong interest in identifying locally practical approaches for 
identification of those with undiagnosed diabetes. Screening which refers to the application 
of a test to people who are asymptomatic for the purpose of classifying them with respect to 
their likelihood of having a particular disease (Hennekens and Buring, 1989) , is a practical 
approach to identify those with undiagnosed disease  so that they can benefit from treatment 
with the underlying assumption that these will be detected early before the disease progresses 
to critical stages.  
Diabetes care in Tanzania is organized at the secondary and tertiary health care facilities. 
Diabetes clinics have now been established at all regional hospitals. In Dar es Salaam and the 
lake zone Region the network extends to the district level. Plans are underway to establish 
diabetes clinics in all district hospitals throughout the country (Ramaiya, 2005). The health 
care system comprises of different levels of health care with the lowest level being the 
dispensary and health centres, which are mainly equipped to provide maternal and child 
health services. The next level of care is the district hospitals which provide secondary level 
care and the tertiary level of care are the regional hospitals and the zonal referral hospitals. 
Access to diabetes care at the community and primary care level is still low; therefore 
making a diabetes diagnosis at this level is still a challenge therefore presenting a missed 
opportunity to identify cases that might have benefited from early diagnosis and care. 
Diabetes screening is emerging as an important topic in the field of diabetes and has recently 
received critical attention, with the increasing burden of the disease. A considerable amount 
of literature has been published on the various screening methods for diabetes, including 
diabetes risk scores (Echouffo-Tcheugui et al., 2012, Buijsse et al., 2011), and on the 
importance of using the simple risk scores to increase the yield of screening and promote 
efficient use of resources (Brown et al., 2012).  
7 
 
However these studies have been mostly conducted in high and middle income countries. So 
far no study has been published that has looked at aspects of diabetes screening and methods 
for diabetes screening in the African setting. Most studies looking at diabetes risk scores 
were conducted in White and Asian populations and the resulting diabetes scores have not 
been validated in this setting and hence have limited application in Africa (Brown et al., 
2012). 
The aim of this study is to develop and validate a diabetes risk score suitable for populations 
in Africa. In particular this thesis focused at developing a risk score that will be applicable 
across different settings/countries in Africa. Previous studies have demonstrated differences 
in background characteristics of the study populations contribute to the differences in 
performance of the risk scores when applied elsewhere. The key question in this thesis is 
whether the performance of a risk score can be improved by deriving the score with data 
from multiple countries to create a score that is applicable to other settings.  
Thus, in this thesis derivation of a diabetes risk score is described and its internal and 
external validation are also reported. The study is focused on the derivation and validation of 
a diabetes risk score to screen for prevalent type 2 diabetes. It is beyond the scope of the 
study to discuss risk scores for predicting future diabetes and this is therefore excluded in the 
discussion. It is worth noting that also discussions relating to diabetes are restricted to type 2 
diabetes and other types such as diabetes type 1 and gestational diabetes are excluded. 
The research data in this thesis are drawn from 2 main sources; data from previous diabetes 
population surveys in Tanzania, Guinea, Senegal and South Africa and data from a cross 
sectional survey in Tanzania. The data from the cross sectional study in Tanzania was based 
on a convenience sample and therefore may not be representative of the Tanzanian 
population. The sample is likely to include individuals that perceive themselves to be at high 
risk because individuals received an open invitation to participate. 
My main reason for choosing this study is the increasing burden of diabetes in my country as 
described in Chapter 2 and the lack of diagnostic services for diabetes in the semi urban and 
rural areas. My conception was that the score would help to identify people at high risk that 
could be referred to the next level of care for diagnosis and further management.  
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The overall lay out of the thesis takes the form of nine chapters, including this introductory 
chapter. The thesis can be divided into three main components which are literature review, 
derivation of the risk score and lastly validation of the risk score and other existing scores in 
different populations.  
Chapter two begins by laying out background information on diabetes and the burden of 
diabetes in Africa. Chapter three looks at approaches to diabetes screening and discusses 
various methods for diabetes screening and their application in the African setting. It lays out 
the discussions to build the case to support screening of people at high risk of diabetes Vis a 
Vis the Wilson and Jungner criteria for screening of diseases (Wilson J, 1968). In chapter 
four existing diabetes risk scores are described and their performances across different 
populations are explored. The aims and objectives of this research are described in chapter 
five after outlining the necessary background information for the research. As stated 
previously, data for the study were obtained from various countries in Africa. Chapter five 
gives background information on each of the study populations.  Data collection methods and 
a description of how the various variables were assessed are provided. A description of how 
the background characteristics are likely to affect results of this study is given in this chapter. 
Chapter five also summarises the characteristics of the different study populations. Chapter 
six describes the process of deriving and internally validating the new diabetes risk score. In 
this chapter both the methods undertaken to derive and to internally validate the score, and 
the results, are described. Since the score was derived from different sources of data meta- 
analysis results of applying the score in individual data is done to assess heterogeneity and 
results are presented in chapter six. Chapter seven looks at the validation of the new score in 
populations independent of the score derivation study populations. The chapter outlines the 
methods, results and discussion, throughout this chapter the performance of the new score is 
compared to existing scores based on known measures used to assess diagnostic studies 
including sensitivity, specificity and measures of discrimination reported as the Area under 
the Receiver Characteristics Curve (AUC). Chapter eight is concerned with validating the 
derived score in data from a clinic study in Tanzania. This setting is said to depict the setting 
in which the score would be used in practice. The utility of the score is discussed in terms of 
the yield and the number needed to screen at different cut points of the score.  
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Discussions are found at the end of each chapter as research objectives were described in 
detail in separate chapters. The last chapter, on page 159, draws up the conclusions and gives 
a brief summary and critique of the findings and includes a discussion of the implications of 
the findings to future research in this area. 
The term undiagnosed diabetes is used throughout this thesis and is used to define individuals 
with diabetes who have never been previously diagnosed with the disease and are identified 
at screening. Also terms “derivation data”, is used to define data from Tanzania, Senegal and 
Guinea that were used to derive the score and “validation data” is used to define data used to 
validate the scores which were from South Africa, Guinea and Tanzania.  
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Chapter 2.  Prevalence of Diabetes Mellitus in Africa 
2.1 Introduction 
The aim of this chapter is to provide background information on diabetes, its definition and 
the diagnostic criteria. This chapter also includes a detailed account of the prevalence of 
diabetes in Africa together with a discussion of the associated risk factors. Because of the 
obvious epidemiological evidence on the differences in diabetes epidemiology among the 
countries in Sub-Saharan Africa (SSA) and those in North Africa, this review is restricted to 
those countries within SSA. Other aspects of diabetes epidemiology in the region such as 
diabetes complications and the economic costs due to diabetes are discussed in Chapter 3 on 
page 32 . The discussion in this chapter is restricted to type 2 diabetes which is the focus of 
this thesis. 
2.2 Definition and Diagnosis of Diabetes Mellitus 
Diabetes Mellitus is a condition that is characterised by chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from defects of insulin 
secretion, action or both. According to WHO, diabetes is defined as fasting plasma glucose 
of ≥ 7 mmol/l (126mg/dl) or a venous plasma 2h glucose tolerance test of ≥11.1 mmol/l 
(200mg/dl) (WHO, 2006) . Diabetes mellitus can be broadly be categorized into four 
categories based on the aetiology, these include diabetes type 1 and type 2, gestational 
diabetes and other specific types. Type 1 diabetes is further classified as auto immune or 
idiopathic see Figure 2-1. Causes of type 2 diabetes could be insulin deficiency, insulin 
resistance or both. The other type are  the specific types that are as a result of either genetic 
defects of beta cell function, genetic defects of insulin action, diseases of the pancreas, 
endocrinopathies, drug or chemical induced diabetes. Other forms diabetes include those that 
are secondary to infections or are immune mediated (WHO, 2006). 
Prediabetes defined as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) is 
a condition of abnormal glucose metabolism and is associated with an increased risk of 
diabetes and other cardiovascular diseases (Abdul-Ghani and DeFronzo, 2009, Ford et al., 
2010, Færch et al., 2008). 
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Figure 2-1 Disorders of glycaemia: Aetiological Types and Clinical Stages (WHO, 2006) 
 
Diabetes is associated with serious long term complications that are broadly categorised as 
micro-vascular: retinopathy, nephropathy and foot complications; and macro-vascular which 
include cardiovascular complications. Type 2 diabetes mellitus has an insidious onset, and 
overt symptoms normally manifest/ occur in later stages of the disease. At the time the 
patients are clinically diagnosed and a number already have complications (WHO, 2006).  
The diagnosis of diabetes is based on a threshold value along the glucose range. The cut 
points for the diagnosis of diabetes are based on plasma glucose levels beyond which the risk 
of micro vascular complications such as retinopathy increases (Barr et al., 2002) . The 
diagnostic criteria have been reviewed several times to incorporate new evidence regarding 
the onset of micro and macro vascular complications along the glucose continuum. The latest 
diagnostic criteria were published in 1999 where the cut off points for diagnosis of diabetes 
using fasting glucose were lowered and a concept of impaired fasting glycaemia was 
introduced (WHO, 2006). In 2011, WHO also endorsed the use of HbA1c for diagnosis of 
diabetes and recommended a cut-off point of 6.5% (WHO, 2011b) .  
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Current recommendations for diabetes diagnosis stipulates that diagnosis of diabetes in the 
absence of clear symptoms should be based on two test (WHO, 2006, ADA, 2013). A single 
positive test is not diagnostic under such circumstances. 
Different tests for the diagnosis of diabetes mellitus will be discussed in detail in Chapter 3 
on page 38. Table 2-1 below shows a summary of the current diagnostic criteria for diabetes 
and impaired glycaemia using fasting blood glucose and 2-hr oral glucose tolerance tests. 
Table 2-1 Summary of WHO Diagnostic Criteria for Diabetes and Intermediate  
Hyperglycaemia 
 
 
13 
 
 
2.3 Prevalence of Diabetes and Associated Risk Factors in Africa 
2.3.1 Diabetes in Africa, Estimates and Projections 
The burden of diabetes is increasing worldwide, with studies reporting higher increase in 
diabetes prevalence in developing countries (Shaw et al., 2010, Wild et al., 2004, 2009, 
Whiting et al., 2011, Zimmet et al., 2001). The International Diabetes Federation (IDF) has 
estimated that 366 million adults (8.3%) had diabetes worldwide in 2011 (Whiting et al., 
2011). This estimate by IDF is similar to what has been predicted by the Global Burden of 
Disease Study Group (Danaei et al., 2011), which in their study estimated that in 2008 there 
were a total of 347 million adults living with diabetes.  The majority of people affected with 
diabetes reside mainly in low and middle income countries, with China (90.0 millions) and 
India (61.3 millions) projected to have the largest number of people affected with diabetes in 
the world (Whiting et al., 2011). In a study from China (Yang et al., 2010) reported that 
about 92.4 million people had been affected with diabetes and 148.2 million affected with 
prediabetess (IFG or IGT) signifying a huge burden of disease related to diabetes and 
prediabetess in this population respectively.  The IDF (Whiting et al., 2011) estimates that, 
by 2030, the number of adults with diabetes is projected to increase by 50.7% and 48% of 
absolute increase in number of people in diabetes is expected to occur in China and India 
alone. The largest increase in diabetes is expected in the low income countries with 
projections of about 93% increase in diabetes prevalence by 2030 compared to 25% increase 
in higher income countries (Whiting et al., 2011). The rapid increase in diabetes in 
developing countries is said to be a result of socio economic development that have led to 
changes in people’s lifestyle patterns where people are more likely to be exposed to 
unhealthy diet and low levels of physical activity in turn which attenuates the individuals’ 
inherent risk of diabetes and other cardiovascular diseases (Zimmet, 1992).  Africa is not 
spared in the growing diabetes epidemic that is more apparent in developing countries. In 
2011 the total number of diabetes cases in Africa was estimated to be 14.7 million cases with 
a total prevalence of 5%, with higher estimates of around 6-8% projected by the Global 
Burden of Disease Study Group (Danaei et al., 2011) . It is projected that the total number of 
people with diabetes in Africa will increase by 90% by the year 2030 (Whiting et al., 2011).  
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2.3.2 Review of diabetes studies in Africa 
Search Strategy 
The information presented here was obtained by review of key literature on diabetes 
prevalence and citation tracking from those key publications. Information was also obtained 
by performing a subject specific search in Medline and Embase, using Ovid software as well 
as Scopus. A search on diabetes prevalence in Africa yielded a total of 541, 356, and 394 
papers in Medline, EMBASE and SCOPUS respectively (Table 2-2). Of these, 503, 335 and 
378 papers were excluded at title stage from the above respective databases. At abstract 
stage, after removing duplicates 29 papers were obtained from the 3 databases using an 
inclusion criteria outlined in Table 2-3 below. In addition, one paper was found from citation 
tracking.  Excluded studies were those on genetics, studies from other regions other than 
Africa, studies specifically type 1 diabetes and at abstract stage, those which did not meet the 
inclusion criteria see Table 2-2.  
30 studies on prevalence of diabetes were identified from the search. 5 studies were carried 
out between 1980 and 1990. Different methods were used to diagnose diabetes and other 
forms of glucose intolerance. Different criteria were used to define diagnosis: 3, 14 and 12 
studies used the 1980, 1985, and 1998/1999 WHO criteria, information on 1 study could not 
be obtained.  Only studies using the current diagnostic criteria for diagnosing diabetes were 
included in the review. Of the 12 studies identified using the latest criterion for diagnosis, 1 
study was excluded due to poor methodology hence 11 studies were included in the review. 
Table 2-2 Source of Information for the Literature Search 
Method Sources 
Search within clinical databases MEDLINE, EMBASE, SCOPUS 
Cross referencing Review  and original articles  
Search within organisation WHO, IDF,  UK Diabetes Association, American 
Diabetes Association, Tanzania Diabetes Association,  
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Table 2-3 Search Strategy Results for Studies on Prevalence of Diabetes in Africa 
MEDLINE (Search Dates: 1980-2010) 
Search history Results 
1. Diabetes mellitus.mp. or diabetes mellitus 191122 
2. Prevalence.mp. or prevalence 289714 
3. Exp Africa/ or Africa$.mp. 187809 
4.  1 and 2 and 3 1078 
5. limit 4 to (human and (adult <18 to 64 
years> or aged <65+ years>) 
1077 
6. Population.mp. or population 660022 
7. 5 and 6 541 
8. From 7 keep 26, 48, 60, 101, 104, 113... 38 
EMBASE(Search Dates: 1980-2010) 
1. Diabetes mellitus.mp. or diabetes mellitus 255284 
2. Prevalence.mp. or prevalence 281811   
3. Exp Africa/ or Africa$.mp. 125035 
4.  1 and 2 and 3 1154 
5. limit 4 to (human and (adult <18 to 64 
years> or aged <65+ years>) 
732 
6. Population.mp. or population 585320 
7. 5 and 6 356 
8. From 7 keep 26, 48, 60, 101, 104, 113... 21 
SCOPUS  
1. TITLE-ABS-KEY(diabetes mellitus 
AND Africa AND prevalence) AND 
PUBYEAR AFT 1979 AND (LIMIT-
TO(SUBJAREA, "MEDI") OR LIMIT-
TO(SUBJAREA, "MULT")) 
394 
2. From 1 keep  16 
 
Table 2-4 Inclusion Criteria for Studies on Diabetes Epidemiology in Africa   
Criteria Description 
Population - Studies on burden of diabetes 
- Studies that are specific to Africa 
Intervention - Diabetes defined using 1998 WHO criteria 
Outcome - Prevalence 
Study design - Cross sectional 
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Combined search results 
1294 papers 
75 papers remained  
1219 papers excluded based on title and 
abstract 
 
30 papers remained for full article review 
46 duplicates removed 1 study included from citation 
tracking 
11 papers were included in the 
final review 
19 papers were excluded after reading 
full articles  
Figure 2-2 Consort Diagram of Summarizing the Selection of Papers Included in the Review 
of Diabetes Prevalence Studies in Africa 
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Results 
A review of studies on diabetes prevalence in Africa published within the last decade using 
the 1998 WHO criteria for diagnosing diabetes, shows varying prevalence across countries, 
the results of which are shown in table 2-5 below. From the search strategy, the identified 
studies are from 7 Sub-Saharan countries namely Nigeria (Nyenwe et al., 2003, Okesina et 
al., 1999, Oladapo et al., 2010), South Africa (Erasmus et al., 2001, Alberts et al., 2005, 
Motala et al., 2008), Tanzania (Aspray et al., 2000), Cameroon (Sobngwi et al., 2002), Ghana 
(Amoah et al., 2002), Guinea (Balde et al., 2007) and Kenya(Christensen et al., 2009) .  In 
these studies the diagnosis of diabetes was made either using Oral Glucose Tolerance Test 
(OGTT) (Amoah et al., 2002, Balde et al., 2007, Erasmus et al., 2001, Motala et al., 2008, 
Nyenwe et al., 2003, Christensen et al., 2009) or fasting glucose (Aspray et al., 2000, 
Oladapo et al., 2010, Sobngwi et al., 2002). 
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Table 2-5 Prevalence of Diabetes in Sub-Saharan Africa  
Country (Author, 
Year) 
(Rural/Urban) Sample 
Size 
 Response 
rate % 
Age Diagnosis  Prevalence Diabetes  
[% (95%CI)] 
Undiagnosed 
diabetes 
   M F T    M F T R&U  
Nigeria (Okesina et al., 
1999) 
Rural 278 222 500 - >40  FPG - - *2.6 - - 
 (Nyenwe et al., 
2003) 
Urban 273 229 502 67 >40 WHO 1999 
OGTT 
*7.7(4.6-
10.8) , 9.1 
*5.7(2.7-
8.7), 6.3 
*6.8 (4.6-
9.0), 7.9 
- 41.2% 
 (Oladapo et al., 
2010) 
Rural   2000  18-
64 
FBG 2.1 2.8 2.5  27.0% 
South 
Africa 
(Erasmus et al., 
2001) 
Urban - - 374 - >20 WHO 1998 
OGTT 
- - 4.5(1.54-
7.42 
- - 
 (Alberts et al., 
2005) 
Rural 498 1608 2016 - >30 WHO 1999 
FPG 
*8.5 *8.8 - - - 
  (Motala et al., 
2008) 
Rural 210 815 1025 78.9 >15 WHO 1998 
OGTT 
3.5 3.9 3.9 - 85.0% 
Tanzania (Aspray et al., 
2000) 
Urban 332 438 770 80-85 >15 WHO 1998 
& ADA 
5.9 5.7 - - 79.0% 
  Rural 401 527 928 65-82  FPG 1.7 1.1 - - 92.0% 
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Country (Author, 
Year) 
(Rural/Urban) Sample 
Size 
 Response 
rate % 
Age Diagnosis  Prevalence Diabetes  
[% (95%CI)] 
Undiagnosed 
diabetes 
   M F T    M F T R&U  
Cameroon (Sobngwi et 
al., 2002)  
Urban 525 658 1183 - >15 WHO 1998 
FPG 
6.2 (3.7-8.9) 4.7(2.6-
6.8) 
- - - 
  Rural 523 759 1282 -   4.7 (2.5-6.9) 2.9(1.5-
4.4) 
- - - 
Ghana (Amoah et al., 
2002) 
Urban 1860 2873 4733 75 >25 WHO 1998 
OGTT  
 - -  6.1  - 69.7% 
Guinea (Balde et al., 
2007) 
Urban 371 515 886 - >35  WHO 1998 
OGTT 
- - *7.7 (5.9-
9.4) 
6.7 (5.5-
7.9) 
59.0% 
  Rural 359 292 651 -   - - *4 (2.5-
5.5) 
 100.0% 
Kenya (Christensen et 
al., 2009) 
Urban - - 281 98.2 >17 WHO 1999 
FBG & 
OGTT 
- - 12.2(5.4-
23.2) 
4.2(2.0-
7.7) 
21.0% 
  Rural - - 1178    - - 2.2(0.8-5.2) 48.0% 
Key 
*Crude Prevalence Rates, M= Male, F= Female, T=Total (Both males and Females), R&U= Rural and Urban 
Nyenwe (2003) presents data for both crude and standardised prevalences 
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The prevalence of diabetes in Sub-Saharan countries ranged from less than 2% in rural 
Tanzania (Aspray et al., 2000) to 12.2 in urban Kenya (Christensen et al., 2009) which is the 
highest reported prevalence in sub-Saharan Africa see table 2-5 above. The findings of 
diabetes prevalence across countries were marked with clear urban rural differences, with a 
higher prevalence being reported in urban areas (Figure 2-3). 
 
Figure 2-3 Urban Vs. Rural Prevalence of Diabetes in Africa 
Nigeria, Tanzania and Kenya reported a rural prevalence of diabetes of <3% (Aspray et al., 
2000, Christensen et al., 2009, Okesina et al., 1999, Oladapo et al., 2010), however,  higher 
prevalence of diabetes is  reported in rural areas such as those reported in rural South Africa, 
Cameroon and Guinea (Alberts et al., 2005, Balde et al., 2007, Motala et al., 2008, Sobngwi 
et al., 2002) with rural diabetes prevalence ranging from 3.9% to 8.8%. 
The variation in prevalence between countries could partly be explained by the method used 
for diagnosis (Barr et al., 2002), OGTT tends to identify more cases that would otherwise be 
missed if Fasting Glucose alone is used for diagnosis. A study (Kim et al., 2008) showed that 
compared to OGTT, Fasting Glucose measurement identified only about 56% of the cases. A 
study in Africa also reported that there would be 36% less diabetes cases if fasting alone was 
used for diagnosis (Motala et al., 2008) .  
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The differences in the prevalence of diabetes between countries could also be due to the 
variances in structure of the sampled population such as age, degree of urbanisation, sex and 
other risk factors associated with diabetes.  Also sample size, sampling methods and the 
response rates could have biased the results in some studies. 
All the studies were population based studies with random selection of participants; however 
the study in Kenya (Christensen et al., 2009) included a convenient sample for the urban 
population also the sample size seem to be small to estimate prevalence in this population 
with good precision as evidenced by the large confidence intervals ( urban prevalence 12%, 
95% CI 5.4% to 23.2%). Similarly none of the studies took into account the different 
categories they used in analysing their data e.g. sex and urban vs. rural in their sample size 
calculations, which may introduce bias to the overall estimates. 
Also, studies that reported enrolling participants above the age of 30 yrs. described higher 
prevalence of diabetes in general, especially since some of the studies report only crude 
prevalence rates (Table 2-5). Level of urbanisation among the study areas could also impact 
on the results of the studies; this cannot be thoroughly assessed in the present studies as there 
are no formal indicators of urbanisation presented in majority of the studies, as discussed in 
detail in section below. 
2.3.3 Associated Risk Factors for Type 2 Diabetes  
The variations in prevalence of diabetes between countries and between rural and urban 
settings  could be explained by differences levels of risk factors such as  socio economic 
status , the degree of urbanization and the background characteristics such as age, sex, 
ethnicity, diet and the levels of physical activity as mentioned above (Assah et al., 2011, 
Boyle et al., 2001). Risk factors for diabetes can be grouped into modifiable and non 
modifiable risk factors, these various risk factors for diabetes and their implications on 
diabetes prevalence in Africa are further discussed in subsequent paragraphs. 
Modifiable Risk Factors 
Physical inactivity is one of the modifiable risk factors for diabetes. Previous studies have 
demonstrated that physical activity reduces overall risk of developing diabetes and improves 
cardio-metabolic risk profile (Manson et al., 1991, Helmrich et al., 1991, Hu et al., 2004), the 
mechanism of which is linked to increased secretion and insulin sensitivity as well as 
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increased fat metabolism (Mayer-Davis et al., 1998) whose overall effect is reduction in the 
risk of diabetes.  Available literature on the relationship between levels of physical activity 
and diabetes from Africa suggest an inverse relationship (individuals with high levels of 
physical activity had lower risk of diabetes ) between physical activity and diabetes however 
these studies have been largely cross sectional and have used different methods to define and 
measure physical activity (Aspray et al., 2000, Sobngwi et al., 2002) such as the Global 
Physical Activity Questionnaire (GPAQ), and the Sub Saharan Africa Physical Activity 
Questionnaire. Overall the studies have demonstrated lower levels of physical activity in 
urban compared to the rural settings (Aspray et al., 2000, Sobngwi et al., 2002, Jamison et 
al., 2006) . The physical activity questionnaires are subject to bias and their application vary 
widely across settings as a result contrary to expectations some of these studies did not show 
statistically significant results in diabetes risk reduction with increased physical activity 
levels (Sobngwi et al., 2002). Other studies on physical activity in Africa conducted in 
Cameroon using more objective measures of physical activity showed a clear reduction in 
cardio metabolic risk factors including blood glucose with increased physical activity levels 
(Mensah, 2008, Jamison et al., 2006). 
The association between diabetes and overweight and obesity is a widely known concept in 
the literature. A study in the US (Narayan et al., 2007) showed that the lifetime risk of 
diabetes at 18 years increased from less than 10% to more than 70% in both males and 
female for individuals with normal BMI to individuals with BMI of more than 30kg/m
2
. The 
main limitation of this study was that diabetes and obesity status were based on self-reports 
but results clearly underscore the role of obesity in increasing overall risk of diabetes. 
Several studies on diabetes prevalence from Africa have attempted to describe the 
relationship between diabetes and measures of obesity defined as BMI, Waist Circumference, 
Waist Hip Ratio and Hip Circumference. In these studies results showed that the persons 
diagnosed with diabetes had higher mean values of BMI, waist circumference or waist hip 
ratios depending on the methods used for assessing obesity in the study (Amoah et al., 2002, 
Aspray et al., 2000, Balde et al., 2007, Christensen et al., 2009, Motala et al., 2008, Nyenwe 
et al., 2003) . The relationship between BMI and diabetes varied across research settings, 
where some studies reported BMI to have a stronger association with diabetes among males 
(Aspray et al., 2000, Christensen et al., 2009) , in some studies the association of BMI and 
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diabetes did not reach statistical significance (Balde et al., 2007, Nyenwe et al., 2003). The 
observed differences could be explained by the fact that Africans tend have less visceral fat 
for a given Waist Circumference and BMI compared to Whites and therefore universal cut 
off points used may not confer similar risk in different ethnicities (Caroll et al. 2008, Camhi 
et al. 2011). 
Waist hip ratio as an independent predictor of diabetes showed statistically significant 
association in studies from South Africa, Guinea and Nigeria (Balde et al., 2007, Motala et 
al., 2008, Nyenwe et al., 2003) , but a weaker association was reported in a study from 
Tanzania (Aspray et al., 2000). Christensen et al (2009) (Christensen et al., 2009) compared 
the relation of waist hip ratio by sex and reported a stronger association among males 
compared to females. A study in Guinea (Balde et al., 2007) which compared the association 
of waist hip ratio and waist circumference in relation to the risk of diabetes reported that, 
waist circumference showed a stronger association than waist hip ratio. Hip circumference as 
a measure of central obesity was reported only in one study (Motala et al., 2008) and findings 
demonstrated an inverse relationship between hip circumference and diabetes. 
Non Modifiable Risk Factors 
The prevalence of diabetes is reported to vary across age groups, the different age groups 
with significantly increasing prevalence with increasing age. For example a study in Ghana 
(Amoah et al., 2002) found that the prevalence of diabetes was almost six times in the older 
age category . Increased prevalence of diabetes in older age groups is also reported in a study 
of diabetes in a rural population in South Africa (Motala et al., 2008) and in Nigeria (Nyenwe 
et al., 2003). This could be explained by the changes in population structures with improving 
life expectancy where more adults are now surviving into older age exposing them to such 
degenerative diseases. For example in Tanzania although children and young adults form the 
majority of the population; where almost half the population is below 15years, the proportion 
of those aged 65 years and above has been increasing steadily over the last 2 decades (UN, 
2010), according to the National Bureau of statistics the population of those aged 65 yrs. and 
above in Tanzania was estimated to be 717,098,   981,839 and 1,347,085 in 1978, 1988 and 
2002 respectively. In 2002 the proportion of the population aged 65 and above was estimated 
to be 3.9% (The United Republic of Tanzania Population and Housing Censuses of 1978, 
1988 and 2002) 
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On comparing the mean age of the study populations age distribution having lower mean age 
does not confer lower prevalence of diabetes. For example the urban population surveyed in 
the Tanzania (Aspray et al., 2000) had a mean age of about 30 years, but with a relatively 
higher prevalence of diabetes compared to the rural population which were older but with 
lower overall prevalence of diabetes. Similarly the study in Kenya (Christensen et al., 2009) 
had one of the highest diabetes prevalence but relatively low mean age of study participants 
compared with other studies from Sub-Saharan Africa . These findings indicate that the 
lifestyle factors are more important than aging process alone in the aetiology of diabetes. 
There is variation in the findings reported from studies on the association of diabetes and sex 
across different study populations. There is little information on relationship between sex and 
diabetes in Africa however results from diabetes studies in different countries in Africa 
report higher prevalence of diabetes in males (Aspray et al., 2000, Nyenwe et al., 2003, 
Sobngwi et al., 2002) and others (Alberts et al., 2005, Motala et al., 2008, Oladapo et al., 
2010) report higher diabetes prevalence among the female respondents unlike in Whites 
where male sex is always associated with higher risk of developing diabetes. The observed 
differences in the prevalence of diabetes between males and females seem to correlate with 
the overall distribution of the risk factors in that particular study population, studies with 
higher levels of risk factors such as obesity, smoking, older age etc in men compared to 
women had higher prevalence of diabetes and the reverse is true . Also gender is confounded 
with lifestyle for example, a higher proportion of men smoke and tend to have higher central 
obesity than women. 
Differences in the overall risk of diabetes between males and females need further 
consideration as there is no conclusive evidence on the relationship between diabetes and sex 
in this setting as the current studies have not been able to answer this important question. 
Results from studies in Africa provide inconclusive results over the overall risk of diabetes 
among males and females as the studies themselves are prone to bias due to small sample 
size and male or female predominance in the sampled population (Alberts et al., 2005, 
Amoah et al., 2002, Motala et al., 2008). For example the study by Motala had >70% females 
(Motala et al.2008). 
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As mentioned previously findings from the current (this chapter) study and studies of 
diabetes prevalence in Africa are characterized by a clear urban rural differences with higher 
burden of diabetes in the urban areas (Mbanya et al., 2010, Motala et al., 2008). Drawing 
upon these findings there is evidence to suggest influence of urbanization on the risk of 
developing diabetes. The extent to which urbanization relates to the risk of diabetes has been 
reported in a few studies in Africa measured as current urban residence or duration of stay in 
an urban environment (Aspray et al., 2000, Motala et al., 2008, Sobngwi et al., 2002). These 
measures are hardly generalizable as there is no uniform definition of urbanization in these 
studies .The duration of exposure to an urban environment also relates to age of the 
individual which needs to be considered when assessing the association between urbanization 
and diabetes risk. Despite these drawbacks, findings from studies seem to support the present 
hypothesis. A study in Tanzania showed that living in the urban area increased the odds of 
diabetes by five to six fold (Aspray et al., 2000), urban residency was also associated with an 
increased risk of diabetes of up to 3.7 times in a study from Kenya (Christensen et al., 2009) . 
In addition a study  from South Africa reported a positive significant relationship between the 
prevalence of diabetes and the proportion of time people spent in an urban environment, in 
this particular study urbanization is defined as >40% of life spent in the city (Motala et al., 
2008). Other studies for example  from Tanzania and Cameroon urbanization was defined as 
living in an urban area regardless of the time spent in that area (Aspray et al. 2000, Assah et 
al.2011). These findings call for standardization of indicators so that risk factors can be 
assessed uniformly and more objectively across settings. 
A longitudinal study on the effects of urbanization was reported by Unwin et al (Unwin et al., 
2010), where they measured behavioral and biological risk factors for diabetes and other non-
communicable diseases among individuals before they moved to urban areas and followed 
them up a year later found that there were significant increase in their levels of cardio-
metabolic risk profile after they had lived in the urban area. Similar findings are also reported 
in a review of effects of urbanization on metabolic risk factors by Hernandez and colleagues 
(Hernández et al., 2012).The possible explanation on the association between urbanization 
and increased risk of diabetes is increased exposure to environmental factors that promote 
poor dietary patterns and low levels of physical activity in urban areas (Gong et al., 2012).  
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Family history of diabetes is also an independent risk factor for diabetes (Valdez et al., 
2007). It has been shown previously that a person with a family history of diabetes is two to 
six times more likely to have diabetes compared to an individual without family history of 
diabetes and the strength of the association relates to the number of family members affected 
(Harrison et al., 2003). Some studies of diabetes prevalence in Africa explored the 
association between family history of diabetes and the risk of diabetes. The strength of the 
association ranged from a non-significant weak association in Kenya  (OR 1.12, 95% CI 0.57 
to 2.85 ) (Christensen et al., 2009) to strong association in Nigeria (OR 9.45, 95% CI 3.49 to 
35.54) (Nyenwe et al., 2003).  With regard to ethnicity a few studies have looked at the 
prevalence of diabetes in different ethnic groups these include studies from Kenya and 
Nigeria. These studies have demonstrated a clear difference in the risk of diabetes in the 
different ethnic groups. A study in Kenya has demonstrated a higher risk of diabetes among 
the Luo ethnic groups compared to the Kamba and Maasai (Christensen et al., 2009). In West 
Africa higher prevalence of diabetes has been reported among the Fulani ethnic groups 
(Balde et al., 2007, Nyenwe et al., 2003). Ethnic differences could probably explain the 
observed differences in diabetes prevalence across countries. 
Social economic status has also been found to be associated with diabetes in previous studies 
(Kumari et al., 2004, Timothy et al., 2011) ; in these studies individuals of higher 
socioeconomic status had lower risk of diabetes however in this review no study was found 
describing the relationship between diabetes and different levels of income. Income levels 
tend to modify the exposure to the different modifiable risk factors. 
2.4 Undiagnosed Diabetes in Africa   
In the previous section the prevalence of diabetes and the contributing risk factors were 
discussed and there is evidence that diabetes is no longer the disease of the rich and is 
prevalent even in rural areas. One of the challenges identified in these studies is the high 
prevalence of undiagnosed diabetes. In the identified studies the prevalence of undiagnosed 
diabetes was high with prevalence of undiagnosed diabetes ranging from 21% in urban 
Kenya (Christensen et al., 2009) to 100% in rural Guinea (Balde et al., 2007) . The 
prevalence of undiagnosed diabetes was generally higher in rural than urban areas for 
example in Guinea the prevalence of undiagnosed diabetes was 59% in urban Guinea whilst 
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all (100%) individuals in the rural area were diagnosed at screening (Balde et al., 2007), 
Similarly studies in Kenya and Tanzania showed a similar pattern (Aspray et al., 2000, 
Christensen et al., 2009) . The high prevalence of undiagnosed diabetes in the African setting 
is a reflection of the poor access to health facilities and also lack of diagnostic capacity at the 
available health care facilities which is more evident in rural compared to urban areas. 
2.5 Discussion 
The aim of this chapter was to provide background information on burden of diabetes and to 
review the prevalence of diabetes in African countries.  
The global burden of diabetes has increased compared to what had been previously predicted 
as described by the recent studies (Danaei et al., 2011, Whiting et al., 2011). Previous studies 
had underestimated the true burden of diabetes in their projections (Shaw et al., 2010, Wild et 
al., 2004). In their study, Shaw et al predicted that there will be 285 million people living 
with diabetes in 2010, however current data show that there over 300 million people living 
with diabetes. The differences could be due to availability of more data emanating from 
recent diabetes studies showing a true increase or due to differences in methodology and the 
type and number of studies included from the different countries. 
These studies provide the projections of diabetes burden but do come with a few limitations 
which affect the precision of their estimates including lack of accurate data. For example 
most of the data used in these studies to make projections come from studies that are not 
nationally representative, in the Global Burden of Disease Study only 29% of the studies 
used came from national surveys, about 46% of all countries included in the analysis had no 
country data, the data used was extrapolated from studies in neighbouring countries (Danaei 
et al., 2011).  
This chapter also included a review of diabetes studies from Africa. The review was 
restricted to studies using the 1999 diagnostic criteria for diabetes (2006). This review has 
shown that diabetes is prevalent in both urban and rural areas of sub-Saharan Africa, with the 
highest rates of diabetes (12.2%, 95% CI 5.4% to 23.2%)  reported in Kenya (Christensen et 
al., 2009). Compared to previous studies diabetes seems to have increased in different parts 
of Africa. For example, in Nigeria compared to previous studies (Erasmus et al., 1989, 
Owoaje et al., 1997, Olatunbosun et al., 1998)., prevalence of  diabetes has increased two to 
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three fold compared to results from recent surveys; from less than 2% in 1989 (Erasmus et 
al., 1989) to more than 6% in 2003 (Nyenwe et al., 2003). Similarly, the same trend is 
observed in Cameroon, Tanzania and South Africa where the studies showed an incremental 
increase in the prevalence of diabetes in subsequent studies compared to previous studies 
(Ahren and Corrigan, 1984, Aspray et al., 2000, Erasmus et al., 1989, Mbanya et al., 1997, 
McLarty et al., 1989, Omar et al., 1985, Omar et al., 1993, Sobngwi et al., 2002). 
With the exception of the high prevalence of diabetes reported from Kenya (Christensen et 
al., 2009), the prevalence of diabetes found in this review is lower than what has been 
reported previously in other African countries where studies reported high prevalence of 
diabetes, such as in Mauritius (13%-18%) (Söderberg et al., 2005, Söderberg et al., 2004), 
Seychelles (11%) (Faeh et al., 2007), Tunisia (9.3%) (Gharbi et al., 2002), Northern Sudan 
(8.3) (Elbagir et al., 1998) and Egypt (9.3%) (Herman et al., 1995). These differences in 
diabetes prevalence might be due to genetic susceptibility and also environmental factors 
such as lack of physical activity and unhealthy diet. Previous studies have reported higher 
prevalence of diabetes in individuals of Arab and Asian origin, with IDF estimates showing 
that countries in North Africa and the Middle East have the highest prevalence of diabetes 
(Whiting et al., 2011). Similarly, studies in Sub Saharan Africa (SSA) have shown higher 
prevalence of diabetes among individuals of Asian Origin compared to native Africans, for 
example in Tanzania the prevalence of diabetes in this ethnic group was 9.1% (Ramaiya et 
al., 1991) higher than what is reported in the general population. Higher diabetes prevalence 
has also been reported within the native Africa ethnic groups such as the Fulani in West 
Africa (Balde et al., 2007, Nyenwe et al., 2003) and among the Luo in Kenya (Christensen et 
al., 2009), but these studies could not explain the reasons for the observed differences.  
Therefore, more research is needed in this area to explain these unanswered questions. These 
studies clearly show that diabetes is no longer just a disease of western countries. 
Urbanization and sedentary lifestyle has been pointed out as a major factor for the rise of 
diabetes cases and its associated risk factors in developing countries. Diabetes prevalence in 
Africa has been characterized by urban rural differences, as shown in this review, whereby 
there is tendency towards higher prevalence in urban areas but with rapid urbanization of 
rural areas there is loss in the urban rural gradient in the prevalence of diabetes in Africa.  As 
has been reported in this review, studies are now reporting high prevalence of diabetes in the 
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rural areas when compared to what was reported in older studies (Motala et al., 2008, 
Sobngwi et al., 2002). 
The prevalence of diabetes in Africa seems to peak at a somewhat younger age compared to 
what has been reported from developed countries (Whiting et al., 2011). In this review the 
prevalence of diabetes escalates after the age of 40 and in most studies reaches a maximum in 
the 50 – 60 years age band (Amoah et al., 2002) whilst in developed countries the peak age is 
above 60, and in others > 70 years age group . This could explained by the population 
structure where the majority of the population are in the younger age groups for example in 
developed countries the like Sweden, United Kingdom, USA and Japan the population of 
those aged 60 years and above was 39.5%, 36%, 29.2% and 40.7% respectively, compared to 
only 11.6%, 9.6%, 9.5% and 7.1% in South Africa, Tanzania, Malawi and Nigeria 
respectively (United Nations Demographic Year Book, 2001). 
Obesity has been found to be a risk factor for diabetes, a finding which is consistent with 
what is widely known in the literature; however there is no conclusive evidence on the utility 
of the various anthropometric measures such as BMI, waist circumference and waist hip 
ratio. The lack of consistent significant association between these measures and diabetes 
found in this review could be due to the lack of appropriate cut off points that define risk in 
this population. For example, a study in China showed that the appropriate cut off points 
varied across sex categories and they were below the universally recommended cut points for 
both BMI and waist circumference (Xu et al., 2010).  Qing and Nyamdori (Qiao and 
Nyamdorj, 2010) also found  in their study that there were no universal cut points for 
anthropometric measures and that generally Whites had higher cut off points for the 
anthropometric measures compared to populations of Asian origin. Therefore, there is a need 
for further studies in this area in Africa to derive appropriate threshold values to define 
diabetes in this population. 
Studies in this review have also demonstrated an association between physical activity and 
the risk of type 2 diabetes.  The association is weaker than what has been reported elsewhere 
but this could be explained by the more subjective methods employed to measure levels of 
physical activities in these studies and this area deserves further consideration.  There is need 
to improve and validate the existing methods with more objective measures, and design 
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studies to explore issues that may affect levels of physical activity and their assessment in 
this setting which is culturally diverse. 
Data on the effects of economic status on diabetes from the reviewed studies are scarce 
Herman and colleagues. (Herman et al., 1995) studied the association of socio economic 
status (SES) and diabetes in Egypt and they report higher levels of diabetes, sedentary 
lifestyle and obesity among people of higher SES.  For example, in their  study  Herman and 
colleague reported a prevalence of diabetes of 13.5 % among persons of low SES versus 20% 
among those in with high SES contrary to what is reported from developed countries where 
people of low socioeconomic status are at more risk of diabetes (Kumari et al., 2004, 
Connolly et al., 2000). In Africa, this could be explained by increased exposure to a western 
way of living in those with higher economic status than their counterpart and also higher 
levels of obesity, rather than SES being an independent risk.  
The reason for lack of data on SES in studies from SSA could be due to lack of uniformly 
applicable methods of assessment as SES is defined in different ways including income 
levels, possession of household amenities, occupation/working status or level of education, 
having electricity and electrical items, type of roofing etc. These indicators are especially 
difficult to measure in African settings where the majority of people do not have formal 
education, or employment and also it may be difficult to express their wealth in terms that 
can be consistently assessed across settings. Other measures of economic status such as; 
housing tenure; car ownership may not be applicable in many settings, especially in rural 
areas. Classification of income levels also depends on the general wealth of the population 
and therefore differs across settings. Income level also changes over time and is influenced 
by family size. Studies have demonstrated that even Africans are at risk and show higher 
prevalence of diabetes when they move abroad compared to individuals with similar ethnic 
backgrounds, with the improvement in SES and increased exposure to western lifestyle, the 
burden of diabetes in Africa is likely to increase at an alarming rate.  
It is clear that diabetes is increasing in Africa and some of the risk factors for diabetes are 
modifiable.  If the current trends continue the burden of diabetes will be unbearable with 
economic, health and social consequences. There is a need to strengthen the health care 
system in these countries to respond to these emerging conditions with strategies along the 
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whole continuum from primary, secondary to tertiary prevention. There is need to put in 
place mechanisms to identify high risk individuals so that they can receive appropriate care.  
Given the high rates of undiagnosed diabetes screening could be a feasible approach to 
identifying those that need prevention and treatment interventions. The next chapter will 
discuss issues related to diabetes screening and the different strategies to identify individuals 
at high risk of diabetes and the existing opportunities for primary and secondary prevention 
of type 2 diabetes.
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Chapter 3. Diabetes Screening 
3.1 Introduction 
As the previous chapter illustrated, the burden of diabetes is increasing worldwide. The 
prevalence of undiagnosed diabetes is also high especially in low income countries where 
people have poor access to health care. Studies have shown that diabetes and diabetes related 
complications can be reduced by lifestyle or pharmacological interventions.  A review of 
available evidence has shown that diabetes screening could be worthwhile (Engelgau et al., 
2000, Echouffo-Tcheugui et al., 2011, Simmons et al., 2010, Waugh et al., 2007); however 
there is a lack of literature regarding the evidence for diabetes screening with application to 
African settings. This chapter therefore looks at the available evidence on diabetes screening 
vis-à-vis the criteria for screening for diseases in the African context.  
3.2 Definition of Screening 
‘Screening is the process of identifying those individuals who are at sufficiently high risk of 
a specific disorder to warrant further investigation or direct action’ (Wilson J, 1968). Three 
approaches to screening will be considered, these include; screening the entire population 
(mass screening), selective (targeted) screening which is applied to subjects being identified 
at high risk, and opportunistic screening, where screening is offered to subjects who attend to 
health care professionals for a reason other than the disorder targeted for screening (WHO, 
2003).  
3.3 Criteria for Screening of Diseases versus Diabetes Screening 
For a disease to be recommended for screening, several conditions, proposed by Wilson and 
Jungner (Wilson J, 1968) must be met (see text box) 
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Wilson and Jungner Criteria for Screening of Diseases 
Below is the critical review of the available evidence on each of the criteria in relation to 
diabetes screening 
1. The disease should be an important health problem  
2. There should be an accepted treatment for patients with 
recognised disease 
3. Facilities for diagnosis and treatment should be available 
4. There should be a recognisable latent or early asymptomatic stage  
5. There should be a suitable test or examination and should be 
acceptable to the population  
6. The natural history of the condition including development from 
latent to overt stages of the disease should be adequately 
understood  
7. There should be a clear policy whom to treat as patients  
8. The cost of case finding including diagnosis and treatment of 
patients diagnosed should be economically balanced in relation to 
possible expenditures on medical care as a whole  
9. Case finding should be an on-going process 
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3.3.1 Is Diabetes an Important Health Problem in Africa? 
Emerging evidence shows that diabetes is an increasing problem especially in low and 
middle income countries such as countries in Africa (Whiting et al., 2011). Diabetes is 
associated with a substantial burden of premature morbidity and mortality. Studies from 
White populations have shown that the risk of death among people with diabetes is about two 
fold that of individuals without diabetes  (Chiasson et al., 1998, Barr et al., 2007), with a 
global estimate of excess deaths attributable to diabetes of 6.8% in 2009 (Roglic and Unwin, 
2010). It is estimated that in Africa 280,000 deaths are attributable to diabetes accounting for 
6.1% of all deaths among those age 20-79 years also, diabetes is an important cause of 
premature mortality in the region (2012, Roglic and Unwin, 2010). Diabetes mortality in 
Africa is probably underestimated given the high proportion of people with undiagnosed 
diabetes and also diabetes is infrequently recorded as a cause of death, because the tendency 
is towards recording the immediate cause of  death and not the underlying conditions (Roglic 
and Unwin, 2010). 
Diabetes is also known to increase the risk of macro vascular disease by 2 to 4 fold (WHO, 
2011a, WHO, 2007) and is related to high rates of microvascular complications (end-stage 
renal disease (Herman et al., 2005), visual impairment (Saaddine et al., 2006), and peripheral 
neuropathy (Narayan et al., 2007).  
Diabetes also puts a strain on health care systems of these poor resource countries, in 2010 it 
was estimated that the cost of diabetes care in Africa was about 7% of total health 
expenditure (Zhang et al., 2010). IDF estimates that a total of 2.8 billion USD was spent on 
diabetes care in Africa in 2011, and is expected to rise by 61% in 2030 (Ali et al., 2012). A 
study in Tanzania estimated that the cost of diabetes care for the year 1989/1990 was 287 
USD and103 USD for patients requiring insulin and those not requiring insulin respectively 
in a population with gross capital income ranging between 160 to 200 USD, creating a huge 
burden to the government, the patients and their families (ADA, 2013). Kirigia et al 2009 
also estimated that in the year 2000 countries in Africa incurred a total economic loss of 
about USD 25.5 billion due to diabetes (Kirigia et al., 2009) . The cost estimates would 
probably be higher if disease-related medical costs for the extremely high proportion of 
people with undiagnosed diabetes were recognized and accounted for, also indirect costs 
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from lost productivity due to disability, premature mortality and absenteeism can be 
staggering (ADA, 2013, Barcelo et al., 2003, Kirigia et al., 2009). 
3.3.2 Is the Natural History of Diabetes Adequately Understood? 
The natural history of type 2 diabetes is relatively well understood and includes an 
asymptomatic phase comprised of prediabetess with an estimated average duration of 8.5 to 
10.3 years (Bertram and Vos, 2010), and preclinical latent diabetes stage that could last for 
about 9 to 12 years (Harris et al., 1992). In various populations, prediabetess states are less 
likely to regress to normoglycaemia, and are associated with a high risk of progression to 
overt type 2 diabetes, with an annualized relative risk of 4.7-12 % and absolute annual risks 
of 5-10% (Gerstein et al., 2007). The progression rate may be particularly high in populations 
like South Asians where annual progression rates as high as 18.5% have been reported 
(Ramachandran et al., 2006). Higher rates of conversion  from prediabetess to diabetes are 
described in persons with impaired glucose tolerance and both impaired glucose tolerance 
and impaired  fasting glucose (Rasmussen et al., 2007, Gerstein et al., 2007, Meigs et al., 
2003, Qiao et al., 2003, Rasmussen et al., 2008, Gao et al., 2010) 
Initial stages of diabetes are subclinical and by the time patients start experiencing symptoms 
complications may have occurred. Studies mostly in Whites with newly diagnosed diabetes, 
either conventionally or through screen-detection, have revealed the presence of chronic 
diabetes complications in up to 50% of cases at the time of diagnosis  (Echouffo-Tcheugui et 
al., 2011, Spijkerman et al., 2003, Herman et al., 1998). Given the susceptibility of some 
populations of developing countries (e.g., South Asians) to diabetes-related complications 
and their high progression rate (Ramachandran et al., 2006), the prevalence of complications 
among screen-detected patients from these groups is likely higher than that observed among 
Whites. There is limited information on the prevalence of complications among new diabetes 
patients in Africa but a  study in Uganda reported that at the time of diagnosis patients had 
both macro and micro vascular complications, with 46% having neuropathy and about 28% 
reporting having poor vision (Nambuya et al., 1996). The prevalence of complications among 
new patients is likely to be higher at presentation because of poor access to care and hence 
patients are likely to be diagnosed at a later stage of the disease. 
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3.3.3 Is There Accepted Treatment for Patients with Recognized Disease? 
Interventions for Undiagnosed Diabetes  
There is no direct evidence from randomized trials on the benefit of early detection of 
diabetes from Africa but the Anglo Danish Dutch Study of Intensive Treatment In peOple 
with screeN-detected diabetes in primary care study (ADDITION) explored the benefit of 
early intensive multifactorial treatment in an exclusively screen-detected diabetes cohort 
(Griffin et al., 2011) . The ADDITION intensive intervention was inspired by the STENO-2 
trial (Gaede et al., 2003). In ADDITION, intensive multifactorial treatment over five years 
period was associated with a non-significant 17% reduction in a composite cardiovascular 
primary endpoint compared to routine care, but greater improvements in levels of 
cardiovascular risk factors, 12% reduction in cardiovascular death, 30% for nonfatal 
myocardial infarction, and 21% for revascularization (Buijsse et al., 2011). These modest 
results may partly be explained by improvements in the quality of diabetes care during the 
trial period, a phenomenon that is likely to happen in any screening trial. Nonetheless, 
ADDITION showed some macro vascular benefits of early treatment for screen-detected 
diabetes. The extension of the follow-up of the ADDITION study will provide a more 
definitive answer on the effect of early treatment in people with screen-detected diabetes. In 
the meantime, data from intervention studies comparing the effects of individual treatment to 
lower blood glucose (Holman et al., 2008), blood pressure (UKPDS, 1998), and serum 
cholesterol (Costa et al., 2006, Turnbull et al., 2005), as well as lifestyle modification (Wing 
et al., 2011) in conventionally diagnosed diabetic populations can inform early treatment 
strategies with adaptation to suit local settings e.g. adoption of the WHO guidelines for 
prevention of cardiovascular diseases (WHO, 2007). 
Interventions for Prediabetes 
The focus of this thesis is on the identification of people with undiagnosed diabetes. 
However, individuals with IFG and IGT (prediabetess) are a high risk of developing diabetes, 
any diabetes screening program need to take into account how to manage those at high risk of 
developing diabetes. This section briefly gives an account of the available treatment options 
for individuals with prediabetes.  Screen detected prediabetes can be managed with lifestyle 
intervention and/or pharmacotherapy, which have been shown to delay or prevent diabetes in 
several landmark diabetes prevention trials (Crandall et al., 2008, Gillies et al., 2007). In the 
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published randomized controlled trials, lifestyle intervention slowed the progression from 
IGT to diabetes by 30-60%, and this was across a broad range of ethnic groups (Crandall et 
al., 2008, Gillies et al., 2007). The vast majority of these trials were conducted in populations 
of developed countries. However, the US Diabetes Prevention Program (DPP) recruited an 
ethnically diverse population with no racial/ethnic disparities in response rates. In the US-
DPP, the lifestyle intervention and metformin reduced  diabetes incidence by 58% and 31% 
respectively, compared with the placebo, after 2.8 years (Knowler et al., 2002), with similar 
benefits observed in all ethnic groups. Furthermore, two of the diabetes-prevention trials 
were conducted in populations exclusively from developing countries. The Da Qing study, 
which enrolled rural Chinese subjects with IGT, demonstrated significant effects of healthy 
eating, increased physical activity, and weight reduction in decreasing the risk of type 2 
diabetes during 6 years of follow up (Pan et al., 1997).  
The Indian Diabetes Prevention Program (IDPP) randomized South Asians with IGT to four 
arms: control (with standard advice), lifestyle modification (diet and exercise), low-dose 
metformin, and lifestyle modification plus low-dose metformin (Ramachandran et al., 2006). 
The relative reductions in diabetes incidence were 28.5% with lifestyle modification, 26.4% 
with metformin and 28.2% with lifestyle modification and metformin (Ramachandran et al., 
2006). Results from the diabetes-prevention trials suggest that lifestyle modification would 
be a much more compelling approach to diabetes prevention in the developing countries such 
as those in Africa. In addition to effects on diabetes incidence, lifestyle modification also 
improved cardiovascular risk profile in these trials (Crandall et al., 2008, Knowler et al., 
2009, Li et al., 2008). New trials of diabetes prevention are not necessarily needed in 
developing countries, unless these are setup to address novels questions. Developing 
countries need implementation studies testing the adaptability of proven diabetes prevention 
strategies to local conditions. A few community-based translations studies, using culturally 
adapted individual- and group-based lifestyle interventions delivered by trained lay persons, 
have been reported in developing countries (Balagopal et al., 2008, Oba et al., 2011). 
However, these prevention programs have been small in size, were non-randomized studies, 
and lacked sufficient follow-up to determine the sustained effects of the intervention. 
Moreover, the lifestyle modification curricula in these studies were not evidence-based, 
intervention goals were not always specified, and the costs were not evaluated.  
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3.3.4 Is There a Suitable Test or Examination Acceptable to the Population? 
Discussion of the available screening methods for diabetes is based on criteria by Wilson and 
Jungner, (Wilson J, 1968) which suggests evaluating the efficiency of a screening test by its 
validity (the ability of the test to separate those with the condition sought to those who do 
not when the test is compared to a gold standard) and  reliability (the degree to which results 
obtained from any given test can be replicated). Below is an account of the existing tests to 
define diabetes. Methods/tests for diagnosing diabetes that are discussed in this chapter 
include urine glucose, random blood glucose, fasting glucose, glycated haemoglobin, oral 
glucose tolerance tests and diabetes risk scores. 
Urine Glucose 
Urine glucose appears to be an inappropriate  screening instrument for diabetes given the low 
sensitivity (16-64%), and positive predictive value (11-37%) (Engelgau et al., 2000). 
Accordingly, the large proportions of individuals with diabetes are misclassified and remain 
undetected using this method. 
Random Blood Glucose 
A study conducted in the US population found that compared to OGTT, a RBG cut-off of 
≥6.9 mmol/l considered to be cost-effective exhibits a 93% specificity and a 41% sensitivity 
(Ziemer et al., 2008). Results of a study conducted in India found that compared to OGTT 
highest performance in terms of sensitivity and specificity were achieved with a cut-off point 
of ≥ 7.8 with sensitivity and specificity of 86.5% and 80.7% respectively (Somannavar et al., 
2009) . Although RBG is easy to obtain, since it does not require fasting, its performance as a 
screening tool is limited by the low sensitivity also RBG cut-offs are dependent on the 
background characteristics of specific populations (e.g., age, sex) and factors like time since 
last meal, and there may be no universally applicable cut-off.  
Fasting Plasma Glucose  
FPG is relatively simple (single plasma level measured) and highly correlated with the risk of 
diabetes complications. It may have modest sensitivity for hyperglycaemia screening. 
Compared to OGTT, a FPG threshold of ≥7 mmol/l may detect only 55.7% of people with 
diabetes , but  with 100% specificity (Kim et al., 2008). At the recommended optimal cut-off 
for FPG of >6.1 mmol/l the sensitivity increased to 85.2% but specificity also decreased to 
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88.5%. For identifying IGT,  FPG is not as sensitive as OGTT (Cheng et al., 2006). A FPG 
threshold of >5.6 mmol/l may detect only 28.9% of IGT cases whereas OGTT would identify 
87.4% of cases. 
Glycated Haemoglobin 
HbA1c has been adopted by the American Diabetes Association (ADA) as a diagnostic test 
for diabetes at a threshold of ≥ 6.5%. Unfortunately, the ADA criteria for HbA1c do not 
specifically define IFG and IGT categories, but rather a “high-risk” category corresponding 
to an HbA1c between 5.7 and 6.4% (ADA, 2013). WHO recommends the 6.5% cut point of 
HbA1c for diagnosing diabetes, as an alternative to plasma glucose measurements if stringent 
quality assurance tests are in place and assays are standardized to criteria aligned to the 
international reference values, and there are no conditions present which preclude its accurate 
measurement (WHO, 2011b). A value less than 6.5% does not exclude diabetes diagnosed 
using glucose tests. However, WHO does not make any formal recommendation on the 
interpretation of HbA1c levels below 6.5% (WHO, 2011b) .  
Studies, largely based in Whites have generally indicated a variable performance of HbA1c 
 ≥ 6.5% for type 2 diabetes  diagnosis, with an acceptable agreement with ADA/FPG 
diagnostic criteria (60 to 70%) (Carson et al., 2010, Lorenzo and Haffner, 2010, Cowie et al., 
2010), and a lesser agreement with OGTT diagnostic criteria (12 to 30%) (Lorenzo and 
Haffner, 2010, Cowie et al., 2010, Kramer et al., 2010) ). Furthermore the effect of HbA1c ≥ 
6.5% on type 2 diabetes prevalence compared to glucose criteria may be ethnicity dependent 
(Christensen et al., 2010, Cowie et al., 2010) . Indeed, several studies now suggest that race 
and ethnicity impact on HbA1c, and thus on its performance for detecting diabetes 
(Christensen et al., 2010, Herman et al., 2007) . Although these racial and ethnic differences 
remain unexplained, the general trend is that, with everything else being equal, the highest 
HbA1c values would be recorded among Blacks, followed by Hispanics and then Whites. 
Studies showing these results have been confined to populations of developed countries. 
HbA1c is an appealing screening tool, as it is a stable marker of long-term glycaemic level, 
does not require to be measured in fasting samples, has values that are not affected by short-
term lifestyle changes, may only require a point-of-care testing capillary sample, and has a 
lower intra individual variability than fasting plasma glucose. However, the costs, 
unavailability of the test and lack of standardization are limitations to the use of HbA1c 
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(Saudek et al., 2008). Furthermore, HbA1c tests results can be affected by a number of 
factors that may be more prevalent in some developing countries such as 
hemoglobinopathies, other conditions that shorten the lifespan of erythrocytes, iron 
deficiency, and chronic kidney disease (Gomez-Perez et al., 2010, Herman et al., 2007) . The 
best cut off points for the diagnosis of diabetes varies across studies with varying sensitivity 
patterns ranging from 15% in a study in France (Guillausseau et al., 1990)  to 92% in Pima 
Indians (Hanson et al., 1993) , with specificity ranging from 79% in Chinese subjects (Ko et 
al., 2000) to 100% (Guillausseau et al., 1990) at cut off points ranging from ≥ 5.6 to ≥ 8.6 
(Engelgau et al., 2000). 
75 g Oral Glucose Tolerance Test  
Oral glucose tolerance (OGTT) is currently considered the gold standard for diabetes 
diagnosis. In addition, it is the only method to formally detect or diagnosed IGT. OGTT 
identifies about 2% more individuals with diabetes than does FPG (Ramaiya et al., 1991) . 
However, OGTT has poor reproducibility compared to other glucose-based tests or HbA1c 
(Ko et al., 1998, Sacks, 2011) . OGTT also has many practical downsides, which are the 
required 8-hour fast before testing, commitment of staff, and the length of the test itself.  For 
all these reasons, OGTT has been less favoured as a screening test, and is likely to be 
impractical for African countries.  
Capillary Blood (Point of Care) Testing  
The simplicity and potentially low cost of capillary blood testing make it appealing for use in 
low resource settings in developing countries. Nonetheless, the utility of capillary blood 
testing for screening remains unclear, largely because of concerns of imprecision in the few 
existing studies and the lack of standardization. An Indian-based study comparing capillary 
fasting and 2-hour post load blood glucose measurements with fasting and 2-hour post-load 
venous plasma glucose measurements in screening for diabetes and prediabetess showed a 
moderate-to-acceptable correlation between a fasting capillary and venous values. Based on 
the ADA fasting criteria, 31.9% versus 21.1% (capillary vs. venous) had diabetes, whereas 
based on the WHO criteria, 43.2% versus 38.6% had diabetes (Priya et al., 2011) . In terms 
of performance at detecting hyperglycaemic states, the C-statistics for prediction of 
dysglycaemia and diabetes were 0.76 and 0.71 for capillary FPG and 0.87 and 0.81 for 
venous FPG, respectively in an Australian population (Rush et al., 2008). However, a much 
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larger study among South-Asians found a much better performance of capillary FPG [C-
statistic 0.87 (95% CI 0.81–0.93) ] to be significantly better (P< 0.001) for C-statistic 
comparison at predicting diabetes than risk scoring models based upon clinical variables 
alone [C-statistic for the best clinical model including age, BMI, hypertension, waist 
circumference: 0.69 (95% CI 0.62– 0.77) ] (Ritchie et al., 2011) . 
Diabetes Risk Scores 
Risk scoring system/questionnaires, particularly the ones not requiring laboratory testing are 
very attractive solutions for identifying people at high risk of having undiagnosed prevalent 
or future diabetes, these are discussed in detail in the next chapter on page 49. 
3.3.5 Is There a Clear Policy of Whom to Treat as Patients? 
For any screening program to be effective a clear policy will need to be in place of whom to 
treat as patients. The screening policy need to state clearly the aims and objectives of the 
screening program (WHO, 2003) , whether the aim is to identify; those with pre diabetes, 
those with undiagnosed diabetes or both . The policy will have to state explicitly the 
subsequent interventions for each of the outcomes. The screening policy need to state 
explicitly how the individuals will be identified, what type of tests, define cut off points 
based on available evidence based on yield , cost effectiveness and availability of resources. 
The choice of the cut off point for the screening test should bear in mind the capacity of the 
health system to deal with individuals that will be picked up as high risk that will require a 
subsequent confirmatory tests and interventions. 
3.3.6 Is the Cost of Case Finding and Treatment of Those Found to Have the 
Disease Economically Balanced with the Health Care Costs in General? 
The cost of case finding through screening and the cost of treating those found to have the 
disease need to be well balanced against the overall health care costs. In Africa especially 
where there are limited resources with the double burden of diseases it is imperative that the 
screening programs are implemented in a manner that is cost effective and should be guided 
by the available evidence such as adaptation of cost effective interventions proposed by 
WHO for resource limited countries .The available diabetes screening cost effectiveness trial 
(ADDITION) included a majority of Whites. Moreover, it was conducted in the primary care 
settings of three European countries where there is good access to care. Implementation of 
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multiple risk factors intervention used in ADDITION in developing countries may pose 
challenges related to the lack of a primary care framework to deliver the interventions, and 
the many gaps in the quality of care for diabetes (Walley et al., 2008). 
The health system and infrastructure, especially in a context of competing national priorities 
may be limitation, however there  is evidence of organized diabetes care that could serve as a 
platform to deliver diabetes screening interventions and management of diabetic and high 
risk individuals (Echouffo-Tcheugui et al., 2012, Ramaiya, 2005).  
Given the higher rates of undiagnosed disease implementing a screening program in an 
African setting is likely to have a higher yield and confer higher benefits in terms of 
preventing and managing complications. Thus, implementing screening for hyperglycaemia 
may require a strengthening of the health systems, which could be challenging. However, a 
potential benefit of organized screening prediabetess and T2DM is an improvement in the 
standards of care and treatment for people with diabetes in general and an improvement in 
the identification of cases and prevention of diabetes complications. 
Implementation of prevention programs for individuals of high risk also has its challenges in 
a system that is mainly focused to providing curative services. There is little information 
regarding the cost effectiveness and the pragmatism of implementing such programs in the 
African setting as no research has been conducted in this area. In general, translation of 
diabetes prevention principles into practice has confronted many challenges (Ali et al., 2012), 
which may be compounded in developing countries by the lack of qualified investigators, the 
limited research funding, and the lack of infrastructure. These potential challenges of 
diabetes translation prevention in developing countries are of many types: First, strategies for 
identification of high-risk people will have to be clarified. Up till now, diabetes prevention 
trials have used OGTT to screen for prediabetess, which is impractical for large-scale 
diabetes prevention programs. Although FPG may be easier, it also presents logistic 
difficulties for population-based programs. Alternate and practical methods that  could be 
applied in a community setting for identifying people at high risk of type 2 diabetes who 
would be offered preventative interventions, are risk assessment tools or questionnaires 
(Buijsse et al., 2011, Noble et al., 2011). These tools will limit the proportion of people that 
will receive a blood test, and are therefore more practical and potentially economical, 
however up to now there is no existing risk score that has been developed and validated for 
use in the African setting. Second, there is a shortage of trained personnel (dieticians, 
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medical nutritionists, and exercise physiologists) to deliver lifestyle modification in 
developing countries. However, specialists may not be essential, and lay persons can be 
trained to deliver physical activity intervention and nutrition counselling, as demonstrated 
elsewhere (Ali et al., 2012). Indeed, in many US-based studies of diabetes prevention 
translation, the change in weight among participants was similar regardless of whether the 
lifestyle intervention was delivered by clinically trained professionals or lay educators (Ali et 
al., 2012). Third, the intensive individualized approaches used to deliver the lifestyle 
intervention in diabetes prevention trials may not be practical in real-world setting of the 
developing world. Hence, community group-based approaches appear as the way forward. 
Furthermore, models for the delivery of physical activity and dietary interventions would 
need to use culturally relevant approaches, in order to overcome the potential barriers. 
Depending on the regions in the developing world these barriers will be of various types. 
Those related to nutrition include the absence of systematic food labelling and standardized 
packaging as well as low literacy rates limiting the impact of any food labelling. Barriers 
related to physical activity are the absence of appropriate infrastructure (e.g., lack of safe 
walkways, public parks, recreational spaces and cycle trails), environmental obstacles (e.g., 
high temperatures or humidity in some tropical countries), and limited leisure time to engage 
in physical activity especially among low-income groups. Other potential obstacles to 
effective diabetes prevention are cultural perceptions of obesity, as a sign of well-being and 
thus a source of respect and influence in places like Sub-Saharan Africa (Kamadjeu et al., 
2006). Fourth, the cost of rolling-out lifestyle intervention for preventing diabetes may be a 
challenge (Ackermann et al., 2008). The future benefits prevention of type 2 diabetes to both 
health-care budgets and the society are clear, but the immediate cost of financing type 2 
diabetes prevention programs can be an obstacle in poorer countries (Balagopal et al., 2008). 
The Diabetes Community Lifestyle Improvement Program (Weber et al., 2011), an ongoing 
translation trial, should provide more robust data on the effectiveness and cost-effectiveness 
of diabetes prevention in developing countries.  
3.3.7 Are There Programs to ensure that Case Finding is an Ongoing Process? 
The screening program has to be an ongoing process for it to be effective. There is no clear 
evidence to guide the frequency of screening and the age at which to start screening. A study 
in US suggested that in US screening for diabetes is cost effective when started at the age of 
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30 to 40 years with screening repeated every three to five years (Kahn et al., 2010). This was 
a simulated study and not findings from real life study however provides much needed 
evidence to inform decisions for implementation of screening programs in real life settings. 
The US, based on ADA guidelines recommends starting screening individuals at the age of 
45 (for individuals without compelling risk factors), repeated every three years for those with 
normal results and yearly for high risk individuals (ADA, 2013). Screening the whole 
population may not be applicable for low resource countries like those in Africa but 
considerations for screening those at high risk is imperative. Decisions of who to screen and 
how often to screen should be guided by the available epidemiological evidence (WHO, 
2003). In developed countries because of well-organized health care systems individuals 
eligible for screening can be identified and invited for screening through the primary health 
care infrastructure. This is a challenge especially for African countries as no such system 
exists, use of community health infrastructure and community health workers has proved 
successful in Africa on other community based interventions such as mass drug 
administration for neglected diseases, HIV, TB and Malaria programs. Similarly community 
health workers to could be trained to identify individuals at high risk of diabetes and refer 
them for screening as per the country’s screening policy guidelines. 
3.3.8 Approaches for Diabetes Screening 
Different approaches for diabetes screening exist; screening the entire population (mass 
screening) such as the nationwide screening for diabetes that was conducted in Brazil (Nucci 
et al., 2004), where all individuals above the age of 40 years were invited for screening, 
about 16% were found to have diabetes. Conducting and sustaining such as screening 
program is costly especially for poor countries and considerations are needed on the capacity 
of the health care system to cope with providing care for the identified cases and prevention 
programs those with prediabetess. Selective multistage screening is another approach which 
is applied to subjects being identified at high risk after a pre-selection criteria has been 
applied, an example of which is the Australian Diabetes Screening Protocol (Colagiuri et al., 
2004), where risk factors were used as a pre-selection criteria followed by fasting blood 
glucose, and further testing with OGTT or HbA1c measurement if the fasting glucose was 
inconclusive. Another example of selective screening is ADDITION screening protocol 
which was a step wise screening program, that used a combination of diabetes risk factors (a 
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diabetes risk score) as an initial screening tool, to stratify individuals at high risk, that need to 
undergo further testing (Griffin et al., 2011). The advantage of the multistage screening is it 
reduces the burden of having to screen the whole population and rather allows more efficient 
use of resources, where screening is done on those at higher risk of disease (Mohan et al., 
2005, Mohan et al., 2011). Opportunistic screening, is the physician initiated screening  
where screening is offered to subjects who attend to health care professionals for a reason 
other than the disorder targeted for screening (Ealovega et al., 2004, Edelman et al., 2002, 
Fisher et al., 2011, Franciosi et al., 2005, Klein Woolthuis et al., 2007, Klein Woolthuis et 
al., 2009). This form of screening is of value in settings where the health care system is 
inefficient for population wide screening such as those in African countries. 
3.3.9 Diabetes Screening in Sub-Saharan Africa 
Currently there are no specific recommendations for diabetes screening in Sub-Saharan 
Africa, WHO recommends that countries should have a diabetes screening policy that takes 
into account the epidemiological (burden of diabetes in the population), health systems 
(health system capacity to carry out screening, provide effective care to those with and at 
high risk of diabetes), population (acceptability and psychosocial impact) and economic 
considerations (WHO, 2003).  
Given the increasing burden of diabetes in Sub-Saharan countries and that routine blood tests 
are not carried out, organised opportunistic screening at health facilities and community 
gatherings could be an entry point for early case detection for those with undiagnosed 
diabetes for those at high risk. The burden of diabetes in Africa is now better understood with 
many more countries now starting to carry out regular surveys for non-communicable 
diseases, and the data can be used to study the epidemiological pattern of diabetes and other 
cardiovascular diseases that may help inform the populations at high risk. 
The main challenge in initiating screening programs in Africa will be the poor health care 
systems, for example Tanzania does not implement any organised screening programs but 
has on going screening services for cervical cancer which is implemented at the health 
facility level for women who wish to get screened for cervical cancer (Ngoma, 2006, WHO, 
2012). 
Initiating diabetes screening programs will entail a paradigm shift towards more efficient 
screening programs that will require investment in the capacity to carry out the screening 
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(staff training, equipment, and the screening methods) and also improvement in the care 
facilities for those identified to be at risk or at high risk of diabetes. This could be achieved 
by integrating the screening into the existing health care facilities rather than introducing 
diabetes screening as a vertical program. 
The screening program by itself could be an opportunity for health system strengthening as a 
result of increased demand for services. There is lack of data from Africa, but this was 
observed in Brazil, where more glucose testing was carried out at outpatient laboratories and 
resulted in strengthening of diabetes prevention and management in primary care facilities 
following the nationwide community screening in 2001 (Nucci et al., 2004, Toscano et al., 
2008), this was a positive impact, although not advocating that a national wide screening is a 
cost effective way of identifying people with undiagnosed diabetes. 
It is unclear how acceptable the screening program will be to the population and the resulting 
psychosocial effects of labelling individuals to be at high risk or to have diabetes, but there 
has been quite a success with the HIV screening campaigns with the roll out of voluntary 
counselling and testing centres. Studies have also shone some light that there are no 
significant adverse psychological outcomes with screening people for diabetes (Eborall et al., 
2007, Park et al., 2008). However given the cultural differences from where these studies 
were conducted, it is important that appraisal of the screening programs also includes 
evaluation of program acceptability by both the health workers and the people who are being 
screened. 
The key issue that determines the cost effectiveness of the screening programs is the yield 
(number detected) of the screening and the costs involved (Icks et al., 2005, Kahn et al., 
2010). The costs include the direct, indirect and the opportunity costs. The yield of the 
program is determined by the protocol used to screen and the resulting sensitivity and the 
specificity of the chosen screening alogarithm and the post screening interventions to those at 
high risk and those diagnosed with diabetes. All these factors will need to be put into 
consideration before initiating screening programs in Africa. Countries will need to generate 
local cost effectiveness evidence by investing in pilot studies to evaluate various screening 
strategies based on available evidence from randomised trials. 
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3.4 Discussion 
This chapter discussed the criteria for screening for diseases Vis a Vis diabetes screening. As 
noted previously there is enough evidence to suggest that diabetes is a growing problem in 
Africa and the current trends cannot be left unattended. Prediabetess and diabetes are 
increasingly common in these settings, with high progression rates from prediabetess to 
diabetes in some populations, and high rates of diabetes-related complications.  
Although there is no direct evidence from randomized controlled trials on the effects of 
treatment of prediabetess, diabetes and its complications from Africa studies from developed 
countries provide enough evidence on the effectiveness of such interventions to warrant 
screening for diabetes and prediabetess in high risk individuals (Borch-Johnsen et al., 2003, 
Echouffo-Tcheugui et al., 2011, Engelgau et al., 2000, Nathan and Herman, 2004, Simmons 
et al., 2010, Wareham and Griffin, 2001, Waugh et al., 2007, USPSTF, 2003). However, the 
implementation of these interventions in real-world settings of developing countries can pose 
a challenge to health systems, which in some cases are delivering suboptimal care.  
Several reliable and acceptable biochemical tests that can aid early detection of 
hyperglycaemic states are available such as the fasting glucose tests, HbA1c and OGTT. The 
use of random capillary glucose is limited because of the low sensitivity and highly variable 
cut off points that are dependent on the background characteristics of the population, and the 
use OGTT has limitation for use as a screening tool because it is a time consuming test and 
has low reproducibility. Fasting glucose provides a better alternative for the diagnosis of 
diabetes but there are no data from Africa describing its diagnostic performance and 
appropriate cut off points vies a vies the gold standard, OGTT and the same applies to 
HbA1c. Diabetes risk scores provide a cheaper and convenient alternative as an initial 
screening tool, especially at the primary health care and the community level, but the risk 
scores tend to be specific to the population from which they were developed and the existing 
risk scores have limited application for screening in African populations.  These would need 
to be validated and adjusted for use if they were to be applied to the African setting. The 
performance of point-of-care testing for capillary blood glucose and possibly HbA1c, which 
is even simpler, less invasive and more convenient than venous testing, deserve further 
considerations.  
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Cost-effectiveness of screening for diabetes and prediabetess should be investigated 
extensively in developing countries. Further studies are needed to look at the yield and the 
cost effectiveness of various screening algorithms. The aforementioned concerns call for 
caution when considering a screening program in Africa. However, designing policies for 
hyperglycaemia screening offers an opportunity to scale-up diabetes care and cardiovascular 
prevention at large, strengthen the health care systems of developing countries, and thus 
potentially limit future health care costs. 
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Chapter 4.   Diabetes Risk Scores 
4.1 Introduction 
A risk score is defined as an objective assessment of the probability of the presence or future 
development of an adverse health condition based on a combination of risk factors. Risk 
scores have been used within the field of Cardiovascular Disease (CVD) for many years to 
estimate the future risk of CVD events and aid clinical decision making (D’Agostino et al., 
2008, Kannel et al., 1976). Use of risk scores in the field of diabetes is more recent, with 
predictions mainly focused on the following outcomes; prediction of prevalent or 
undiagnosed diabetes (Brown et al., 2012) and prediction of future development of the 
disease (Buijsse et al., 2011). Some of the scores for example the FINDRISK (Lindstrom and 
Tuomilehto, 2003) were initially developed for predicting future disease but have also been 
used to predict undiagnosed or prevalent diabetes (Lin et al., 2009, Rathmann et al., 2005, 
Witte et al., 2010, Bergmann et al., 2007, Saaristo et al., 2005). 
The risk scores can be developed either as computerized algorithm that uses routinely 
available data in clinical practice to screen for high risk individuals who are then invited for 
screening, such as the Cambridge diabetes Risk Score (Griffin  et al., 2000). Others are 
developed as simple score questionnaires that can also be used as self-assessment tools by lay 
individuals (Lindstrom and Tuomilehto, 2003).  
The risk scores have been applied in the field of medicine to assess the risk of a particular 
disease or outcome, based on the level of risk clinicians are able to recommend a specific 
course of action e.g. behavioural change or specific therapies. 
Diabetes risk scores have been used widely as screening tools to identify high-risk 
individuals who would then be referred for further blood glucose or HbA1c testing. A 
number of diabetes scores have been developed and published (Brown et al., 2012, Noble et 
al., 2011, Buijsse et al., 2011). Many of the diabetes risk scores have been developed in 
developed countries in Whites and Asian populations, It is unclear to what extent a score 
derived in these populations may be applicable to the African setting.  
50 
 
Given the rising burden of diabetes in Africa and the high proportion of undiagnosed cases 
and lack of access to diagnostic facilities in this setting, the simple risk scores for 
undiagnosed diabetes that can be applied in a rural African setting are the focus of this paper. 
Only simple questionnaire based scores that do not require biochemical measurements are 
reviewed. The aim of this chapter is therefore to undertake a review of risk scores that are 
based on self-reported or available clinical data with undiagnosed diabetes as the main 
outcome, to compare the variables used in the different scores and their performance in 
derivation and validation populations. This chapter summarizes the finding from review of 
literature focusing on the diabetes risk scores for detection of undiagnosed type 2 diabetes. 
4.2 Methods 
4.2.1 Search Strategy 
This review was undertaken as part of collaborative work and the methods have been 
published previously (Brown et al., 2012) with the exception that this report however focuses 
on the studies that predict diabetes with undiagnosed diabetes as the outcome. My role in the 
study was from identification of studies to the review write up, my specific tasks during the 
review process was to extract data and to review the studies methodological quality. 
Electronic databases (Medline and Embase) were searched for relevant publications on 
diabetes risk scores, searches were also done on google search engine using the keywords 
diabetes risk score; also citation tracking was done to identify other articles that may have 
been missed from the search of the electronic databases. The initial combined search yielded 
a total of 1029 papers, at abstract stage 123 papers were identified, 74 of those were 
excluded, 2 more articles were identified later after citation tracking, leaving 51 papers for 
data extraction ( Table 4-1).  Eighteen (18) studies on scores that were developed to predict 
future diabetes as an outcome were excluded (Aekplakorn et al., 2006, Balkau et al., 2008, 
Kahn et al., 2009, Liu et al., 2011, Gupta et al., 2008, Hippisley-Cox et al., 2009, Schulze et 
al., 2007, Chen et al., 2010, Chien et al., 2009, Gao et al., 2009, Kolberg et al., 2009, Stern et 
al., 2002, Sun et al., 2009, Lindstrom and Tuomilehto, 2003, Tuomilehto et al., 2010, Wilson 
et al., 2007, Schmidt et al., 2005).  
 Also studies of scores that combine both undiagnosed and diagnosed diabetes as the 
outcome were not considered (Heikes et al., 2008, Griffin  et al., 2000, Bindraban et al., 
51 
 
2008), Finally 12 studies were included in this study after excluding studies that were only 
validating other scores and scores that did not have undiagnosed diabetes as their main 
outcome (Table 4-2). This particular review focused on risk scores that predict undiagnosed 
diabetes, the decision was made based on the fact that I wanted to compare the score that I 
am developing to existing scores that predict similar outcomes. 
Table 4-1 Search Strategy for Publications on Diabetes Risk Scores 
No.  Search 
 
Results 
1 exp Diabetes Mellitus, Type 2/ 52918  
2 exp Diabetes Mellitus, Type 2/di, ep, pc [Diagnosis, 
Epidemiology, Prevention & Control] 
10157  
3 type 2 diabetes.mp. 28837  
4 type 2 diabetes.tw. 28836  
5 diabetes type 2.tw. 352  
6 diabetes type II.tw. 170  
7 type II diabetes.tw. 4102  
8 exp Diabetes Mellitus/ 237369  
9 exp Diabetes Mellitus/pc, ep, di [Prevention & Control, 
Epidemiology, Diagnosis] 
47311  
10 DM.tw. 16241  
11 Non#insulin depend#nt diabetes mellitus.tw. 0  
12 non insulin depend#nt diabetes mellitus.tw. 6544  
13 NIDDM.tw. 6681  
14 adult#onset diabetes.tw. 0  
15 adult onset diabetes.tw. 337  
16 adult-onset diabetes.tw. 337 
17 adult$onset diabetes.tw. 1 
18 adult?onset diabetes.tw. 1  
19 prediabetess.tw. 220  
20 pre diabetes.tw. 220  
21 exp Prediabetic State/ 2456  
22 exp Prediabetic State/ep, pc, di [Epidemiology, Prevention & 
Control, Diagnosis] 
826  
23 *Prediabetic State/ 1352  
24 *Prediabetic State/ep, pc, di [Epidemiology, Prevention & 
Control, Diagnosis] 
362  
25 undiagnosed diabetes.tw. 397  
26 hyperglyc?emia.tw. 22328  
27 exp Hyperglycemia/ 17635  
28 exp Hyperglycemia/di, pc, ep [Diagnosis, Prevention & 
Control, Epidemiology] 
3468  
29 exp Glucose Intolerance/ 3764  
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30 exp Glucose Intolerance/ep, pc, di [Epidemiology, Prevention & 
Control, Diagnosis] 
1191  
31 impaired glucose tolerance.tw. 5633  
32 IGT.tw. 2231  
33 *Glucose Tolerance Test/ 4415  
34 impaired fasting glucose.tw. 1057  
35 IFG.tw. 855  
36 dysglyc?emia.tw. 149  
37 glucose intolerance.tw. 4859  
38 type 2 diabet$.tw.  
39 diabet$ type 2.tw.  
40 type II diabet$.tw.  
41 diabet$ type II.tw.  
42 33 or 32 or 21 or 7 or 26 or 17 or 2 or 1 or 18 or 30 or 16 or 27 
or 25 or 28 or 40 or 20 or 14 or 24 or 10 or 31 or 35 or 11 or 22 
or 13 or 23 or 29 or 6 or 39 or 36 or 3 or 9 or 41 or 12 or 15 or 
38 or 8 or 4 or 34 or 37 or 19 or 5  
274599 
43 risk score.tw. 2199  
44 risk calculat$.tw. 536  
45 risk scor$.tw. 2969  
46 risk factor calculat$.tw. 6  
47 risk scoring method.tw. 8  
48 risk scoring scheme.tw. 4  
49 risk factor assessment.tw. 339  
50 risk equation.tw. 99  
51 risk prediction.tw. 1078  
52 risk prediction score.tw. 15  
53 risk predict$.tw. 1755  
54 predict$ score.tw. 275  
55 risk function.tw. 195  
56 predict risk.tw. 490  
57 predict$ risk.tw. 1809  
58 project risk.tw. 26  
59 project$ risk.tw. 60  
60 predictive instrument.tw. 86  
61 predictive tool.tw. 331  
62 exp Multiphasic Screening/ 1046  
63 exp Multiphasic Screening/is, mt [Instrumentation, Methods] 74  
64 screening tool.tw. 4280  
65 (screening adj3 tool).tw. 5345  
66 11 or 21 or 7 or 17 or 2 or 22 or 1 or 18 or 23 or 16 or 13 or 6 or 
3 or 9 or 12 or 20 or 14 or 15 or 8 or 4 or 19 or 10 or 5 
14812  
67 42 and 66 923 
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Figure 4-1 Consort Diagram of Summarizing the Selection of Papers Included in the Review of 
Diabetes Risk Scores 
Combined search output  
1029 papers 
Refined output 
1009 papers 
20 duplicates removed 
Initial output after removing papers at abstract stage 
123 papers 
 
123 papers  
 
8 papers excluded as not available 
in English language  
 
Data extraction 
51 papers 
 
74 papers excluded based on full 
article 
 
886 papers excluded 
based on title & abstract 
 
Final papers included in the review  
33 papers  
 
18 papers excluded as scores 
identified those 'at future risk' of type 
2 diabetes 
8 papers included from internet and 
reference list searching 
Papers that developed a risk score with 
undiagnosed diabetes as outcome  
12 papers 
2 papers included at citation 
tracking 
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Table 4-2 Criteria Used to Include Studies for the Review of Diabetes Risk Scores 
Criteria Description 
Population - Adults 
Intervention - Screening for type 2 diabetes and, 
- Questionnaire based screening and, 
- Abnormal fasting glucose, or impaired glucose 
tolerance, or undiagnosed diabetes,  
- Risk score  derivation 
- Undiagnosed diabetes 
Outcome - Sensitivity, Specificity, ROC curve AUC 
Study Setting - Community  
Study design - Any study design with evidence of random 
selection of participants  
 
4.2.2 Quality Assessment of Studies Included in the Review 
The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) is a tool that was 
developed for assessing quality of studies reporting evaluation of diagnostic tools (Whiting et 
al., 2003, Whiting et al., 2006). Given that this is a review of risk score screening studies 
only the applicable items from the QUADAS tool were used in this review to assess study 
quality. Each item was scored as yes, no or unclear, based in the QUADAS guide for scoring 
items (Whiting et al., 2003), the description of how each item was scored is attached in 
Appendix 2. Most of the studies did well on the quality assessment with more that 90% 
scoring a yes for most of the items, the items which scored poorly are those on description of 
how the reference test were carried out and whether missing results were explained (item 8 
and 9) in Table 4-3 below, which may relate to under reporting of methods in studies rather 
than the study being of poor quality (Whiting et al., 2006). 
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Table 4-3 Quality Assessment of the Studies using the QUADAS Quality Assessment Tool 
QUADAS Item 
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1. Was the spectrum of patient’s 
representative of the patients who 
will receive the test in practice?  
Y Y Y Y Y Y U Y Y Y Y Y 
2. Were selection criteria clearly 
described? 
Y Y Y Y Y Y Y Y Y Y Y Y 
3. Is the reference standard likely 
to correctly classify the target 
condition?  
Y Y Y Y Y Y Y Y Y Y Y Y 
4. Did the whole sample or a 
random selection of the sample, 
receive verification using a 
reference standard of diagnosis? 
Y Y Y Y Y Y Y Y Y Y Y Y 
5. Did patients receive the same 
reference standard regardless of 
the index test result? 
Y Y Y N Y Y Y Y Y Y Y Y 
6. Was the reference standard 
independent of the index test (i.e. 
the index test did not form part of 
the reference standard)? 
Y Y Y Y Y Y Y Y Y Y Y Y 
7. Was the execution of the index 
test described in sufficient detail 
to permit replication of the test? 
Y Y Y Y Y U Y Y Y Y Y Y 
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8. Was the execution of the 
reference standard described in 
sufficient detail to permit its 
replication? 
Y N Y N Y Y N Y Y Y Y U 
9. Were uninterpretable/ 
intermediate test results reported?  
U U Y U U Y N U Y U Y U 
10. Were withdrawals from the 
study explained? 
Y Y Y Y Y Y N Y Y Y Y Y 
             Key; Y= Yes, N= No, U= Unclear 
 
           Each item was scored as yes, no or unclear, based in the QUADAS guide for scoring items (Whiting et al., 2003), the description of how 
each item was scored is attached in Appendix 2
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4.3 Results 
Below are the studies that were identified that met the inclusion criteria, which was of studies 
reporting development of a risk score to detect undiagnosed diabetes (Al Khalaf et al., 2010, 
Al-Lawati and Tuomilehto, 2007, Baan et al., 1999, Ruige et al., 1997, Bang et al., 2009, 
Chaturvedi et al., 2008, Gao et al., 2010, Glümer et al., 2004, Keesukphan et al., 2007, 
Mohan et al., 2005, Ramachandran et al., 2005, Pires de Sousa et al., 2009) and their results 
are summarized in Table 4-4 below. 
4.3.1 Study Characteristics 
The identified studies were from the Netherlands (Baan et al., 1999, Ruige et al., 1997), 
China (Gao et al., 2010), USA (Bang et al., 2009), India (Chaturvedi et al., 2008, Mohan et 
al., 2005, Ramachandran et al., 2005), Brazil (Pires de Sousa et al., 2009), Oman (Al-Lawati 
and Tuomilehto, 2007), Kuwait(Al Khalaf et al., 2010), Thailand (Keesukphan et al., 2007) 
and Denmark (Glümer et al., 2004) representing mainly Asian and White populations. The 
score developmental studies ranged from small studies of less than 500 (Keesukphan et al., 
2007) participants to larger studies of more than 10,000 participants (Ramachandran et al., 
2005) . None of the studies commented on the adequacy of their sample size, which is 
dependent upon the number of individuals in their sample who have the outcome of interest 
which is undiagnosed diabetes.  
It is recommended that there should be 10 events per variable, for a sample to be adequate for 
a prediction model (Moons et al., 2012, Steyerberg et al., 2000). For example the Thai risk 
score (Keesukphan et al., 2007) which has the smallest number of participants, has 3 
predictor variables which means for the sample to be adequate at least 30 individuals in the 
sample should have the outcome translating into a prevalence of about 7%, this information 
is not provided for the score developmental sample but in the validation sample authors 
report a prevalence of 13%, which provide enough power to validate the score. With the 
Kuwaitian score (Al Khalaf et al., 2010), the study population has only 2.3% undiagnosed 
diabetes among 460 study participants, therefore the sample was inadequate for the selected 
number of variables (4) in the score therefore subject to affect the performance of the score 
(Frank E. Harell, 2001, Steyerberg, 2009) . The age of participants among the various studies 
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also varied considerably. Studies in the Netherlands recruited older individuals above the age 
of 50yrs (Baan et al., 1999, Ruige et al., 1997), other studies included younger participants, 
as young as 18years of age (Keesukphan et al., 2007).  
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Table 4-4 Risk Score for Undiagnosed Diabetes 
 Score 
(Country) 
Population 
characteristics 
Variables in the Model Performance in 
Derivation  
Performance in 
Validation 
Performance in independent Validation 
Rotterdam score 
(Netherlands) 
(Baan et al., 
1999) 
  
a) 1016                         
b) 55-75 years  
c) NR               
d) NR                     
RPM1 Age, sex, 
obesity, BP medication                    
RPM2 same as RPM1 
plus family history of 
DM, BMI, physical 
activity 
NR Age 50-74 
RPM1 Cut of point 
of >6 
Specificity 55.0% 
Sensitivity 78.0% 
AUC 0.68 (0.64-
0.72) 
 
RPM2 Cut of point 
of >36  
RPM2 0.74 (0.70-
0.78) 
Sensitivity 72.0% 
Specificity 55.0% 
Oman population (Al-Lawati and 
Tuomilehto, 2007), age >20 yrs. ; RPM 
1 , cut off ≥11,  
Sensitivity 52.9% to 54.4%  
Specificity 49.7% to 50.3% 
AUC 0.53 to 0.54 
Kuwait population (Al Khalaf et al., 
2010), age >20yrs, RPM 1cut off point 
>6 
Sensitivity 43.0% 
Specificity 79.0% 
AUC NR 
Germany population (Rathmann et al., 
2005), age 55-74yrs ; RPM1 cut off >6  
Sensitivity 74.0% 
Specificity 39.0% 
AUC 0.61 
Chinese population (Gao et al., 2010), 
20-74yrs, RPM 1 cut off >6 
Sensitivity 18.8% 
Specificity 90.4% 
AUC 0.63 
Taiwanese population (Lin et al., 
2009), aged >18yrs, RPM 1 cut off >6 
Sensitivity 61.0% 
Specificity 70.0% 
AUC 0.69 (0.64-0.73) 
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 Score 
(Country) 
Population 
characteristics 
Variables in the Model Performance in 
Derivation  
Performance in 
Validation 
Performance in independent Validation 
US population (Bang et al., 2009), aged 
>20yrs, cut off >6 
Sensitivity 81-89% 
Specificity 46-55% 
AUC NR 
Danish population (Glumer et al., 
2006), age NR, Cut off >6 
Sensitivity 41.9% 
Specificity 84.0 % 
AUC 0.69 (0.65-0.72) 
Spanish population (Glumer et al., 
2006), age NR, Cut off >6 
Sensitivity 42.6% 
Specificity 81.6% 
AUC 0.66 (0.61-0.71) 
Australian population (Glumer et al., 
2006), age, NR, cut off >6 
Sensitivity 49.0% 
Specificity 82.7% 
AUC 0.7 (0.67-0.73) 
US population (Glumer et al., 2006), 
age NR, cut off >6 
Sensitivity 56.5% 
Specificity 72.0% 
AUC 0.68 (0.64-0.71) 
Korean population(Glumer et al., 
2006), age NR, cut off >6 
Sensitivity 20.8% 
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 Score 
(Country) 
Population 
characteristics 
Variables in the Model Performance in 
Derivation  
Performance in 
Validation 
Performance in independent Validation 
Specificity 89.6% 
AUC 0.60 (0.58-0.63) 
Asian Population(Glumer et al., 2006), 
age NR, cut off >6 
Sensitivity 11.5% 
Specificity 92.8% 
AUC 0.54 (0.49-0.59) 
African population (Cameroon)(Glumer 
et al., 2006), Age NR, cut off >6) 
Sensitivity 16.7% 
Specificity 91.5% 
AUC 0.53 (0.48-0.71) 
Nauru and Tonga populations (Glumer 
et al., 2006), Age NR, cut off >6 
Sensitivity 51.4% 
Specificity 65.1% 
AUC 0.62 (0.56-0.66) 
 
Symptoms risk 
Questionnaire 
_SRQ 
(Netherlands) 
(Ruige et al., 
1997) 
a) 2364                      
b) 50-74 years            
c) NR                        
d) White                      
Age, sex, pain or 
shortness of breath 
during walking, 
frequent thirst, obesity, 
family history of DM, 
BP medication, 
reluctance to use 
bicycle for transport 
Cut off point >5 
Sensitivity NR 
Specificity NR 
AUC 0.80                                
(0.75-0.85) 
Age 45-75yrs 
Sensitivity 72% 
Specificity 56 
AUC 0.69 (0.60-
0.79) 
None 
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 Score 
(Country) 
Population 
characteristics 
Variables in the Model Performance in 
Derivation  
Performance in 
Validation 
Performance in independent Validation 
Chinese risk 
score (China) 
(Gao et al., 
2010) 
  
a)1986                       
b)20-74years               
c) 62.7% 
female                          
d) Chinese                                
Waist, Age and family 
history of diabetes 
NR Age 20-74 yrs 
Cut of point ≥14 
Sensitivity 87.0%; 
Men 
Sensitivity 80.7%; 
Women 
Specificity 27.4%; 
Men 
Specificity 47.5% 
Women 
AUC 0.63 (0.59-
0.68) Men 
AUC  
0.69(0.64-0.72) 
Women 
 None 
  
 
 
 
 
US Risk Score 
(USA) 
(Bang et al., 
2009) 
a)5258                         
b)>20 years                  
c)NR                           
d)Various                                     
Age, Sex, Family 
history of diabetes, 
history of 
hypertension, Obesity 
and physical activity 
Cut off ≥5 
Sensitivity 82.0% 
Specificity 63.0% 
AUC 0.79 
Age >20yrs 
Cut point >5 
Sensitivity 79.0% 
Specificity 67.0% 
AUC 0.74 to 0.83 
None 
India Clinical 
Risk Score 
(India) 
(Chaturvedi et 
al., 2008) 
 
a) 4044 
b) 35-64yrs 
c) NR 
d) Asian 
Indian 
 Age, blood pressure, 
waist circumference, 
family history of 
diabetes 
Cut off point >16 
Sensitivity 66.0% 
Specificity 67.0% 
AUC 0.72 
(0.68-0.75) 
 
Age 20-69 yrs 
Cut off point >16 
Sensitivity 73.0% 
Specificity 56.0% 
AUC 0.69  
(0.66-0.71) 
None 
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 Score 
(Country) 
Population 
characteristics 
Variables in the Model Performance in 
Derivation  
Performance in 
Validation 
Performance in independent Validation 
Indian Risk 
Score (India) 
(Ramachandran 
et al., 2005) 
  
a)10003                              
b)>20years              
c)NR                           
d)Asian Indian                 
age, family history of 
diabetes, BMI, waist 
circumference, and 
physical activity 
Cut off point >21 
Sensitivity 76.6% 
(70.9-81.7) 
Specificity 59.9% 
(58.5-61.3) 
AUC 0.73 (0.70-
0.76) 
Age Varied, 3 
cohorts 
 Cut off >21 
Sensitivity 72.4% 
to 92.2% 
Specificity 21.6% 
to 61.0% 
AUC 0.67 to 0.73 
Chinese population (Gao et al., 2010), 
aged 20-74, cut off point >21 
 Sensitivity 96.1% 
Specificity 18.7% 
AUC 0.63 (0.60-0.65) 
Taiwanese population (Lin et al., 
2009), aged >18yrs, cut off point NR 
Sensitivity 63.0% 
Specificity 69.0% 
AUC 0.70 (0.66-0.74) 
Simplified 
Indian Risk 
Score (India) 
(Mohan et al., 
2005)  
a) 2350                        
b)>35 years                 
c)NR                         
d)South Asian 
Age, Waist 
Circumference, family 
history of DM, 
physical activity 
Cut off point ≥60 
Sensitivity 72.5% 
Specificity 60.1% 
AUC 0.69                                     
(0.66-0.73) 
NR Kuwait population 
(Al Khalaf et al., 2010), aged >20, cut 
off ≥60 
Sensitivity 87% 
Specificity 50% 
AUC NR 
Brazilian Risk 
Score (Brazil) 
(Pires de Sousa 
et al., 2009) 
  
a)1224                         
b)>35 years                  
c)NR                        
d) Various                                     
age, BMI and 
Hypertension 
Cut off point ≥18 
Sensitivity 75.9% 
Specificity 66.8% 
AUC 0.77(0.73-
0.81) 
Brazilian 
population Cut off 
point ≥18 
85.7% 
44.8% 
AUC 0.72(0.64-
0.80) 
None 
  
 
 
 
Kuwaitian Risk 
Score (Kuwait) 
(Al Khalaf et 
a)562                        
b)>20 years               
c)52.8% 
Age, WC, BP 
medication, family 
history of DM 
Cut off ≥32 
Sensitivity 87.0% 
Specificity 64.0% 
NR None 
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 Score 
(Country) 
Population 
characteristics 
Variables in the Model Performance in 
Derivation  
Performance in 
Validation 
Performance in independent Validation 
al., 2010) female                          
d) Arabic                    
AUC 0.82                      
CI not reported 
 
 
 
Thai Risk Score 
(Thailand) 
(Keesukphan et 
al., 2007) 
a) 429 
b) 18-81yrs 
c) 63% female 
d) Thai 
Age, BMI and history 
of hypertension 
Cut off point ≥240 
Sensitivity 96.8% 
Specificity 24.0% 
AUC 0.74 
Age 16-80 yrs 
Cut off point ≥240 
Sensitivity 87.1% 
Specificity 38.0% 
AUC 0.71 
NR 
 
 
 
 
Danish Risk 
Score 
(Denmark) 
(Glümer et al., 
2004) 
a)6784                       
b)30-60 years              
c)NR                        
d)NR                           
Age, sex, BMI, 
physical activity, 
known hypertension, 
family history of DM 
Cut off >31 
Sensitivity 73.3% 
Specificity 74.3% 
AUC 0.80                                 
(0.76-0.83) 
Age 30-60yrs 
Cut off >31 
Sensitivity 66.7% 
to 75.9% 
Specificity 72.2% 
to 73.6% 
AUC 0.76 to 0.80 
Taiwanese population (Lin et al., 
2009), aged >18yrs, cut off NR 
Sensitivity 63% 
Specificity 70% 
AUC 0.72 (0.68-0.76) 
Chinese  population (Gao et al., 2010), 
age 20-74, cut off >29 
Sensitivity 55.1%% 
Specificity 72.1 
AUC 0.69 (0.66-0.71) 
Australian population (Glumer et al., 
2005), aged 30-60yrs, cut off >23 
Sensitivity 71% 
Specificity 70% 
AUC 0.75 (0.71-0.78) 
Kuwait population(Al Khalaf et al., 
2010) , aged >20yrs, Cut off point >31 
Sensitivity 39% 
Specificity 87% 
AUC NR 
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 Score 
(Country) 
Population 
characteristics 
Variables in the Model Performance in 
Derivation  
Performance in 
Validation 
Performance in independent Validation 
 
 
Oman Risk 
Score (Oman) 
(Al-Lawati and 
Tuomilehto, 
2007) 
a)4881                      
b)>20years                    
c)57.6% 
female            
d) Arabic                        
Age, Waist 
Circumference, Body 
Mass Index, Family 
history of diabetes and 
current hypertension 
status 
Cut of point >10 
Sensitivity 78.6% 
Specificity 73.4% 
AUC 0.83 (0.82-
0.84) 
Age>20yrs, cut off 
>10 
Sensitivity 62.8% 
Specificity 78.2% 
AUC 0.76 (0.74-
0.79) 
Kuwait population(Al Khalaf et al., 
2010), aged >20yrs, cut off >10 
Sensitivity 96% 
Specificity 42% 
AUC NR 
Taiwanese population(Lin et al., 2009), 
aged >18yrs, cut off >10 
Sensitivity 65% 
Specificity 67% 
AUC 0.72 (0.69-0.75) 
 
Key 
a=sample size, b= age of study participants, c= sex, d=ethnicity 
NR = Not Reported 
AUC = Area under the Curve 
RPM = Rotterdam Prediction Model 
BMI = Body Mass Index 
DM = Diabetes Mellitus 
Score performance reported as Sensitivity, Specificity and AUC (95% Confidence Interval) 
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4.4 Variables Included in the Developed Risk Scores 
The identified studies incorporated similar variables. The commonest variables were age and 
family history. Age was included in all the scores, and was applied as a categorical variable 
which varied across settings, with the association with the outcome increasing with 
increasing age across all studies. Family history was included in 10 out of the 12 scores (Al-
Lawati and Tuomilehto, 2007, Baan et al., 1999, Bang et al., 2009, Gao et al., 2010, Ruige et 
al., 1997, Chaturvedi et al., 2008, Mohan et al., 2005, Ramachandran et al., 2005, Glümer et 
al., 2004, Al Khalaf et al., 2010) 
The way family history was measured varied across studies, in some studies family history 
was reported as any first degree relative with diabetes (Baan et al., 1999, Ruige et al., 1997, 
Gao et al., 2010, Bang et al., 2009, Chaturvedi et al., 2008, Ramachandran et al., 2005, Al-
Lawati and Tuomilehto, 2007) , or parental diabetes history (Glümer et al., 2004, Mohan et 
al., 2005), or whether only one of the parent has diabetes or both (Keesukphan et al., 2007). 
In the Kuwait score (Al Khalaf et al., 2010) family history variable is reported as presence or 
absence of diabetes history in one’s siblings . Sex as predictor variable was explored in 
several studies (Baan et al., 1999, Ruige et al., 1997, Bang et al., 2009, Glümer et al., 2004, 
Al Khalaf et al., 2010, Pires de Sousa et al., 2009, Ramachandran et al., 2005) but was a 
significant predictor only in the Dutch (Baan et al., 1999, Ruige et al., 1997) , US (Bang et 
al., 2009), and the Danish Scores (Glümer et al., 2004). 
Measurements relating to anthropometric measures were used in all scores, either measured 
as Waist circumference (Gao et al., 2010, Chaturvedi et al., 2008, Mohan et al., 2005, Al 
Khalaf et al., 2010) , BMI (Baan et al., 1999, Ruige et al., 1997, Keesukphan et al., 2007, 
Pires de Sousa et al., 2009) or both (Bang et al., 2009, Ramachandran et al., 2005, Glümer et 
al., 2004, Al-Lawati and Tuomilehto, 2007). The variables were included in the model as 
categorical variables using ethnic specific cut off points. 
Hypertension is one of predictors that were incorporated in many of the scores; Hypertension 
was included in 9 out of the 12 scores. Hypertension was defined as use of hypertensive 
medication (Baan et al., 1999, Ruige et al., 1997, Al Khalaf et al., 2010), history of 
hypertension, whether diagnosed previously to have hypertension (Bang et al., 2009, 
Keesukphan et al., 2007, Pires de Sousa et al., 2009, Glümer et al., 2004, Al-Lawati and 
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Tuomilehto, 2007). One of the Indian scores, incorporated hypertension as the presence of 
hypertension at blood a pressure measurement and defines high blood pressure as normal, 
pre-hypertension and hypertension (Chaturvedi et al., 2008). 
Lifestyle variables were also evaluated in some of the studies, including diet, smoking and 
physical activity/fitness. Physical activity was included in 5 (Baan et al., 1999, Ruige et al., 
1997, Bang et al., 2009, Chaturvedi et al., 2008, Mohan et al., 2005, Ramachandran et al., 
2005) of the 12 scores. There was wide variability in the way physical activity was measured 
across settings, with some of the measures being specific to certain settings which  may not 
be universally applicable for example in the Dutch scores (Baan et al., 1999, Ruige et al., 
1997)  physical activity was assessed as reluctance to use bicycle for transportation. One of 
the risk scores (Ruige et al., 1997), includes also several symptoms in the model that are 
predictive of diabetes such as frequent thirst, pain and shortness of breath during walking 
which are highly subjective  and may be difficult to measure consistently across settings and 
if using clinic data to evaluate risk of individuals in a catchment area like it is being done in 
certain European settings, the score may be difficult to apply because this information is not 
available in the clinic databases and the symptoms are rarely specific for example epigastric 
pain may be described as chest pain. 
4.5 Performance of the Risk Scores  
Performance of the risk score in this review was assessed using sensitivity, specificity and 
the area under the ROC curve (AUC), other measures of diagnostic tests performance such as 
the likelihood ratios, and the measures of calibration were not used because they were not 
always reported. In presenting score performance statistics, performance in validation 
represents results of studies reported by the same authors usually done using similar 
populations to score derivation study population and performance in independent validation, 
usually across a different setting and by different study teams independent of the score 
derivation team (Table 4-4). 
In the studies included in this review, sensitivity and specificity were reported for all the 
scores for a specified chosen cut-off point see Table 4-4. The methods for choosing a specific 
cut of point were not always described. Most studies reported that the cut off point was 
chosen to maximize sensitivity and specificity. 
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In some of the validation studies the cut-off points were also modified to fit the new 
population (Al Khalaf et al., 2010). The highest combinations of sensitivity and specificity 
for developmental risk scores were 78.6 % and 73.4% achieved by the Oman risk score (Al-
Lawati and Tuomilehto, 2007). Sensitivities of the risk scores in developmental populations 
ranged from 66 (Chaturvedi et al., 2008) to 96.8% (Keesukphan et al., 2007). Only 3 studies 
reported sensitivity > 80% (Aekplakorn et al., 2006, Bang et al., 2009, Al Khalaf et al., 
2010). Specificity for the derivation studies ranged 24% in the Thai risk scores (Keesukphan 
et al., 2007) to 74.4% in the Danish score (Glümer et al., 2004) respectively. The AUCs for 
the derivation studies ranged from 0.69 ( 95% CI 0.66 to 0.73)  (Mohan et al., 2005) to 0.83 
(95% CI 0.82 to 0.84) (Al-Lawati and Tuomilehto, 2007) indicating good performance in all 
the scores. In General when the scores were validated within the studies the performances 
were comparable in sensitivities, specificities and AUCs, there were small differences but 
their confidence intervals overlapped showing that the differences were not statistically 
significant (Table 4-4) except for the Oman score (Al-Lawati and Tuomilehto, 2007) which 
showed lower performance at validation, a concept known as over fitting (Steyerberg, 2009) 
which may signify that  the performance of the model may have been over estimated in the 
developmental sample. 
Of the reviewed risk scores, 5 scores (Baan et al., 1999, Ramachandran et al., 2005, Mohan 
et al., 2005, Glümer et al., 2004, Al-Lawati and Tuomilehto, 2007) were found to have been 
independently validated in other populations. The mostly validated score in this review were 
the Rotterdam (RPM1) (Baan et al., 1999) and the Danish (Glümer et al., 2004) risk scores. 
The sensitivity and specificity of the validated scores varied greatly across settings and 
compared to the performance in the developmental sample (Table 4-4). For example the 
sensitivity of the Rotterdam score (Baan et al., 1999) was 78.0 % in the derivation study but 
was as low as 11.5% in the validation studies (Glumer et al., 2006) .  The score performance 
in terms of both sensitivity and the AUCs was dependent on the study population with worse 
performance in populations of African, Asian and Arab origin (Glumer et al., 2006). Thus 
overall validation studies tended to perform less well than developmental studies. There was 
no clear evidence that the performance of the scores is related to the number of variables 
included, a good example is the comparison of the RPM 1 and the RPM2 which showed no 
differences in the overall performance of the score despite RPM2 having more variables than 
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RPM1(Baan et al., 1999). Also across other studies risk scores with more variables did not 
differ in performance any better compared to those with fewer variables (Brown et al., 2012). 
4.6 Discussion 
This review identified 12 studies exploring the performance of risk scores to identify 
undiagnosed type 2 diabetes using self-reported or available clinical data.  
Many risk scores incorporated similar variables. The score predictive performance was not 
related to the number of variables included. Some studies did not compare their newly 
developed score to existing ones to determine if the new score added any further benefit. For 
example, in India three studies were found (Chaturvedi et al., 2008, Mohan et al., 2005, 
Ramachandran et al., 2005) incorporating similar variables but none of them validated the 
existing risk scores already available in India, similarly for the two Netherlands studies (Baan 
et al., 1999, Ruige et al., 1997). In addition, different studies used different approaches to 
defining diabetes; most of the studies used FPG and three (Al-Lawati and Tuomilehto, 2007, 
Glümer et al., 2004, Ramachandran et al., 2005) used OGTT. Overall, these studies found 
that the published risk scores tested did not differ significantly in their performance based on 
AUCs which is a measure not affected by the background prevalence of the outcome and 
other characteristics and so can be used to make comparison across scores. The impact of the 
diagnostic criteria used to define diabetes and the overall performance of the risk score is 
unknown as none of the identified studies compared or validated the risk scores based on 
different diagnostic criteria for diabetes presenting a challenge in comparing the performance 
of the various scores. The differences in diagnostic criteria did not seem to affect the 
performance of the risk scores in this review, with studies showing overlapping performances 
regardless of whether FPG or OGTT was used for diagnosis. None of the scores have been 
validated using.  
Only five scores were independently validated; the Rotterdam (Baan et al., 1999), the Indian 
(Ramachandran et al., 2005), the simplified Indian (Mohan et al., 2005), the Danish (Glümer 
et al., 2004) and the Oman (Al-Lawati and Tuomilehto, 2007) risk scores. In general, risk 
scores developed in one population had less performance when validated in other 
populations. None of the studies internally validated their scores, therefore it is unclear 
whether the differences in performance of the scores at validation or were due to actual 
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differences in the background characteristics of the study population or was due to 
overestimation of performance in derivation studies (Steyerberg et al., 2001). 
Given that the purpose of diabetes risk scores that predict prevalent diabetes is to identify 
those at risk of undiagnosed type 2 diabetes , the findings of this review suggest that the 
scores are able to identify those at risk i.e. are able to pick 8  (highest ROC AUC of 0.83 for 
example) out of every 10 high risk individuals. 
Therefore risk scores are a practical approach to stratify individuals at risk during community 
and outpatient screening through targeted screening, avoiding unnecessary blood glucose or 
HbA1c measurements. 
Studies have shown that those identified by the risk score (true positives) tend to be at higher 
risk of micro and macro vascular complications than those who are missed (false negatives) 
and therefore risk scores are suitable as a screening tools (Mohan et al., 2011). However, 
there is a need to better understand the risks of adverse outcomes in the significant minority 
of individuals with undiagnosed diabetes who would be missed by the risk score (false 
negatives).  In evaluating screening programs there is need to also look at the outcome of 
those classified as low risk by the score being used. The yield of the screening tool depend on 
the chosen cut off point, the less stringent the criteria the bigger the number that will require 
a confirmatory test and the lower the specificity but higher sensitivity. Depending on the 
availability of the resources and the aim of the screening program the cut-off point can be 
adjusted to suit the local needs. The use of a risk score for initial screening to determine who 
should go on to biochemical testing could therefore be invaluable in poorer countries. 
A recent study in India (Mohan et al., 2011), for example, evaluated the use of an OGTT 
alone, or in combination with the Indian Diabetes Risk Score (Mohan et al., 2005), and 
showed that  use of the risk score followed by OGTT for those at high risk was more efficient 
and substantially cheaper. The potential benefits in terms of efficiency and costs from using a 
risk score will be highly dependent on the score’s characteristics, particularly its sensitivity 
and specificity. The Chinese risk score (Gao et al., 2010) for example, had good sensitivity 
but low specificity (Table 4-4) page 59, yielding a much higher number of false positives and 
a lower yield for a given number of confirmatory tests. This has resource implications if the 
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score were to be used as an initial test for screening, resulting in a larger number of people 
needing a confirmatory test if the published cutoff points are to be applied. 
Self-completion questionnaires may also have value as easy to use health promotion tools in 
low and middle income settings, helping to inform individuals of risk factors for diabetes and 
providing a potential entry point to lifestyle change. However, more research on the utility of 
risk scores from this perspective is needed. Also, the use of self completion diabetes risk 
scores could be limited by the low level literacy as is the case in many developing countries, 
also the model of delivery would be a challenge with low coverage of postal and internet 
services, but mobile phone technology could provide a platform for leveraging such health 
care services. 
In conclusion, a number of published risk scores for undiagnosed type 2 diabetes are from 
Asian and White populations, there is no single score developed for the African population, 
there is need to develop and or evaluate cost effective approaches to detecting undiagnosed 
diabetes in this setting. 
One approach would be to validate the existing score and update for use in this setting as this 
review has demonstrated that there is no universally good score, the choice of which score to 
choose and evaluate in a given population should be driven by pragmatic considerations, 
based on the setting in which the score would be applied as well as the data and resources 
available.  For example, scores that may require clinical assessment such as blood pressure 
measurements (Mohan et al., 2005) may not be appropriate in settings where no such services 
are available. Key resource considerations include the local capacity for diagnostic testing 
and the effective management of newly identified cases. The other approach would be to 
develop and validate a diabetes risk score from Africa and evaluate its performance across 
settings in Africa a process which is being described in this thesis. 
The exclusion of diabetes risk score that predict future risk of diabetes could have led to 
omission of potentially useful scores, but there are no specific recommendations at this stage 
that states that scores developed to predict future risk can be used to predict prevalent 
diabetes and vice versa, hower the Finnish diabetes risk score has been validated in several 
studies for prediction of prevalent undiagnosed diabetes with a slightly lower performance 
compared to the derivation study but the results were promising. In the Finnish population 
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when validated cross sectionally the score had an AUC of 0.72 (95 % CI 0.68 to 0.77) in men 
and 0.73 (95% CI 0.68 to 0.78) in women compared to 0.87  in the original study (Saaristo et 
al., 2005) . When tested in other populations the Finnish score had an AUC ranging from 
0.65 to 0.74 (Bergmann et al., 2007, Gao et al., 2010, Rathmann et al., 2005, Saaristo et al., 
2005, Witte et al., 2010). This topic deserves further considerations and further studies to 
investigate the utility of these risk scores accros different populations. 
A major strength of this review was the fact that an extensive search strategy was applied to 
key databases in addition to text-based queries of internet search engines. Cross-checking of 
the reference lists of pertinent papers further validated the search findings. The deliberate 
broad design of the inclusion criteria also facilitated the initial identification of over 1000 
studies. Two independent reviewers sifted the data with pre-specified criteria to decide which 
papers were to be included, performed data extraction, and assessed risk of bias using the 
QUADAS tool to ensure a standardized approach. 
There are also limitations to this review. Firstly, the search strategy only included two 
electronic databases. It must be acknowledged that searching other databases may have 
identified other risk score studies. Secondly, only papers available in English were 
considered. Thirdly the studies used different methods to diagnose diabetes, which may bias 
the findings of the performance of the scores. 
The next chapter will discuss the aims and objectives of this study and the overview of study 
populations 
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Chapter 5. Study Aims, Objectives and Overview of Study Populations 
5.1 Study Aims and Objectives 
5.1.1 Introduction 
As mentioned in chapter 2 on page 10 diabetes is an important public health problem in 
Africa, and many of the diagnosed cases are identified late often with multiple complications 
and poor survival rates. Diabetes also poses a high economic burden even for developed 
countries, thus prevention is an important public health strategy in reducing the burden due to 
diabetes. This study therefore proposes to develop and validate a simple questionnaire based 
tool that can be used for early identification of those at risk of diabetes for targeted 
preventive interventions in the African context. Most diabetes risk scores have been 
developed and validated in Whites and no tool has yet been derived and validated in an 
African population. 
5.1.2 Aim 
To develop and validate a diabetes risk score to identify undiagnosed diabetes for African 
populations, and evaluate its utility within a clinical setting in Tanzania 
5.1.3 Objectives 
1. To derive a diabetes risk scoring tool from data sets of studies carried out in African 
populations 
2. To externally validate the new risk score in independent populations from Africa 
3. To compare performance of the new score with commonly used  diabetes risk scores  
4. To evaluate the yield, and comment on the cost, of applying the tool in a clinical 
setting in Tanzania 
5.2 Broad Methods 
The study had 3 phases: derivation of the risk score tool for detecting undiagnosed diabetes 
using available population data; validation in independent population data sets and; and 
validation in a clinical setting. The detailed methods are described in detail in respective 
chapters. 
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5.2.1 Deriving the Risk Scores 
The risk score was derived from the analysis of data from African diabetes population 
surveys from Tanzania, Senegal and Guinea. A regression model was built for the diabetes 
risk factors within the data set, and model coefficients were estimated for the different risk 
factors. The risk factors with strong association with undiagnosed diabetes were then 
included in the final model. Each of these risk factors in the final model was assigned a score 
from which a simple questionnaire was derived based on the predictor variables. The derived 
risk score was then internally validated to estimate its predictive accuracy within the 
developmental sample using bootstrap procedure; detailed methods are outlined in chapter 
six. 
5.2.2 External Validation of the Risk Score 
The risk score derived above was externally validated in data sets from population based 
surveys from South Africa, and Guinea. The derived risk score was validated by applying the 
point based score to the validation studies applying the cut off point which maximised both 
sensitivity and specificity. More information is found in chapter 7. 
5.2.3 Comparison of the New Score to Existing Diabetes Risk Scores 
In addition to external validation, the new score was compared with existing scores, by 
applying the risk scores to the validation data sets using the original cut off points and 
performance compared using sensitivity, specificity and AUC. Further methods are described 
in chapter 7 and 8. 
5.2.4 Assessing the Score Performance in a Clinical Setting 
To assess the score performance in a clinical setting, the score was applied to data collected 
from screening of diabetes in a clinical setting in Tanzania, where participants were enrolled 
by invitation. This depicts a setting where the derived tool could be applied. The performance 
of the score is reported in terms of the sensitivity and specificity and also a comparison of the 
number needed to screen to identify one case of diabetes when using and not using the risk 
score. An urban setting was chosen to maximise the yield of individuals with diabetes as 
studies have shown that prevalence of diabetes was higher in urban settings. Also the chosen 
study area has well established diabetes care services were individuals who were diagnosed 
with diabetes were refered for further management. Further details on data collection and 
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methods are outlined in later in this chaper and also in chapter 8 and also in the field manual 
attached in appendix 6. 
5.3 Obtaining the Data Sets 
The data sets for the study was obtained by contacting the study PI’s and Co-PI’s via email 
or in person. The investigators were provided with the information about the study and the 
intended use of the data a description of the variables of interest. The process of obtaining 
data was quite challenging and took about 2 years to get all the data together, also the 
Senegal data set was originally in French, I had to have it translated to English before 
beginning the data analysis process. 
The advantage of the data sets was that data was collected using more or less similar methods 
based on the WHO STEPS guideline with adaptation to suit local settings. The data sets were 
then modified to uniform variables by redefining the categorical variables as outlined in 
Table 5-2. The process of combining the categorical variables was more to do with 
collapsing the different categories to get uniform categories across all studies rather than 
redefining the variables. 
The decision to use a study for either validation or derivation was based on the geographical 
location of the countries and also the availability of data. For example both the South African 
data sets were obtained later on in the course of my studies. 
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5.4 Overview of Study Populations 
5.4.1 Introduction 
The study data was obtained from studies from 4 different countries in Africa. For risk score 
development, data was from population surveys of diabetes prevalence in Tanzania, Guinea 
and Senegal. To assess whether the derived score is applicable to other population, data from 
diabetes population surveys in South Africa were used to externally validate it. Other sets of 
data for validation were from a clinical setting in Tanzania and from a cross sectional survey 
of diabetes in Guinea. 
This chapter provides a snap shot of the background characteristics of participants in each 
study, a brief overview of data collection methods and a summary of study participant 
characteristics across the studies. 
5.4.2 Country Profiles 
General background of countries from which study populations were drawn is included in 
Table 5-1 below. The Republic of Tanzania is an East African country with a population of 
about 45 million (WB, 2010). The country has a total area of about 947,300 square 
kilometres almost four times the size of Guinea and Senegal. Senegal lies at the westernmost 
part of the African continent next to the Atlantic Ocean, at the junction of Europe, Africa and 
America, with a population of about 12 million people (WB, 2010).  
Guinea is a West African country. According to the World Bank Development Indicators 
Database (2010) (WB, 2010), Guinea has a population of about 10 million people. South 
Africa on the other hand is located at the southern tip of Africa, with a population of almost 
50 million people and a total area of just over 1.2 million square kilometres. 
The socio-demographic indicators vary between these four countries (WB, 2010). There is 
marked difference on the income levels between the countries. Gross Domestic Product 
(GDP), is a proxy to measure for standard of living/ wealth. The GDP is highest in South 
Africa.  The value of GDP for South Africa (7,280 USD), is almost seven times that of 
Senegal (1034 USD) and 14 times that of Tanzania (524 USD) and Guinea (452 USD). 
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The level of urbanisation is highest in South Africa, where 62% of the population is urban, 
and lowest in Tanzania where almost 80% of the population is rural. Life expectancy at birth 
is highest in Senegal (57 years) and lowest in South Africa (52 years). The low life 
expectancy in South Africa despite economic growth could be explained by high HIV 
prevalence rates that have devastated the country over the last two decades. 
 
Figure 5-1 Map of Africa Showing Countries Where Data was  Obtained for the Study 
(downloaded from google maps) 
78 
 
 
Table 5-1 General Background Information Profile of Countries Included in the Study 
 Indicator Tanzania Senegal Guinea South Africa 
Area of country (Square Km)* 947,300  196,700  245,900  1,219,100  
Total population (million)*  44.84 12.43 9.98 49.99 
Urban population (% of total)* 26% 43% 35% 62% 
Life expectancy at birth 
(years)* 
57 59 54 52 
GDP per capita (USD)*  524 1,034 452 7,280 
Diabetes prevalence (2011) ** 2.8 3.3 4.4 7.1 
Diabetes prevalence 
projections (2030) ** 
3.5 3.4 4.5 7.4 
 
Source World Bank Development Indicators Database, 2010 (WB, 2010) **IDF (Whiting et 
al., 2011) 
 
The risk of diabetes has been linked to socioeconomic characteristics such as the economic 
status and the degree of urbanization and the population structure. Tanzania, Senegal and 
Guinea have comparable estimates with regard to diabetes prevalence at 2.8%, 3.3% and 
4.4% respectively (Whiting et al., 2011). South Africa had the highest diabetes prevalence of 
about 7%, much higher than many other African countries, which could be explained by 
differences in background characteristics such as the degree of urbanization and exposure to 
western lifestyle (Mayosi et al., 2012). Prevalence of diabetes is expected to increase 
globally; of the four countries Tanzania has the highest predicted increment of 25% in 
prevalence of diabetes by 2030 (Whiting et al., 2011). The section below provides a brief 
description of data collection methods in each of the studies. 
5.4.3 Overview of Data Collection Methods for Studies Used for Deriving the Risk 
Score  
Tanzania Study  
This study was conducted as part of non-communicable diseases project by the Temeke 
Municipality. The study was conducted in Temeke Municipality in Tanzania. Temeke 
Municipality is one of the 3 districts of the capital city of Dar es Salaam.  
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Figure 5-2 Map of Tanzania (image downloaded from www.mapsoftheworld.com) 
According to the 2002 census Temeke Municipality had an estimated population of 768,451 
individuals. The district is mainly sub urban and the majority of its inhabitants are of low 
socioeconomic status compared to other districts of Dar es Salaam. The Objective of this 
study was to examine the prevalence of diabetes and other cardiovascular risk factors in 
Temeke Municipality. This was part of a non-communicable diseases project, which was 
being implemented by the Municipality. 
This was a cross sectional study conducted in 2006. The study enrolled participants aged 24 
to 64 years. Cluster random sampling was used to select participants. The primary sampling 
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unit was the enumeration list from the 2002 census. The secondary sampling units were the 
ten cell clusters, which were used to sample households. Selection of participants at the 
household level was done using Kish method. The total sample size was calculated for the 
study was 1600 participants. A sample size of 768 individuals were calculated based on 5% 
precision and 95% confidence interval, 50% prevalence and design effect of 2. This sample 
size was multiplied by two to give sufficient sample size for gender subgroup analyses. 1637 
individuals were contacted to participate in the study; a total of 1486 individuals took part, 
which gives a response rate of 91%. The survey questionnaire used was an adaptation of the 
WHO STEPS survey questionnaire (WHO, 2009). The questionnaire captured the following; 
demographic information; behavioral measures on the consumption of tobacco, alcohol, 
fruits and vegetables and assessment of physical activity.  Self-reported information on 
hypertension, diabetes, dyslipidemia and family history of cardiovascular diseases was also 
included. In addition the questionnaire also contained measures of socio economic status. 
Measures of diet and physical activity were also self-reported. 
Blood pressure was taken using an electronic sphygmomanometer (OMRON®).  Blood 
pressure was taken at rest, with patient seated and the arm elevated at the level of the heart. 
The weighing was done in kilograms (kg) with a digital weighing scale (NIKAI®) on a 
stable and flat surface in a person with light clothing. Height was measured in centimetres, 
using a folding wooden height ruler. Waist circumference measurements were done using a 
tape measure using standard methods. Fasting blood samples were taken following an 
overnight fast. Fasting blood glucose and total cholesterol were measured using an 
Accutrend® portable machine.   
The strength of the study is that this was a population based survey incorporating individuals 
who were randomly selected for participation in the study. Data collection was done using an 
adaptation of a standard questionnaire (WHO, 2009)  which has been widely used in the 
African context and therefore is likely to be comparable with studies that have used a similar 
method.The major weakness of the study is that there were no objective measures of physical 
activity and the assessment of dietary measures did not use standard validated methods. Use 
of fasting blood glucose and use of portable meters to define diabetes status, is likely to 
under estimate the true prevalence of diabetes in this population. The study population is 
likely to have low prevalence of diabetes being suburban, and may lead to over fitting of the 
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model in this population due to low number of participants with the outcome (Frank E. 
Harell, 2001) therefore the findings may not reflect the true performance of the risk score in 
this population.  
The St. Louis Study (Senegal) 
The study was conducted by the faculty of Medicine at the University of Sheikh Anta Diop in 
Dakar Senegal.The study was conducted in the city of Saint Louis. Saint Louis is the former 
capital of the colony of Senegal, third largest city of the country and second maritime port of 
Senegal. Saint-Louis has an estimated population of 190,000 inhabitants. 
Objectives of this study were to examine the burden of cardiovascular risk factors such as 
prevalence of obesity, dyslipidemia, hypertension and behavioral risk factors in urban areas 
of Saint Louis in Senegal.  
This was a cross sectional study, conducted in 2010 which included participants 15 years and 
older. Participants were sampled using clustered systematic random sampling. The sampling 
frame was represented by data General Census and housing Survey of Saint Louis. A total of 
120 clusters of 10 individuals each were taken to constitute the study sample. Sampling was 
based on probabilities proportional to the size of the primary sampling units. The most 
populous districts had more clusters. Taking 2% accuracy, a prevalence of 6.7% and a 
confidence level of 95%, the calculated sample size was 600 individuals. To cancel the effect 
cluster phenomenon, the estimated minimum sample size required was 1200 individuals.  
The sudy enrolled a total of 1,424 participants, about 17% more cases than the calculated 
sample size, with more than 99% response rate for the almost all variables included in the 
study (Table 5-3).  
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Figure 5-3 A map of Senegal (image downloaded from www.mapsoftheworld.com) 
The survey questionnaire used was also an adaptation of the WHO STEPS survey 
questionnaire (WHO, 2009) . The questionnaire captured the following; demographic 
information; Behavioral measures on the consumption of tobacco, alcohol, fruits and 
vegetables and assessment of physical activity. Included also were questions on background 
information on hypertension, diabetes, dyslipidemia, general health and family history of 
cardiovascular diseases.  
Blood pressure was taken using an electronic sphygmomanometer (OMRON®).  Blood 
pressure was taken at rest, with patient seated and the arm elevated at the level of the heart. 
The weighing was done in kgs with a bathroom scale on a stable and flat surface in a person 
with light clothing. Height was measured in centimetres, using a portable stadiometer .Waist 
circumference measurements were done using a standard nine metre tape measure, applied 
directly to the skin. This measure was done at the axillary line, halfway between the lower 
base of the last rib and the iliac crest on each side. 
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Participants were invited for laboratory measurements. Blood samples were collected for 
fasting glucose (FBG), serum creatinine, total cholesterol (TC), HDL cholesterol, 
triglycerides (TG), and urea and serum creatinine from all individuals and analysed 
immediately using Reflotron Plus ® (Boehringer Mannheim) machine. 
Similarly data were collected using an adaptation of the WHO steps questionnaire (WHO, 
2009). The study was conducted in an urban area of Senegal; therefore prevalence of diabetes 
is likely to be high in this population compared to the Tanzania data, which was collected in 
a sub urban population, and therefore likely to have high number of people with the outcome 
of interest.  
The weakness of this study is similar to the Tanzania study in respect that diagnosis of 
diabetes was made using a single fasting glucose measurement. The questions on diet and 
physical activity were modified to suit that particular population and do not particularly 
measure the two indices objectively.  Findings are therefore likely to be biased. 
The Guinea Derivation Study 
 
The study was conducted in collaboration between the Ministry of Health Guinea and 
University Hospital of Conakry - Donka in Guinea. The overall objective of the study was to 
conduct a national NCD survey  to contribute to the development of promotional programs, a 
healthy diet, prevention and treatment of hypertension, obesity, diabetes, high cholesterol, 
smoking and physical inactivity in Guinea. The specific objectives were to describe the 
current epidemiological characteristics of NCDs and their risk factors in Guinea, to have a 
representative database for epidemiological surveillance and to collect data to determine the 
health needs for NCDs. 
 
The study was conducted in the seven administrative regions Guinea (N'Zérékoré, Kankan, 
Faranah, Mamou, Labe, Boke, Kindia) and Conakry. In total 330 and 303 urban and rural 
communities were sampled respectively from the regions.   The study was a descriptive and 
analytical observational, cross-sectional study (cross sectional study) on Arterial 
Hypertension, obesity, diabetes, tobacco use, physical activity and cholesterol. 
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Figure 5-4 Map of Guinea (image downloaded from www.mapsoftheworld.com) 
 
The study used an adaptation of the STEPS questionnaire (WHO, 2009). The first step (Step 
1) concerns the socio-demographic information, measures behavioral issues of physical 
activity, and food hygiene. The behaviour measures were related to tobacco and alcohol. 
Questions on health food, consumption of fruits and vegetables were adapted to Guinean 
habits. In the second (Step 2) the following physical parameters were assessed: height, waist 
circumference, weighing and blood pressure. Height was measured in centimetres, using a 
portable measuring board on the floor. Weight was measured in kilograms (kg) and reading 
taken to the nearest 100g using a balance scale placed on a stable surface, with person 
dressed in light clothing. Waist circumference was measured using a tape measure, applied 
directly to the skin, at the axillary line midway between the lower base of the last rib and the 
iliac crest of each side, the measurement was taken once to the nearest 0.1 cm. Blood 
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pressure was be taken using an electronics Blood pressure device measured twice. Systolic 
and diastolic blood pressures were taken on the right arm after 5 minutes of rest without 
crossing the arms/ legs. In Step 3, four biochemical parameters were measured: fasting 
glucose, triglycerides, total cholesterol and HDL-cholesterol.Blood glucose is measured 
using a Hemocue analyser. Triglycerides and HDL-cholesterol were measured only in a 
subsample of subjects and analysis was done using a Daytona Spectrophotometer ® brand 
Randox at the Central Laboratory of the University Hospital of Donka-Conakry.  Assays 
were done by enzymatic methods. 
Sampling was done using stratified cluster sampling (representative selection of 
neighbourhoods and districts). To reflect this, the sample size was multiplied by the effect 
size of the sampling plan. An effect size of 2 (two) was assumed. Available data estimate the 
prevalence of diabetes in 6% and 8% obesity and hypertension in 30% in rural areas (Balde 
et al., 2007). With desired precision of 0.05, and Cluster effect of two (2) and anticipated 
non-respondents of 20% the calculated sample size is approximately 1000 subjects per site 
rural and urban. Participant eligible for the study were those; aged 25 years or older, residing 
in the geographic locations (neighbourhood or district) selected, regardless of gender, 
religious, ethnic or social group and have lived 6 months or more in the selected area. The 
refusal to participate in the survey was a criterion for non-inclusion in the study. 
To account for the assumption of rural gradient / urban distribution in the NCD burden 
stratification by urbanization was made in each of the natural regions. The criteria for 
classification urban and rural was the size and population density, accessibility, the 
traditional way of life, degree of urbanization and the main economic activity. 
Geographic locations (urban and rural) were drawn from each stratum.  The five primary 
units were defined in advance. These were the four natural regions (Lower Guinea, Middle 
Guinea, and Upper Guinea Forest Guinea) and Special Area of Conakry. Secondary sampling 
units were the districts and tertiary units were the households. The final sampling unit were 
the individuals whose age is between 25 and 64 years. The study enrolled 2490 participants, 
25% more participants than the estimated required sample size, with about 99 % response 
rates of variables included in the study (Table 5-3). 
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A procedure for checking the quality of data and quality control was put in place including; 
validation of the questionnaire and protocol, pre-test, training of investigators, duplicate data 
entry, Centralization of laboratory tests and quality controls. The research protocol was 
approved by the National Ethics Committee of the Ministry of Health Guinea. 
The strength of this data was that data was a nationally representative sample collected from 
all administrative regions. Data was collected using an adaptation of the WHO steps tool 
therefore data can be merged with other studies without the need to redefine variables.  
The weakness of the study is that it did not have a family history variable therefore this was 
not included in the process of developing the model.
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5.4.4 Overview of Data Collection Methods for Studies Used for Externally 
Validating the Risk Score  
The Capetown Study (CRIBSA) 
The study was conducted by the University of Capetown. The study population involved 
participants selected from Black African areas of Langa, Guguletu, Crossroads, Nyanga and 
Khayelitsha townships in Cape Town (Peer et al., 2012). 
 
Figure 5-5 Map of South Africa (image downloaded from www.mapsoftheworld.com) 
The study sought to; (1) ascertain the prevalence of, and associations with, diabetes in adults 
living in predominantly black residential areas of Cape Town and to compare these findings 
with a previous diabetes prevalence study which was conducted in 1990; (2) examine the 
association between diabetes and psychosocial stress using selected validated questionnaires 
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This was a cross sectional study. Data were collected in 2008/2009. The target population 
was 25-74-year-old residents living in the predominantly black African areas mentioned 
above. These were sampled to provide some overlap with the surveys conducted previously 
in 1990 (Levitt et al., 1993). The estimated sample size of 1000 was based on an estimated 
diabetes prevalence of 8% with a precision of 1.5% two-sided with 95% confidence.  
Participants were sampled using the 2001 census data and aerial maps, a 3-stage cluster 
sampling stratified by area and housing type was done as follows: stage 1) random sampling 
of residential blocks within the main strata; stage 2) systematic sampling of plots, flats or 
structures within blocks; stage 3) individuals from households were selected using quotas for 
pre-specified age and gender categories. Sampling across the areas and age groups were 
disproportionate. Langa was oversampled to accommodate a secondary study. Younger age 
groups were under-sampled and older age groups were over- sampled to ensure at least 50 
men and women in each gender category. The following were excluded; unable to give 
consent, on tuberculosis treatment, on antiretroviral therapy, received cancer treatment within 
the last year, bed ridden, pregnant or lactating, or resident in Cape Town for less than 3 
months. Replacements were allowed when individuals who met the exclusion criteria above 
refused, or the randomly selected participant of the randomly selected household could not be 
contacted on the third attempt. The number of participants enrolled in the study was more 
than the calculated sample size, but the overall response rate for the study is reported to be 
86%. For the variables included in this study, the response rate was more than 99% of almost 
all the variables except for OGTT measurement which had a response rate of 96.2% (Table 
5-3). 
Fieldworkers administered questionnaires to obtain socio-demographic and migratory 
information, self-reported medical and family history, physical activity patterns (Global 
Physical Activity Questionnaire (GPAQ) and tobacco and alcohol use were assessed based 
on WHO NCD STEPSwise surveillance questionnaire (WHO, 2009). Self-reported food 
intake during the preceding 24 hours was determined by a single 24-hour dietary recall using 
semi-structured interviews.  
Height, weight, and waist and hip circumferences were measured using standardised 
techniques (Alberti et al., 2005) . Three blood pressure (BP) measurements were taken at 
two-minute intervals using an automated Omron® BP monitor with an appropriately sized 
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cuff after the participant had been seated for five minutes. The average of the second and 
third BP measurements was used in the analysis. 
Blood samples, for glucose were taken after an overnight fast of 10 hours.  A standard oral 
glucose tolerance test (OGTT), using 75 grams of anhydrous glucose in 250 ml of water, was 
administered, and blood samples taken 120 minutes later. Blood samples were kept on ice 
and transported to the laboratory within six hours to be centrifuged and aliquoted. Samples 
were analysed using glucose oxidase method with an auto analyser (Beckman, Fullerton, CA) 
The strength of this study is that it is also a population survey with participants randomly 
selected. The study was conducted among black communities and therefore presents an 
opportunity to validate the score in populations of similar ethnic background as the score 
derivation data, as studies have suggested coloured South Africans  have much higher 
diabetes prevalence (Erasmus et al., 2001, Omar et al., 1985). The major strength of this 
study is that the diagnosis of diabetes was made using plasma samples and 2hr OGTT. The 
OGTT results present an opportunity to validate the score using various definitions of 
diabetes; fasting alone, fasting and 2hr OGTT and also to look at the performance of the 
score with regard to identifying cases with Impaired Glucose Tolerance. 
The weakness of the study is that older adults were oversampled; therefore the prevalence of 
diabetes in this population is likely to be an overestimation of the true prevalence of diabetes 
in black South Africans 
The Kwazulu Natal Study 
The study was conducted by the University of Kwazulu Natal. Kwazulu Natal is one of the 9 
provinces of South Africa (Figure 5-5), densely populated accounting for more than one-fifth 
of the total South African population. The total population of Kwazulu Natal was, 
10,819,100 (2011 estimates). Africans constitute the majority of the population. The study 
was done in the Ubombo District of rural Kwazulu Natal. 
The objectives of the study were to determine the prevalence of diabetes, impaired glucose 
tolerance, impaired fasting glycaemia and its associated risk factors in a rural South African 
Black community. 
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This was a cross sectional study of a predominantly rural South African community. Details 
of the methods and findings have been published (Motala et al., 2008). The study enrolled 
individuals more than 15years living in Ubombo district. The estimated sample size was 
1300 calculated assuming a prevalence of 9%, and a precision of 2.5% at a 95% confidence 
level, and adjusting for a 30% non-response rate. The study employed a cluster random 
sampling method to select households for the survey. Of the total 1300 participants sampled, 
1025 (210 men and 815 women) participated, giving an overall response rate of 78.9%. 
Seventy percent (70%) of the non-responders were men. The response rate for the study 
variables was over 99% for all the variables included in this study (Table 5-3). 
Questionnaires were translated into the local language; interviews were conducted by trained 
personnel either at the respondent’s home or at a local community centre. The questionnaire 
was developed based on the WHO field guide for diabetes and non-communicable diseases 
risk factors (WHO, 2009). The questionnaire included questions on socio-demographic 
information, urbanization, family history of diabetes, and behavioral risk factors such as 
smoking, current alcohol consumption and physical activity. 
Height was measured with a measuring tape to the nearest cm. Weight was measured in light 
clothing and without shoes, using a floor digital scale to the nearest 0.1 kg. Waist and hip 
circumference were measured using a flexible tape measure following standard methods 
(Alberti et al., 2005) 
Blood pressure was measured twice, 30 minutes apart, with the participant sitting, using a 
sphygmomanometer; the mean of the 2 readings was used in the analysis. 
All participants underwent Oral Glucose Tolerance measurement. Venous blood samples 
were drawn after an overnight fast and 2 hours after the ingestion of 75g glucose load 
dissolved in 250 mls of water. The blood samples were then kept on ice, transported to the 
lab and centrifuged within 6 hours of collection. The separated plasma was stored at -30 
degrees until analysis. Plasma glucose was determined using glucose oxidase method 
Boehringer Mannheim (Mannheim, Germany). 
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The strength of this study is that it was a population based study with random selection of 
participants. Diagnosis of diabetes was also based on 2 hr OGTT and therefore provides good 
estimates of diabetes prevalence.  
The main weakness of the study is that the study has an overrepresentation of female 
participants; almost 75% of respondents were females. The higher percentage of female 
respondents could affect the performance of the score in this population, because of possible 
differences between sexes in various diabetes risk factors such as obesity, physical activity 
levels etc. 
Tanzania Validation Study  
Data for this study was collected as part on my PhD study. The study was conducted in Dar 
es Salaam region, in Temeke, Mwananyamala and Amana Municipalities. Participants were 
recruited at the 3 Municipal Hospitals following invitations to participate using posters and 
outreach mobile vans that were sent to the communities around these 3 hospitals. The 
objective of this was to collect data to evaluate the performance of a diabetes risk score 
within a setting where individuals are freely invited to participate. This was a cross sectional 
study conducted in 2011 to 2012. Participants aged 34-65 were invited. Details of methods 
are included in Appendix 6.  
The total sample size calculated for the study was 1200 participants. The sample size was 
calculated based on the minimum number of patients with the outcome and the expected 
prevalence. About 1081 people were enrolled to the study, with the overall response rate of 
90% and about 99% response rates to almost all the variables included in the study see Table 
5-3. Data were collected by 2 to 3 study nurses in each site who had been previously trained 
on diabetes, and received a 2 days training on the questionnaire and how to perform the 
physical measurements for the study. Blood and urine samples were collected by the study 
laboratory assistant. The main challenge for the data collection was having to supervised 3 
different data collection sites; a decision was then made to collect data from the sites on 
alternate weeks after the first week of data collection. 
The survey questionnaire used was an adaptation of the WHO STEPS survey questionnaire 
(WHO, 2009). The questionnaire captured the following; demographic information; 
behavioural measures on the consumption of tobacco, alcohol, fruits and vegetables and 
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assessment of physical activity. Self-reported information on hypertension, diabetes, 
dyslipidemia, and family history of cardiovascular diseases was also included. In addition the 
questionnaire also contained measures of socio economic status, diet and physical activity 
which were also self-reported. Blood pressure was taken using an electronic 
sphygmomanometer (OMRON®).  Blood pressure was taken at rest, with patient seated and 
the arm elevated at the level of the heart.  
The weighing was done in kilogram (kg) with a digital weighing scale (SECA®) on a stable 
and flat surface in a person with light clothing. Height was measured in centimetres, using a 
portable stadiometer (SECA®). Waist circumference measurements were done using a tape 
measure using standard methods (Alberti et al., 2005).  
In addition to the questionnaires and physical examination, patients were requested to return 
to the clinics to provide fasting blood sample for blood glucose, creatinine and cholesterol 
measurements, as well as bring morning urine samples for urine albumin and creatinine 
measurements. Patients were instructed to fast for at least 8 hours before the test. All tests 
were performed by a trained technician. Blood was taken by finger prick, and measured using 
Hemoque® 201 analyser.  
Blood was also taken for lipid measurements; High Density Lipoprotein Cholesterol (HDL), 
Total Cholesterol (TC), and triglycerides (TG) and Creatinine. Four mls of venous blood was 
drawn from anterior cubital fossae, and placed in a plain vacutainer. Blood was kept at room 
temperature and was analysed the same day, within hours of sample collection. Samples were 
analysed using fully automated biochemistry analysers by the direct end point enzymatic 
method. 
Patients were instructed to bring morning urine samples, after providing them with a sterile 
urine container, samples were analysed on the same day of collection, if the samples could 
not be analysed within hours of collection, they were refrigerated and analysed within days 
after allowing returning to normal temperature. Prior to analysis of albumin and creatinine, 
samples were screened for infection and overt proteinuria using MULTISTIX® 10 SG strips. 
Those found to have blood traces, leucocytes or protein were excluded. Samples were then 
analysed for albumin and creatinine using CLINITEK® Microalbumin Reagent Strips on the 
CLINITEK STATUS® urine analyser. The two values were used to calculate albumin 
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creatinine ratio. Albumin Creatinine ratio was classified into normal (<30mg/g), 
microalbuminuria (30 to 300mg/g) and macroalbuminuria (>300mg/g) (Sacks et al., 2002). 
A third of the patients at Mwananyamala hospital underwent Electrocardiography (ECG) 
measurements (12 lead ECG) using a MAC® 1200 ECG machine. However due to time 
constraint these were not analysed and therefore the finding are not included in this report 
Data was entered using Epi Data Software, the data entry questionnaire was designed with 
checks to ensure that incorrect entry are minimised for example the probable minimum and 
maximum values for continuous variables. The data was then exported to STATA 12 
software for cleaning and analysis.  
The strength of the study is that data were collected using an adaptation of standard 
questionnaire which has also been used by a number of studies including those included in 
this study. The study has a number of variables that can be used to compare the yield of 
scores across different outcomes of interest, such as micro-albuminuria and lipids levels. 
The major weakness of the study was that participant enrolment was by convenient sampling 
where individuals fitting the inclusion criteria were invited to participate therefore more 
likely to attract individuals at high risk, and hence more likely the score will have more yield 
than if the score were to be applied to a general population selected at random. Also the 
results of the study may be biased and therefore can not be generalised to the Tanzanian 
population. 
The Guinea Validation Study 
The study was conducted by University Hospital of Conakry - Donka in Guinea. Guinea is a 
West African country with a tropical climate. At the time when the study was conduted in 
2003, according Guinean census, the population was made up of 7156,406 inhabitants with 
49% men and 51% women. The rural population was estimated at 70% of subjects and 60% 
of Guineans are under 20 years of age. 
Futa Jallon province, in the north of the country, had a population of 1639,617 inhabitants 
and the Fulani represent the predominant ethnic group. Labé, the largest city in Futa Jallon, 
was selected for the urban survey while Fellö-Koundoua (in the prefecture of Tougué) was 
chosen for rural sampling. Labé is the fourth largest city in Guinea, situated 431 km north-
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east of Conakry with a population of 79,347. Fellö-Koundoua is 193 km further north, 
between Labé and Tougué, and has a population of 5932. Choice of this latter site was based 
on criteria defining its rural situation (isolation, difficulty of access by road, low levels of 
infrastructure, traditional lifestyle and diet) contrasting with that of the urban zone of Labé 
(Figure 5-4). 
Objectives of the study were to study the prevalence of diabetes and its associated risk 
factors. This was a cross sectional study, conducted in February 2003 , methods and  results 
of which have been published previously (Balde et al., 2007). A sample size of 384 was 
determined, based on an estimate of diabetes prevalence of 50%, to obtain an absolute 
precision of 5% for the 95% confidence interval. This sample size was multiplied by the 
maximum design effect for clustering of two to give a sample of 768. To allow for a non-
response rate of 30%, a final sample size of 1000 per community was employed. Houses 
were randomly selected from the list of the Guinean census. All residents of these houses 
aged 35 years and over were invited to take part in the study. Non-participation linked to 
absence was recorded after two visits to the household. The overall participation rate was 
70% with 1537 of the 2000 individuals who were to be enrolled. 
After informed consent was obtained, subjects were taken through a questionnaire 
administered in one session which recorded name, age, sex, ethnic group, medical history, 
obstetric history and family history of diabetes mellitus. The questionnaire was orally 
translated into Fulani for persons who did not understand French Height was measured with a 
measuring tape to the nearest cm. Weight was measured in light clothing and without shoes, 
using a floor digital scale to the nearest 0.1 kg. Waist and hip circumference were measured 
using a flexible tape measure. After at least 10 min rest, blood pressure was measured in the 
right arm of seated subjects on two occasions, at an interval of 1 min, using an appropriate 
size sphygmomanometer. Subjects were examined during the morning after fasting since the 
previous evening meal. Capillary whole blood was obtained from a finger puncture and was 
immediately analysed using a Hemocue blood glucose analyser (Hemocue
®
 AB, Box 1204, 
26223 Angelholm, Sweden). 
Strength of the study is that the study enrolled participants randomly and there was a uniform 
data collection tool using STEPS methods. 
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5.4.5 Summary of the Studies 
Summary of Study Characteristics 
The score derivation cohorts included participants from cross sectional studies. The studies 
included participants from rural, peri-urban and urban areas. The studies enrolled participants 
aged 15 years and above. The derivation cohort comprised of a total of 5411 participants, 
1496 (27.6%) from Tanzania, 1424 (26.3%) from Senegal and 2490 (46%) from Guinea 
respectively. The surveys were carried out from 2006 to 2011 based on the WHO STEPS 
methods for chronic non-communicable disease research. Information from participants was 
obtained by interviewer administered questionnaires and physical measurements were 
performed by trained personnel. Information on lifestyle factors such as physical activity and 
smoking were self-reported. Table 5-2 summarizes how each of the categorical variables was 
coded in the data sets.  
Physical activity was assessed using the GPAQ in Tanzania and Guinea data sets where 
participants were asked about the domains (leisure, work, commuting), number of days 
(frequency) and intensity of physical activity. In the Senegal survey the assessment was 
based on the type of physical activity that participants engaged with. Regarding smoking 
behaviour participants were asked whether they were current/ past smoker or non-smoker. 
History of high blood pressure and diabetes was ascertained by asking participants whether 
they have ever been diagnosed with the condition by a health care worker. Presence of 
hypertension was defined as a positive history of hypertension and or systolic blood pressure 
of more or equal to 140 mmHg and or a diastolic blood pressure of more or equal to 90 
mmHg. Family history of diabetes was assessed by asking participants about history of 
diabetes in their first degree relatives (parents, children or siblings). Information on family 
history of diabetes was only available for the Senegal data. In all the derivation studies blood 
glucose was measured by a single fasting blood glucose measurement. 
Four studies were used to validate the score and to compare performance of the newly 
developed score to existing diabetes scores for predicting prevalent diabetes. Three of the 
studies used for validation are community based studies; these include the 2 South Africa 
studies and the Guinea study. The Tanzania validation study was a hospital based study 
where individuals were invited for screening, depicting a typical clinical setting where the 
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score could be applied to screen individuals at high risk. Two of the studies are from South 
Africa, one conducted in a rural black community in Kwazulu Natal where a total of 1025 
participants were enrolled and the other from a predominantly black community in Cape 
Town in 2008 with a total of 1116 participants. The Tanzania and Guinea validation studies 
had a total of 1081 and 1537 participants respectively. Assessment of lifestyle measures and 
other categorical variables were the same as described for the derivation studies except for 
physical activity in the South African studies where it was assessed as leisure and 
occupational physical activity. Occupational physical activity was assessed by intensity only, 
where participants were asked to rate their occupational physical activity as either sedentary, 
light, moderate, or vigorous and leisure physical activity was assessed by frequency ranging 
from never to more than 3 times a week, Table 5-2. In the validation studies blood glucose 
was measured by fasting and oral glucose tolerance test; (OGTT) in the 2 South African 
studies and by fasting glucose alone in the Tanzania and Guinea validation studies. 
 The different studies used different diagnostic criteria for diagnosing diabetes; the studies 
that used fasting glucose alone might have underestimated the true prevalence of diabetes in 
the studied populations and therefore may affect the overall performance of the score in the 
populations but given that also in the derivation studies the diagnosis of diabetes was done 
based on fasting glucose alone, the risk score comparisons are done based on the fasting 
glucose. In addition OGTT is also used as the gold standard in evaluating the performance of 
the risk score in the South Afrcan validation studies, given that fasting glucose and OGTT 
identify different spectrum of people the performance of the score is likely to be different 
between the two groups.  
Completeness of Data 
Table 5-3 shows a summary of the availability of data across countries for all variables used 
in the analysis. The studies overall had good response rates of more than 80%, except for the 
Guinea study that was used for validation which had a low response rate of 70, there is no 
available data on the individuals who did not participate in the Guinea study to make possible 
comparisons with those who participated. 
Attempts were made to analyse the pattern of missing data using the misstable command in 
STATA in the different data sets and these revealed that the data were missing completely at 
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random (MCAR) , there were no specific patterns of missing data that were observed. Since 
data were missing at random and only about < 5% of the data were missing, complete case 
analysis was done for both model derivation and validation. Although complete case analysis 
is acceptable with low levels of missing data, it could introduce bias since not all the 
information is available for the analysis, and may reduce statistical power if many cases are 
left out in the analysis. 
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Table 5-2 Categorical Variable Coding in Derivation and Validation Data Studies 
Variable Derivation studies Validation studies  
Tanzania Senegal Guinea CRIBSA KZN Tanzania Guinea Combined 
Educatio
n level 
Less than 
primary/ 
primary/sec
ondary/ 
college/grad
uate /post 
graduate 
Less than 
primary/ 
primary/seco
ndary/ 
college/gradu
ate /post 
graduate 
No formal 
schooling/ 
Less than primary 
school/ 
Primary school 
completed/ 
Secondary school 
completed/ 
High school 
completed/ 
College/University 
completed/ 
Post graduate 
degree 
No variable No variable No formal 
schooling/ 
Less than primary 
school/ 
Primary school 
completed/ 
Secondary school 
completed/ 
High school 
completed/ 
College/University 
completed/ 
Post graduate 
degree 
 
No formal 
schooling/ 
Less than 
primary school/ 
Primary school 
completed/ 
Secondary 
school 
completed/ 
High school 
completed/ 
College/Univer
sity completed/ 
Post graduate 
degree 
Less than 
primary/primary/s
econdary/tertiary 
History 
of high 
Blood 
Pressure 
(ever told 
by health 
worker) 
 (yes/no) (yes/no)  yes/no  Yes/ No/ 
Don’t know 
 Yes/ No/ 
Don’t know 
Yes/No Yes/No Yes/No 
Physical 
activity 
Participate 
in 
occupational 
or leisure; 
moderate/Vi
Participate in 
physical 
activity (Yes, 
No) 
Type of 
Participate in 
occupational or 
leisure; 
moderate/Vigorou
s physical activity 
Occupational 
physical 
activity; 
sedentary/    
light/moderat
Occupationa
l physical 
activity; 
sedentary/    
light/modera
Participate in 
occupational or 
leisure; 
moderate/Vigorou
s physical activity 
Participate in 
occupational or 
leisure; 
moderate/Vigor
ous physical 
Variable omitted 
in model 
derivation, used in 
validation 
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Variable Derivation studies Validation studies  
Tanzania Senegal Guinea CRIBSA KZN Tanzania Guinea Combined 
gorous 
physical 
activity 
(yes/no) 
 days and 
duration 
physical 
activity 
Number of 
days and 
duration 
(yes/no) 
 Number of days 
and duration 
e/heavy 
Leisure 
physical 
activity; 
never/ < once 
per wk/ 1-2 
times per wk/ 
3+ times per 
wk 
te/heavy 
Leisure 
physical 
activity; 
never/ < 
once per wk/ 
1-2 times 
per wk/ 3+ 
times per wk 
(yes/no) 
 Number of days 
and duration 
Activity 
(yes/no) 
 Number of 
days and 
duration 
Tobacco Current, 
Daily, past 
smoker (yes 
/no) 
Number and 
type 
Current, 
Daily, past 
smoker (yes 
/no) 
Number and 
type 
Current, daily, 
past smoker (yes 
/no) 
Number and type 
Yes/ No /ex-
smoker 
Yes/ No /ex-
smoker 
Current, Daily, 
past smoker (yes 
/no) 
Number and type 
Current, Daily, 
past smoker 
(yes /no) 
Number and 
type 
Never/ 
current/past 
smoker 
History 
of 
Diabetes  
Yes/ No Yes/No Yes/ No Diabetes 
1=yes 2=no 
Diabetes 
1=yes 2=no 
Yes/ No Yes/ No Yes/No 
Family 
history of 
diabetes 
No variable Yes/No No variable Yes/No Yes/No Yes/No No variable Variable not used 
in validation 
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Table 5-3 Pattern of Missing Data in the Derivation and Validation Studies 
Characteristic Derivation Validation 
 Overall Tanzania Senegal Guinea CRIBSA KZN Tanzania Guinea 
N 5411 1496 1424 2490 1116 1025 1081 1537 
Age 100% 100% 100% 100% 100% 99.8% 100% 100% 
Sex 100% 100% 100% 100% 100% 100% 100% 100% 
Waist 
Circumference 
99.3% 97.9% 99.9% 99.8% 99.9% 99.3% 98.8% 100% 
BMI 99.3% 99.5% 99.8% 99% 100% 99.2% 97.4% 100% 
History of 
Hypertension 
100% 100% 100% 100% 100% 99.8% 99.9 - 
Mean SBP 99.7% 99.2% 100% 99.9% 99.8% 99.8% 99.4% 100% 
Mean DBP 99.7% 99.2% 100% 99.9% 99.8% 99.8% 99.4% 100% 
Smoking 99.9% 99.9% 100% 100% 100% 99.8% 100% - 
FBG - 92% - 98.1% 98.6% 99.6% 96.7% 100% 
2hr OGTT - - - - 96.2% 96.6% - - 
History of Diabetes 100% 100% 100% 100% 99.9% 100% 99.9 100% 
Family History of 
diabetes 
- - 100% - 100% 100% 99.5 - 
Physical activity 98% 100% 95.2% 99.0% 99.7% 99.8% 99.2% - 
Smoking 100% 100% 100% 100% 100% 99.8% 100% - 
Education level 99.9% 100% 100% 99.9% - - 100% - 
Diabetes diagnosis - - 100% - - - - - 
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5.4.6 Characteristics of Respondents in the Derivation and Validation Studies 
Table 5-4 shows the summary characteristic of study respondents for both the derivation and 
validation studies. The mean age for the derivation studies ranged from 34.1 years to 43.6 years, 
with Senegal having the lowest mean age across the 3 countries. Over all mean age for the 
combined derivation cohort were 39.2 years and 47.1 years for the validation studies. The mean 
age for the validation studies ranged from 43.9 years in the Cape Town (CRIBSA) study to 49.4 
years in the Guinea study. Overall participants of all studies were mostly female, highest being the 
Kwazulu Natal study where almost 80% of study respondents were female. In score derivation 
studies the mean waist circumference ranged from 82.0 cm to 85.4 cm in the Guinea and Tanzania 
studies respectively, with a mean of 83.6 cm in the combined score derivation data set. In the 
validation studies high mean waist circumference is reported in the CRIBSA and Tanzania study 
with mean waist circumference of 93.2 cm and 93.3 cm respectively. Mean BMI values follows a 
similar pattern as the waist circumference with highest mean BMI of 26.0 kg/m2 in the Tanzania 
study and the lowest mean BMI of 22.9 kg/m2 in Guinea study among the derivation studies. For 
validation studies BMI ranges from 22.7 kg/m2 in the Guinea study to 29.9 kg/m2 in the CRIBSA 
study. In the derivation studies hypertension was highest in the Senegal study with 44.2% of 
participant being classified as hypertensive by blood pressure measurements, and 23% of their 
study participants had a prior history of hypertension. Mean systolic (135.5 mmHg) and diastolic 
blood pressure (87.9 mmHg) was also highest in the Senegal study compared to other derivation 
studies. Among the validation studies highest prevalence of hypertension was in the Tanzania 
study, with 26.7% of respondents having prior history of hypertension and 36.6% being classified 
hypertensive upon blood pressure measurement, with mean systolic and diastolic blood pressure 
of 134.3 and 81.1 mmHg respectively. 
The prevalence of diabetes varies greatly in the various populations used in this study.  For the 
derivation studies the prevalence of diabetes ranges from 3.6 % in Tanzania to 10.4% in Senegal 
and in validation studies the prevalence of diabetes ranges from 4.4 in the Kwazulu Natal study to 
14.9 in the Tanzania study.
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Table 5-4 Summary of Participants Characteristics in the Derivation and Validation Studies  
 
Characteristic 
Derivation Validation 
Overall Tanzania Senegal Guinea CRIBSA KZN Tanzania Guinea Overall 
N 5411 1496 1424 2490 1116 1025 1081 1537 4759 
Age in years (SD) 
39.2 
(15) 
43.6 
(11.4) 
43.4 
(17.8) 
34.1 
(13.6) 
43.9 
(13.1) 
46.9 
(18.9) 
47.1 
(12.4) 
49.4 
(12.9) 
47.1 
(14.5) 
Sex (% Male) 
2259 
(41.7%) 
676 
(45.3%) 
441 
(31%) 
1140 
(45.8%) 
399 
(35.8%) 
210 
(20.5%) 
347 
(32.1%) 
730 
(47.5%) 
1656 
(35.4%) 
Waist Circumference 
in cm (SD) 
83.6 
(13.7) 
85.4 
(13.1) 
84.6 
(15.9) 
82.0 
(12.7) 
93.2 
(15.5) 
85.6 
(13.2) 
93.3 
(14.5) 
76.7 
(11.5) 
86.2 
(15.4) 
BMI in kg/m
2
 (SD) 
24.4 
(5.8) 
26.0 
(5.7) 
25.5 
(6.4) 
22.9 
(5.0) 
29.9 
(8.4) 
25.2 
(6.7) 
27.2 
(6.0) 
22.7 
(3.8) 
25.9  
(6.8) 
∞
Hypertension, n (%) 
1930 
(35.7%) 
542 
(34.5 %) 
628 
(44.2 %) 
760 
(30.5%) 
365 
(32.5%) 
270 
(26.5%) 
394 
(36.6%) 
483 
(31.4%) 
1512 
(31.7%) 
Hypertension History, 
n (% ) 
803 
(14.8 %) 
270 
(18.0 %) 
328 
(23 %) 
205 
(8.2%) 
342 
(30.6%) 
167 
(16.3%) 
288 
(26.7%) 
- - 
Mean SBP (mmHg) 
131.2 
(22.6) 
131.7 
(23.1) 
135.5 
(26.7) 
130.9 
(22.3) 
126.2 
(23.3) 
126.3 
(27.7) 
134.3 
(25.6) 
126.9 
(25.1) 
128.3 
(25.5) 
Mean DBP (mmHg) 
82.6 
(13) 
82.3 
(13.0) 
87.9 
(15.4) 
79.0 
(13.1) 
82.0 
(13.2) 
80.0 
(17.3) 
81.1 
(14.1) 
78.9 
(12.5) 
80.3  
(14.2) 
Smoking          
Never , n (%) 
4459 
(82.5 %) 
1224 
(81.9 %) 
1213 
(85.2%) 
2022 
(81.2%) 
- 
866 
(84.7%) 
992 
(91.8%) 
- - 
Former (%) 
398 
(7.4 %) 
125 
(8.4 %) 
117 
(8.2%) 
156 
(6.3%) 
- 
29 
(2.8%) 
53 
(4.9%) 
- - 
Current (%) 
551 
(10.2 %) 
145 
(9.7%) 
94 
(6.6%) 
312 
(12.5%) 
297 
(26.6%) 
128 
(12.5%) 
36 
(3.3%) 
- - 
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Characteristic 
Derivation Validation 
Overall Tanzania Senegal Guinea CRIBSA KZN Tanzania Guinea Overall 
Mean FBG in mmol/l 
(SD) 
- 
4.6 
(2.2) 
- 
4.6 
(1.5) 
5.4 
(2.5) 
4.9 
(1.5) 
5.3 
(3.5) 
5.1 
(2.0) 
5.2  
(2.5) 
Mean 2hr OGTT in 
mmol/l (SD) 
- - - - 
6.9 
(4.2) 
6.2 
(2.5) 
- - - 
Total Diabetes, n (%) 
327 
(6.2 %) 
49 
(3.6%) 
148 
(10.4%) 
130 
(5.3%) 
142 
(12.1%) 
46 
(4.4%) 
156 
(14.9%) 
94 
(6.1%) 
438 
 (9.2%) 
New Diabetes, n (%) 
143 
(2.7%) 
35 
(2.5%) 
37 
(2.6%) 
71 
(2.1%) 
40 
(3.7%) 
40 
(3.9%) 
99 
(9.4 %) 
66 
(4.3%) 
245 
 (5.1%) 
 
Key 
∞
 Hypertension is defined as SBP>=140 and or DPB >=90 
SD = Standard Deviation 
SBP = Systolic Blood Pressure 
DBP = Diastolic Blood Pressure 
FBG = Fasting Blood Sugar 
OGTT = Oral Glucose Tolerance 
BMI = Body Mass Index 
N = Total number of participants in the study 
n = Number of participants 
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5.5 Discussion 
This chapter provides a description of studies and characteristics of study participants in 
the studies used for deriving and validating a risk score for use in the African population. 
The review of the methods show that data collection methods were comparable across all 
studies, using the WHO recommended methods of data collection. Although there were 
slight differences in how data for various lifestyle measures were collected, the variables 
could be categorized into uniform variables across all studies, with the exception of 
physical activity and diet which was not considered at all because of differences in 
methods of data collection and the lack of an appropriate standard method for diet 
assessment in the African context. 
Baseline characteristics of study respondents such as age, sex, prevalence of hypertension 
and diabetes also vary across the different studies and these are likely to affect the overall 
model performance in terms of discrimination and calibration which are affected by the 
distribution of risk factors included in the tested model and the baseline risk of diabetes in 
the study populations respectively. Interpretation of model performance will have to take 
into account the differences in these baseline characteristics. 
Combining data from different countries is aimed at developing a risk score that could be 
applicable to a wider population.  It also has the advantage of increasing the number of 
desired outcomes, hence provide an adequate sample for model derivation and reduce the 
risk of overfitting that occurs when a model is developed with inadequate sample. 
Heterogeneity in model performance of the new model will be assessed to account for the 
differences in background characteristics in the overall model performance. 
Despite having the advantages of sample size, there are several limitations to the data. 
There is an overrepresentation of women in all the studies, so care needs to be taken in 
generalizing the study findings to other populations. There were also participants with 
missing values across countries, although few, because a complete case analysis was 
undertaken this could introduce bias in the model performance especially if the variable 
were not missing at random. Some variables were not at all present in some countries 
therefore not all risk scores will be able to be validated in all studies. 
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Chapter 6. Derivation and Internal Validation of a New Model 
6.1 Introduction 
Previous chapters highlighted the increasing prevalence of diabetes and the need for early 
identification of undiagnosed cases in order to implement disease-modifying intervention 
and prevent long-term complications. Recent developments in treatment and prevention 
of diabetes and cardiovascular complications present opportunities for screening of 
people at risk of diabetes. Availability of a simple reliable test is one of the requirements 
before a disease is considered for screening. Available tests for diabetes screening as 
described in the previous chapter include Oral Glucose Tolerance Test (OGTT), Fasting 
Glucose Test (FPG), Random Blood Glucose (RBG) Test Glycated Haemoglobin 
(HbA1c) and diabetes risk questionnaire (scores). Tests such as FPG, RBG, OGTT and 
HbA1c are invasive procedures and are costly and some tests such as OGTT have weak 
reproducibility (Barr et al., 2002), therefore making risk scores more convenient for use a 
first screening method in community settings. 
Diabetes risk questionnaires and known diabetes risk factors have been used in predicting 
the presence of undiagnosed diabetes and have been reported to perform fairly well in 
identifying prevalent cases of diabetes and to improve the yield when used for screening 
in combination with other tests. A study in the Netherlands reported that risk stratification  
using a risk score before performing the biochemical measurements lowered significantly 
the number needed to screen to identify a case of diabetes, in this study, the number 
needed to screen was 233 in the low risk group versus 37 in the high risk group (Klein 
Woolthuis et al., 2009). Similarly a study in India showed that the India Diabetes Risk 
Score was able to identify up to 75% of diabetes cases diagnosed with OGTT, and a two-
step screening alogarithm, comprising of the risk score as an initial test followed by 
OGTT was most cost effective (Mohan et al., 2011). 
A considerable number of risk diabetes scores have been published (Noble et al., 2011). 
However, existing diabetes risk questionnaires/ models have mainly been developed and 
validated in White populations. Glummer and colleagues assessed the Rotterdam risk 
score in eight different ethnic populations including an African population from 
Cameroon (Glumer et al., 2006). The score had an AUC, Sensitivity and Specificity of 
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0.68 (95% CI, 0.64 to 0.72) 78% and 55% respectively in the developmental White 
population. In the African population the score had an AUC, Sensitivity and Specificity 
of 0.53 (95% CI, 0.48 to 0.71), 16.7% and 91% respectively. The poor performance 
observed in this study could be explained by possible interaction between ethnicity and 
the association of the predictor variables with the outcome. The aim of this study is to 
develop a risk score for undiagnosed diabetes applicable to populations in Africa. This 
chapter describes the process of derivation and internal validation of a new risk model to 
predict undiagnosed prevalent diabetes; Included in this chapter is the description of the 
methods, results and discussion. 
6.2 Methods 
6.2.1 Data  
Data used for analysis is a pooled dataset comprising of data from diabetes survey in 
Tanzania, Guinea and Senegal (individual data sets are described in detail in (Chapter 5 
on page 76). A total of 5193 cases excluding those with known diabetes were used for 
analysis, of these 327 (6.2% ) had diabetes and 143 (2.7%) had undiagnosed diabetes , the 
low prevalence of undiagnosed diabetes could be because the data used in risk score 
derivation came recent studies that were conducted after the year 2000 and for example 
the study in Tanzania was conducted in an urban area which was a project site for the 
Adult Morbidity and Mortality Project where similar survey were conducted therefore 
majority of the community members were aware of their diabetes status, similarly this 
was a second diabetes survey for Guinea. The population for deriving the score was 
combined from 3 different countries to get a data set that is large enough to give adequate 
sample size and power. Applying the rule of thumb of 10 events per variable (Harrell Jr et 
al., 1996, Steyerberg et al., 2000) the sample is adequate for a model of up to 14 
variables. 
6.2.2 Outcome Variable 
The outcome variable used in the analysis is presence of newly diagnosed diabetes. The 
outcome variable was defined as fasting blood glucose of >7mmol/l (WHO, 2006). 
6.2.3 Candidate Variables  
Variables considered for inclusion into the model were age, sex, body mass index (BMI), 
level of education(primary or less, secondary and tertiary), waist circumference, smoking 
(current or past smoker), and hypertension (history of hypertension, and or systolic blood 
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pressure of more or equal to 140 mmHg and or diastolic blood pressure of more or equal 
to 90 mmHg). In selecting variables for building the model the following criteria were 
used; 
1) The variables are known risk factors for diabetes from published research 
findings. 
2) Standard measurement procedures exists for example blood pressure, height, 
weight, waist circumference and education status.  
6.2.4 Missing data 
Data analysis was done using complete case analysis.  
6.2.5 Model Development 
Variable Selection 
To develop the model a logistic regression model was fitted with the presence of diabetes 
modelled as a binary outcome, below is an outline of how the variables were selected for 
inclusion into the model. 
Variable selection was done using backward stepwise selection method .The following 
steps were used in variable selection; 
Step 1: Univariable analysis of each of the predictor variables was done to assess the 
relationship of the individual predictors to the outcome. This was done by studying the 
estimated coefficients resulting from fitting the model, and their significance compared to 
the null model. 
Step 2: All predictor variables with a p value of 0.1 were entered together in a model. The 
cut-off point was chosen to ensure that it allows potentially important predictors in to the 
model. Following the fit of a multivariable model, the estimated coefficients and the p 
values of the predictor in the multivariable model were compared to those in the 
univariable analysis, non-significant predictors (p value > 0.1) were then eliminated at 
this stage and a new model with significant predictors was then fitted. Performance of the 
new fitted model was then compared with the full model; the process was repeated until 
the model contained only significant predictors. the decision to remove or keep these 
variables in the model was based on the changes in -2log likelihood ratio (-2LL) and 
where competing models had the same numbers of degrees of freedom the Akaike 
108 
 
Information Criteria was used to select the best model where the lower the value the 
better the model. 
Step 3: To ensure that no significant predictor is left out on the basis of their significance 
at univariate analysis, variables excluded at that stage of analysis were then re-introduced 
and assessed for their effects on the model performance. 
Step 4: After obtaining the preliminary model, the final variables were checked to make 
sure that no term included in the model can be omitted without significantly reducing the 
performance of the model, nor should there be any term that significantly improves model 
performance upon inclusion 
Testing Interactions 
After obtaining the preliminary model in step 3 above, interactions terms for age and 
predictors were added into the model. Variable interactions were therefore assessed by 
including specific interaction terms of the pre specified variables included in the model 
and assessing their effect on overall model performance. Similar cut of point of 0.1 for 
significance was applied for inclusion of interaction terms into the model. Significant 
interactions were then added into the model. 
6.2.6 Assessing Model Assumptions 
In order to  derive an adequate model, the basic assumption of regression analysis namely 
the distribution of the outcome and linearity of the continuous predictors in the model 
have to be achieved, to assess whether the model developed fits this assumption, basic 
regression diagnostic tests were carried out (Frank E. Harell, 2001, Steyerberg, 2009). 
Assessing Linearity 
All continuous predictors were assessed for linearity. Linearity was assessed using 
residual plots, in which standardized deviance residuals from regression analysis of the 
variables were plotted against each of the predictor variables. An index plot of the 
standardized residuals were also made to assess whether the model fits the data well 
which is expected to show no particular pattern if the model is well fitted.  In addition, 
transformations were done by application of restricted cubic splines (RCS) with 3-4 
knots. Best model was then chosen based on the Akaike’s Information Criterion (the 
lower the value the better the model). 
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Assessing overly influential variables 
Assessment of overly influential variables was also done for the continuous variables by 
performing exploratory analysis of the variables such as using box plots and summary 
statistics to detect outliers and also by examining residuals and leverages after building 
the model. DFBETAS were used to examine the effects of the influential values on the 
model, using the DFBETA index plot. DFBETA for a particular observation is the 
difference between the regression coefficient calculated for all of the data and the 
regression coefficient calculated with the observation deleted. Assessment  overly 
influential variables on the model was done by excluding individual cases with 
DFBETAS, residual and leverage values beyond the cut of points and running the model 
with the remaining cases, and comparing model performance with and without these 
cases. 
6.2.7 Testing for Heterogeneity 
Since data for developing the score was obtained from different settings/ countries meta-
analysis of the resulting model performance measures (true negatives, false negatives, 
true positives and false positives at a uniform cut off point) from running the final model 
in country specific data was done. Analysis was performed using random effects model, 
heterogeneity was reported using the Cochrane (Q) and I
2 
statistic (Higgins et al., 2003). 
6.2.8 Assessing Model Performance 
The performance of the model was assessed on 2 scales; calibration and 
discrimination(Frank E. Harell, 2001, Steyerberg, 2009). Discrimination is the overall 
ability to discriminate between those with and without undiagnosed diabetes in this case 
and calibration which is a measure of agreement between observed outcomes and the 
predicted probabilities  
Discrimination 
Model discrimination was measured using the Area under the Receiver Characteristics 
Curve (AUC). The AUC is the probability that a person with the outcome is assigned a 
higher probability of the outcome by the model, than a randomly  chosen person without 
the outcome (Zweig and Campbell, 1993). A perfect model has a value of 1, therefore 
value closer to 1 depicts a better discrimination, a value of 0.5 shows no discrimination. 
In addition to assessing discrimination with AUC, assessment of improvement in overall 
discrimination of the model with additional variables was assessed using Integrated 
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Discrimination Improvement (IDI) and relative IDI. IDI was calculated as the difference 
in discrimination slopes between the baseline model and the model with additional 
variables, where discrimination slope is the difference in the mean predicted probabilities 
in those with and without events(Pencina, 2007). P value for IDI was calculated using the 
formula by Pencina (Pencina, 2007). 
Calibration  
Model calibration was assessed by the Hosmer Lemeshow test, a non-significant test 
depicts good calibration (Hosmer and Lemeshow, 2000, Moons et al., 2012). Calibration 
was also assessed visually by graphically plotting the observed outcome frequencies on 
the y axis against the mean predicted outcome probabilities on the x axis, within 
subgroups (deciles) of participants ranked by increased estimated probability and by 
plotting a bar graph of the estimated probabilities grouped by observed and predicted 
outcomes.  
Yates slope was also used to assess calibration. Yates slope (discrimination slope) is the 
difference in the mean predicted probabilities among those with and without the outcome, 
in comparing models, the higher the value the better the model. 
6.2.9 Internal Validation 
Internal validation is the estimation of predictive accuracy of a model in the same 
population used to develop the model (Steyerberg et al., 2001). Internal validation was 
done using bootstrap procedure (Harrell Jr et al., 1996, Steyerberg, 2009). The validation 
was done using 1000 bootstrap resamples. 1000 bootstrap samples were drawn with 
replacement; the resampling was done by country to allow each sample to have exactly 
the same distribution of participants as in the original sample. A new model was 
constructed in each of the bootstrap sample and performance (AUC) assessed (bootstrap 
performance). The resulting bootstrap model was also applied into the original data set 
(test performance). Optimism was calculated as the difference between bootstrap 
performance and test performance, average optimism from the 100 bootstrap samples was 
used to calculate optimism corrected performance. Optimism corrected performance was 
obtained from subtracting optimism estimate from the model performance in the original 
data set. 
111 
 
6.2.10 The Point Scoring System 
To make the model more practical for use in clinical settings, The regression (β ) 
coefficients of predictors in the model were used to calculate weights for the point based 
scoring system, based on approach developed by Sullivan in the Framingham Heart Study 
(Sullivan et al., 2004). The continuous variables were first organized into categories and 
referent values were chosen. Referent values were set as the midpoint for the categories 
of continuous variables and base category was chosen, 1
st
 and 99
th
 percentile values were 
used to set mid points for the first and last categories. The next step was to determine the 
difference of each category referent value to the base category value in regression units. 
The risk associated with 5 year increase in age was set as the constant multiplier that 
reflects 1 point in the scoring system. Finally the point score was derived by dividing the 
difference obtained above by the set constant and the risk associated with each of the 
point totals were estimated. The risk associated with each of the point score was then 
estimated. 
6.2.11 Cut off Point for the Score 
In order to validate the developed score using the simple point score for the derived score, 
a cut off point was derived using lsens command in STATA, which plots sensitivity vs 
specificity for the possible cut offs for the score from which the cut off which maximised 
sensitivity and specificity was chosen. 
6.3 Results 
6.3.1 Model Building 
The results of fitting univariable logistic regression to the model are shown in  
Table 6-1. For categorical variables, the following were modelled as referent values; Sex, 
Male; Hypertension, No Hypertension; Education Level, less than primary school and 
Smoking, Non Smoker. In univariable analysis, significant predictors of undiagnosed 
prevalent diabetes were: BMI, Age, Hypertension and Waist circumference and smoking.  
At multivariable analysis significant variables (p value < 0.05) were age, hypertension, 
waist circumference and smoking, after removing BMI and education level smoking was 
no longer a significant predictor (p value > 0.05) Table 6-2. Introduction of the non-
significant variables at univariate analysis, namely education level and sex did not 
improve the model performance; therefore none of these predictors were left in the model.  
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Table 6-1 Results of Fitting Univariable Logistic Model 
Variable Odds Ratio (95% CI) Coefficient Std. Err p Value 
Age 1.06 (1.05 to 1.07) 0.061 0.008 <0.001 
Waist 1.06 (1.05 to 1.07) 0.058 0.007 <0.001 
BMI 1.09 (1.07 to 1.13) 0.095 0.013 <0.001 
Sex (Female) 1.24 (0.76 to 2.04) 0.218 0.253 0.39 
Hypertension (Yes) 4.2 (2.58 to 6.93) 1.440 0.253 <0.001 
Level of Education     
Primary 0.74 (0.39 to 1.35) -0.307 0.311 0.32 
Secondary 0.96 (0.51 to 1.78) -0.043 0.318 0.89 
Tertiary 1.09 (0.48 to 2.51) 0.090 0.423 0.83 
Smoking (Yes) 2.21 (0.96 to 5.13) 0.796 0.953 0.06 
CI= Confidence Interval, Std. Err = Standard Error of Coefficients 
Table 6-2 Results of Fitting a Multivariable Logistic Model  
Variable Odds Ratio (95% CI) Coefficient Std. Err. Pvalue 
Smoking (Yes) 2.37 (0.95 to 5.86) 0.862 1.090 0.06 
Waist 1.04 (1.02 to 1.06) 0.037 0.010 <0.001 
Age 1.05 (1.03 to 1.07) 0.049 0.010 <0.001 
Sex (Female) 0.67 (0.36 to 1.23) -0.394 0.207 0.20 
BMI 1.04 (0.98 to 1.08) 0.034 0.025 0.16 
Education Level     
Primary 0.91 (0.48 to 1.73) -0.090 0.299 0.78 
Secondary 1.70 (0.80 to 3.38) 0.532 0.594 0.13 
Tertiary 1.12 (1.09 to 3.21) 0.110 0.510 0.81 
Hypertension (Yes) 1.88 (1.12 to 3.13) 0.630 0.512 0.02 
-2Loglikelihood= -304.14  Pseudo R
2   
= 0.159 
Table 6-3 below shows results of the preliminary model after fitting the significant 
predictors into a multivariable model. The fitted model resulted into a model with AIC of 
625.745 (4 degrees of freedom) and Nagelkerke’s R2 of 0.148. 
Table 6-3 Regression Coefficients (95% CI) and Standard Error of Predictors in the 
Preliminary Model 
Variable Odds Ratio (95% CI) Coefficient (SE) pValue 
Age (per 1 year increase) 1.05 (1.02 to 1.07) 0.045 (0.009) <0.001 
Waist Circumference (per 
cm increase) 
1.05 (1.03 to 1.06) 0.048 (0.007) <0.001 
Hypertension (present) 1.92 (1.12 to 3.26) 0.649 (0.271) 0.017 
Intercept  -11.012(0.811) <0.001 
-2Log likelihood = -308.87,   Pseudo R
2
 = 0.148, SE = Standard Error  
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After obtaining the preliminary model, interaction terms for BMI*age, waist 
circumference*age, and hypertension*age were tested. At univariate analysis, interaction 
terms for waist circumference, BMI were significant and were further tested for inclusion 
into the model.  
When the interaction terms were added in the model none of the variables were 
significant, p value > 0.05. To assess whether the model contain all the significant 
variables at univariate analysis including BMI, interaction terms BMI*age and waist 
circumference*age were each added into the model and its effect of adding in to the 
model were assessed in terms of improvement in risk stratification.  
Highest improvement in risk stratification was achieved on adding BMI, age interaction 
for BMI and waist circumference (signifying that older subjects are more likely to have 
higher waist circumference and higher BMI by virtue of their age) (Table 6-4). However 
the overall improvement was non-significant. 
Table 6-4 Assessment of Improvement in Risk Stratification with Additional Variable in the 
Model 
Model df -2LL AIC IDI 
P 
val rIDI (%) 
Age, Waist and 
Hypertension 4 -308.87 625.75 - - - 
Age, Waist, Hypertension 
and BMI 5 -307.93 625.85 0.0013 0.93 3.93 
Age, Waist, Hypertension , 
BMI and Age*BMI 6 -307.93 625.85 0.0011 0.91 3.54 
Age, Waist , Hypertension 
and Age*Waist 5 -308.87 627.74 0.0006 0.97 1.73 
 
Key 
rIDI = Relative Integrated Discrimination Improvement 
IDI = Integrated Discrimination Improvement 
AIC = Akaike Information Criteria 
Df = Degrees of Freedom 
P Val = P Value 
BMI = Body Mass Index 
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Assessment of Model Fit 
Assessment of overly influential variables was done using DFBETAs and leverage using 
index plots, regression analysis was done with and without the influential variables, there 
were no model improvement after excluding the influential variables. All the variables 
were then kept in the model. 
As mentioned in the methods, linearity assumptions were assessed using residual plots 
such as index plot of the residuals and plots of residuals and the continuous variables in 
the model. Results showed that the model fulfils the basic assumptions of linearity. 
Below, shows a plot of residuals vs. age and waist circumference. The plots do not show 
any particular pattern.  
 
Figure 6-2 Residual Plot for Age 
 
To test linearity assumptions further the model was fitted as linear and also fitted 
continuous variables as restricted cubic splines with 3 and 4 knots and compared with the 
linear model results of which are presented in Table 6-5 below.  Results show that for age 
the model has best performance when age was modelled as linear. However, for waist 
circumference the performance slightly improved when waist circumference was 
modelled with 3 knots showing that the distribution of waist circumference measures may 
be less linear. Waist circumference was not log transformed or modelled with knots 
because there was not much difference in the performance when modelled as linear vs 
with knots, with the aim to keep the model simple. 
 
 
 
Figure 6-1  Residual plot for Waist 
Circumference 
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Table 6-5 Age and Waist Modelled With Restricted Cubic Splines  
Model Position of knots Df -2LL AIC 
Age     
None  3 -320.108 646.2 
Linear   4 -308.873 625.8 
RCS 3 knots 20, 37 and 59 5 -307.960 625.9 
RCS 4 knots 17, 30, 45 and 63 6 -308.009 628.1 
Waist Circumference    
None  3 -328.284 662.6 
Linear   4 -308.873 625.8 
RCS 3 knots 68, 82, 100 5 -307.207 624.4 
RCS 4 knots 65, 77, 88, 107 6 -306.424 624.8 
  
Key 
RCS = Restricted Cubic Splines 
Df = Degrees of Freedom 
-2LL = -2 Log Likelihood  
AIC = Akaike Information Criterion 
 
6.3.2 Final Model 
Assessment of new variables for inclusion in the model did not yield significant results, 
the model presented in Table is chosen as the final model. The probability of undiagnosed 
diabetes using the model is given by;  
P=   exp x  /   1+exp x 
Where x= [(-11.012+ 0.045(Age)+ 0.048 (Waist Circumference) + 0.649 (Hypertension)] 
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6.3.3 Apparent Model Performance 
Discrimination 
The performance of the developed model in predicting undiagnosed diabetes is shown in 
Figure 6-3 below. The Area under the ROC curve for the model is 0.83 (95% CI 0.82 to 
0.84). 
 
Figure 6-3 ROC Curve for the Model in the Development Data Set 
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Calibration 
Below, (Figure 6-4) is a calibration graph showing the agreement between the observed 
outcomes and predictions, over a range of predicted probabilities. The graph shows 
increased proportion with observed outcomes with increasing predicted probabilities. The 
final model has a non-significant Hosmer-Lemeshow statistic (Hosmer and Lemeshow, 
2000) with a p value 1.0, showing that the model has good calibration and a Yates slope 
of 0.03. 
               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 
Figure 6-4 Calibration Graph of Observed Outcome and Predictions vs. Predicted Probabilities  
Key 
H-L = Hosmer Lemeshow  
Χ2 = Chi square statistic
Yates Slope: 0.03 
H-L 2: p value 1.0 
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6.3.4 Fitting the Model in Country Specific Data and Meta-Analysis 
Meta-analysis of the results of fitting the model in the country specific populations, 
presented in Figure 6-5 below yielded an AUC of 0.8 and a Cochrane (Q) statistic of 0.7 
with a resulting I
2
 of 0.  
 
Figure 6-5 Summary ROC Curve for Applying the Model in Country Specific Data 
Key 
SROC = Summary Receiver Operating Characteristic Curve 
AUC = Area under the Curve 
Std. Err. = Standard Error 
Q = Qochrane Statistic 
I
2
 = Inconsistency score 
Symmetric SROC 
AUC: 0.784 
Std. Err. (AUC): 0.04 
Q*: 0.722 
Std. Err. (Q*): 0.03 
I
2
: 0 
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6.3.5 Point Scoring System 
To make the model applicable to a clinical setting, the final model was transcribed into a 
simple point score integer; development of the score points is described in detail in the 
methods in page 111. Table 6-6 below shows the point score for each of the variable 
categories. The total score ranges from -9 which is the lowest risk category to 15 which is 
the highest risk category. Table 6-7  shows the risk function corresponding to the absolute 
risk function corresponding to the risk score totals. The best cut off point for the score 
was ≥7 point totals. 
Table 6-6 Simple Scoring System Based on the Final Model 
Risk factor Categories 
Reference 
Value β 
B ( Value-
Referent) Points 
Age   0.045   
 <30 22.50  -0.540 -2 
 30-39 34.50*  0.000 0 
 40-49 44.50  0.450 2 
 50-59 54.50  0.900 4 
 >60 67.50  1.485 7 
   0.048   
Waist <80 52.50  -1.560 -7 
 80-90 85.00*  0.000 0 
 90-100 95.00  0.480 2 
 >100 110.00  1.200 5 
   0.649   
Hypertension No 0.00*  0 0 
  Yes 1   0.649 3 
 
Key 
*Referent value 
β = Regression Coefficient 
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Table 6-7 Total Points, Absolute and Percentage Risk Function For Undiagnosed Diabetes for 
Each of the Total Score Points 
Points Total Absolute Risk Percentage Risk 
-9 0.00 0.00 
-8 0.00 0.00 
-7 0.00 0.00 
-6 0.00 0.00 
-5 0.00 0.00 
-4 0.00 0.00 
-3 0.00 0.00 
-2 0.00 0.00 
-1 0.00 0.00 
0 0.00 0.46 
1 0.01 1.24 
2 0.03 3.29 
3 0.08 8.47 
4 0.20 20.11 
5 0.41 40.62 
6 0.65 65.03 
7 0.83 83.49 
8 0.93 93.22 
9 0.97 97.39 
10 0.99 99.02 
11 1.00 99.64 
12 1.00 99.87 
13 1.00 99.95 
14 1.00 99.98 
15 1.00 99.99 
 
Distribution of the Total Score Points in Validation Studies  
Distributions of the total score points in the different validation study populations are 
presented in Table 6-8, Table 6-9, Table 6-10 and Table 6-11 below. Results show that 
compared to the percentage risk functions presented in Table 6-7 above the risk score 
performs well in excluding those that do not have diabetes except in the Guinea 
population (Table 6-10) , but overall it overestimates risk in those with high risk score 
totals. The percentage of those with outcome (diabetes) is small therefore the results need 
to be interpreted with caution.
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Table 6-8 Distribution of Total Score by Diabetes Status in the CRIBSA Validation Study 
Population 
Total 
Score 
Points 
Without Diabetes With Diabetes 
Frequency Percent 
Cumulative 
Percent 
Frequency Percent 
Cumulative 
Percent 
-9 70 6.74 6.74 0 0.00 0.00 
-7 62 5.97 12.72 0 0.00 0.00 
-6 7 0.67 13.39 0 0.00 0.00 
-5 26 2.50 15.90 0 0.00 0.00 
-4 19 1.83 17.73 0 0.00 0.00 
-3 9 0.87 18.59 0 0.00 0.00 
-2 48 4.62 23.22 0 0.00 0.00 
0 107 10.31 33.53 2 5.00 5.00 
1 7 0.67 34.20 0 0.00 0.00 
2 61 5.88 40.08 0 0.00 0.00 
3 61 5.88 45.95 0 0.00 0.00 
4 45 4.34 50.29 2 5.00 10.00 
5 81 7.80 58.09 2 5.00 15.00 
6 20 1.93 60.02 1 2.50 17.50 
7 109 10.50 70.52 4 10.00 27.50 
8 33 3.18 73.70 3 7.50 35.00 
9 53 5.11 78.81 6 15.00 50.00 
10 63 6.07 84.87 2 5.00 55.00 
12 108 10.40 95.28 10 25.00 80.00 
15 49 4.72 100.0 8 20.00 100.00 
 
1,038 100.0 
 
40 100.00 
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Table 6-9 Distribution of Total Score by Diabetes Status in the KZN Validation Study 
Population 
Total 
Score 
Points 
Without Diabetes With Diabetes 
Frequency Percent 
Cumulative 
Percent 
Frequency Percent 
Cumulative 
Percent 
-9 115 13.96 13.96 0 0.00 0.00 
-7 42 5.1 19.05 0 0.00 0.00 
-6 12 1.46 20.51 0 0.00 0.00 
-5 32 3.88 24.39 0 0.00 0.00 
-4 8 0.97 25.36 0 0.00 0.00 
-3 16 1.94 27.31 0 0.00 0.00 
-2 44 5.34 32.65 1 2.56 2.56 
0 95 11.53 44.17 4 10.26 12.82 
1 6 0.73 44.9 0 0.00 0.00 
2 38 4.61 49.51 2 5.13 17.95 
3 66 8.01 57.52 2 5.13 23.08 
4 33 4 61.53 0 0.00 0.00 
5 31 3.76 65.29 3 7.69 30.77 
6 15 1.82 67.11 1 2.56 33.33 
7 72 8.74 75.85 6 15.38 48.72 
8 5 0.61 76.46 0 0.00 0.00 
9 37 4.49 80.95 3 7.69 56.41 
10 58 7.04 87.99 4 10.26 66.67 
12 62 7.52 95.51 7 17.95 84.62 
15 37 4.49 100 6 15.38 100.00 
Total 824 100  39 100  
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Table 6-10 Distribution of Total Score by Diabetes Status in the Guinea Validation Study 
Population 
Total 
score 
Points 
Without Diabetes With Diabetes 
Frequency Percent 
Cumulative 
Percent 
Frequency Percent 
Cumulative 
Percent 
-7 363 25.16 25.16 8 12.12 12.12 
-5 180 12.47 37.63 4 6.06 18.18 
-4 27 1.87 39.5 0 0.00 0.00 
-3 130 9.01 48.51 2 3.03 21.21 
-2 45 3.12 51.63 1 1.52 22.73 
0 178 12.34 63.96 6 9.09 31.82 
2 50 3.47 67.43 1 1.52 33.33 
3 94 6.51 73.94 12 18.18 51.52 
4 65 4.5 78.45 1 1.52 53.03 
5 37 2.56 81.01 1 1.52 54.55 
6 19 1.32 82.33 0 0.00 0.00 
7 85 5.89 88.22 5 7.58 62.12 
8 1 0.07 88.29 1 1.52 63.64 
9 45 3.12 91.41 9 13.64 77.27 
10 50 3.47 94.87 7 10.61 87.88 
12 59 4.09 98.96 6 9.09 96.97 
15 15 1.04 100.00 2 3.03 100.00 
Total 1,443 100.00 
 
66 100.00 
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Table 6-11 Distribution of Total Score by Diabetes Status in the Tanzania Validation Study 
Population 
Total 
Score 
Points 
Without Diabetes With Diabetes 
Frequency Percent 
Cumulative 
Percent 
Frequency Percent 
Cumulative 
Percent 
-9 29 3.29 3.29 0 0.00 0.00 
-7 57 6.47 9.76 0 0.00 0.00 
-6 1 0.11 9.88 0 0.00 0.00 
-5 25 2.84 12.71 0 0.00 0.00 
-4 9 1.02 13.73 0 0.00 0.00 
-3 18 2.04 15.78 1 1.01 1.01 
-2 19 2.16 17.93 0 0.00 0.00 
0 68 7.72 25.65 4 4.04 5.05 
1 4 0.45 26.11 0 0.00 0.00 
2 88 9.99 36.10 8 8.08 13.13 
3 28 3.18 39.27 5 5.05 18.18 
4 70 7.95 47.22 2 2.02 20.2 
5 67 7.60 54.82 7 7.07 27.27 
6 28 3.18 58.00 3 3.03 30.3 
7 87 9.88 67.88 11 11.11 41.41 
8 17 1.93 69.81 7 7.07 48.48 
9 56 6.36 76.16 13 13.13 61.62 
10 64 7.26 83.43 11 11.11 72.73 
12 100 11.35 94.78 21 21.21 93.94 
15 46 5.22 100.00 6 6.06 100.00 
Total 881 100  99 100.00  
 
6.3.6 Model Validation 
The model was internally validated using bootstrap procedure. The average optimism 
from the model was 0.03; therefore the optimism corrected performance (AUC) for the 
model is 0.8. 
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6.4 Discussion 
To my knowledge this is the first study in Africa to describe the development of a 
diabetes risk score to detect prevalent diabetes. Recent developments in diabetes 
prevention and treatment have resulted in strong arguments in favour of opportunistic 
diabetes screening (Echouffo-Tcheugui et al., 2011, Echouffo-Tcheugui et al., 2012). For 
any screening programme to be effective there is need for feasible, reliable and cost 
effective screening methods. Several risk scores have been developed to screen for 
undiagnosed diabetes as described in chapter 3, mostly in White populations and these 
scores have poor performance when applied to other ethnic populations. 
This study focused on developing a risk score for detecting prevalent diabetes for use as 
an initial screening tool for undiagnosed diabetes. The score uses risk factors known to be 
associated with diabetes to predict prevalent diabetes. Risk factors included in this score 
are hypertension, age and waist circumference, which have been widely used in other 
diabetes risk scores. The presence of hypertension contributed more points towards risk 
prediction compared to other variables tested for model development.  
Body mass index was not a significant predictor in this model; waist circumference had 
better performance and was chosen for inclusion in the model. The reason why BMI was 
not a good predictor of diabetes could be due to the fact that the overall obesity measured 
by BMI does not necessarily corellate with the level of visceral fat. A study looking at 
ethnic differences in the incidence of diabetes found that BMI was less correlated with 
diabetes for the Africans compared to the Asians and White populations (Shai et al., 
2006), and possibly the appropriate cut off points to define risk are different for different 
ethnic groups. Studies have suggested that waist circumference could be a better predictor 
of diabetes risk than BMI which seem to support the findings in this study (The InterAct, 
2012, Chan et al., 2003). IDF recommends different cut-off points for waist 
circumference (IDF, 2006) with lower cut off points for Asian population and no specific 
cut points for the African population because of lack of data. In this study no 
categorization of data was done all continuous data was modelled as linear. 
Risk factors, such as diet and physical activity, were not considered for inclusion into the 
model because of the lack of standardized methods for measurements in this particular 
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population and also the need to have a simple score with covariates that can be 
consistently measured across different settings.  
Family history of diabetes was also not considered because of the lack of the variable in 
the data sets, it is an important risk factor for diabetes however information on parent or 
sibling diabetes status is likely to be incomplete given the high prevalence of undiagnosed 
cases in the African population that could be due to limited diagnostic facilities and poor 
access to health care.  
The risk score presents a feasible approach for diabetes screening with good 
discrimination (AUC 0.83), identifying individuals at high risk that should be referred for 
further diagnostic tests. The score points have been transformed into simple integer points 
that can easily be computed. For the derivation study the best cut off point for the score 
was ≥ 7 which was chosen to maximise both sensitivity and specifity for the purpose of 
evaluating the performance of the score in this study. In clinical decision making the 
choice of the best cut off point is a complex one and there is no universal cut off point 
that is applicable to all, the choice should be guided by the aim of the screening program, 
the resources available and the weighted cost of false positive and false negative results. 
What is unique about this study is that data used to develop the score were obtained from 
3 different countries in an attempt to make the score applicable to a wider African 
population and also to take advantage of a larger sample size. A meta-analysis of the 
score applied in country specific data showed that the performance of the score was 
homogenous in the 3 countries. 
The study limitations included that fact that cross sectional data was used to develop the 
score and diabetes diagnosis was made based on a single fasting glucose using point of 
care devices in all the 3 studies, therefore the true diabetes prevalence could have been 
underestimated. Also the data used for score derivation, was obtained from different 
studies in different countries therefore may be a source of bias due to heterogeneity of the 
studies. 
In conclusion the derived tool is a potential screening tool for detection of prevalent 
diabetes in African populations. However measuring waist circumference appropriately 
could be a challenge in the application of this risk score in practice and would limit its 
applicability as a self-assessment score. Examples of the approaches will be to use the 
score at the health facility level for opportunistic screening of individuals attending for 
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other ailments or during community outreach programs by the public health nurses, but 
the challenges remain with how the data will be collected, who is responsible for 
evaluating the program and also the resources needed for screening. More studies are 
needed to study the feasibility of using this score in practice and to test its acceptability 
also more studies are needed to validate the score and test performance in other African 
populations. The next chapters will look at external validation of the new model and 
subsequent comparison of the model to a selection of existing diabetes risk scores. 
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Chapter 7. External Validation and Comparison of Performance of the 
New Model to Existing Models 
7.1 Introduction 
Previous chapters described the derivation and internal validation of a new diabetes risk 
score for African populations. The aim of developing the new model was to derive a 
diabetes score that would be applicable with good performance across different 
populations within Africa. The aim of this part of the study described in this chapter is to 
compare the performance of the new tool to independent populations, to test the 
generalizability of the model to other African settings. Existing models for predicting 
prevalent diabetes are also validated and performance compared to the new model.  Only 
simple models without biochemical tests are included for validation.  This chapter details 
the methods, results of external validation of the new model to the new populations and a 
comparison of the performance with existing diabetes risk scores from other settings. 
7.2 Methods 
7.2.1 Study Populations 
To externally validate the score, the score was applied to populations form two studies in 
South Africa; from Cape Town (CRIBSA study) and the Kwazulu Natal study, and 
Guinea. The validation study populations are described in detail in Chapter 6 on page 76.  
7.2.2 Identification of Prediction Models for Validation 
Diabetes risk scores for validation were obtained by performing a keyword search in 
Medline and Embase as described in chapter three on Diabetes Risk Scores. Included are 
the risk scores to predict undiagnosed diabetes, that do not require laboratory testing. The 
simplified scores were used for model validation because the aim is to validate the new 
score in the form that would actually be applied in practice.  
7.2.3 Assessment of Model Performance 
The new score was applied to the validation data score by generating a score for each 
individual by using simplified score (Table 6-6). For the existing score, the score points 
were generated for each individual using the published score points as shown in Table 
7-1. Original published score cut off points were used in the analysis. The cut off used for 
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the scores were ≥ 7 for the new score, ≥ 14 for the Chinese score (Gao et al., 2010), ≥ 10 
for the Oman score (Al-Lawati and Tuomilehto, 2007), ≥ 18 for the Brazil score (Pires de 
Sousa et al., 2009), ≥ 21 (Ramachandran et al., 2005) and ≥ 16 (Chaturvedi et al., 2008) 
for the Indian scores, ≥ 5 for the US score (Bang et al., 2009) and ≥ 6 for the Rotterdam 
score (Baan et al., 1999). 
Model performance was assessed by the Area under the Receiver Operating 
Characteristic curve (AUC), sensitivity and specificity. Sensitivity is defined as 
proportion of individuals with diabetes among those identified positive by the score and 
specificity is the proportion of individuals who truly do not have diabetes among those 
identified as negative by the score. 
7.3 Results 
7.3.1 Risk Scores for Validation 
Below are the risk scores for predicting prevalent undiagnosed diabetes that were 
obtained from the search (Al Khalaf et al., 2010, Al-Lawati and Tuomilehto, 2007, Baan 
et al., 1999, Bang et al., 2009, Chaturvedi et al., 2008, Glümer et al., 2004, Keesukphan et 
al., 2007, Pires de Sousa et al., 2009, Ramachandran et al., 2005, Ruige et al., 1997, 
Tabaei and Herman, 2002, Gao et al., 2010). Of the remaining scores, 5 scores were not 
validated due to lack of suitable variables in the data sets (Al Khalaf et al., 2010, Glümer 
et al., 2004, Keesukphan et al., 2007, Mohan et al., 2005, Ruige et al., 1997). For example 
the Kuwait risk score (Al Khalaf et al., 2010) , the simplified Indian diabetes risk score 
(Mohan et al., 2005) and the Danish risk score (Glümer et al., 2004), could not be 
validated due to   missing variables on history of diabetes in siblings or parents.   
In the validation data history of diabetes was ascertained among first degree relatives and 
was not specified as sibling, mother or father. The Dutch symptom based risk score could 
not be validated because many of its variables were lacking in the data (Ruige et al., 
1997). A total of 7 existing models (Al-Lawati and Tuomilehto, 2007, Baan et al., 1999, 
Bang et al., 2009, Chaturvedi et al., 2008, Ramachandran et al., 2005, Gao et al., 2010, 
Pires de Sousa et al., 2009) and the new model were validated in the South African 
populations and only 2 models ; the new model and the Brazil diabetes risk score (Pires 
de Sousa et al., 2009) were validated in the Guinea population due to lack of data.  
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Table 7-1 below shows a summary of the risk scores that were validated and a summary 
of how the variables were imputed. Almost all the required variables were present in the 
CRIBSA and KZN data sets to validate the models outlined in the table, except for use of 
hypertensive medication for the Dutch model (Baan et al., 1999) where history of 
hypertension was used as a proxy variable in validating this model in the data. Due to 
small number of undiagnosed cases in the CRIBSA and KZN validation data sets, no 
subgroup analyses were performed. In the Guinea data however the total events per 
variable permitted subgroup analysis and results were presented as both overall and by 
sex subgroups. 
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Table 7-1 Variable in Validated Models and Availability of Variables in Validation Data 
Model Variable  Variable definition in Model CRIBSA KZN Guinea Score  
Chinese Risk 
Score 
(Gao et al., 
2010) 
  
Waist (Chinese chi≈33cm) Men     
≤ 2.3 chi Yes Yes Yes 1 
2.4-2.6 chi    4 
 2.7-2.9 chi    8 
 ≥3 chi    12 
 Women     
 ≤ 2.0chi    1 
 2.1-2.3chi    3 
 2.4-2.6 chi    6 
  ≥2.7chi       
9 
Age (years) ≤35yrs Yes Yes Yes 1 
 36-45yrs    3 
 46-55yrs    6 
 56-65yrs    9 
  ≥65yrs    12 
 Family history of diabetes Yes Yes Yes No 8 
  No       1 
Rotterdam Risk 
Score 
(Gao et al., 
2010) 
Age (years) Age per 5 year increment form 55 years Yes Yes Yes 2 
Sex 0, female; 1 male Yes Yes Yes 5 
Use of antihypertensive 
medication  
0, no; 1, yes Proxy variable 
previous 
history of 
hypertension 
Proxy 
variable 
previous 
history of 
hypertension 
No 4 
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Model Variable  Variable definition in Model CRIBSA KZN Guinea Score  
  Obesity (BMI>=30kg/m2) 
both sex) 
0, no; 1 yes  Yes Yes Yes 5 
India Risk 
Score 
(Chaturvedi et 
al., 2008) 
  
Age (years) <40yrs Yes Yes Yes 0 
 40-49yrs    4 
  >49yrs       6 
Blood Pressure (mmHg) Optimal blood pressure (Systolic <120mmHg and 
Diastolic <80mmHg) 
Yes Yes Yes 0 
 Pre-Hypertension (Systolic 120-139mmHg and 
Diastolic 80-89mmHg) 
   5 
  Hypertension (Systolic ≥ 140 mmHg or Diastolic 
≥90 mmHg) 
      7 
Waist Circumference (cm) Waist circumference ≤75cm (women) and ≤80 
(men) 
Yes Yes Yes 0 
 Waist circumference >75cm but ≤85cm (women) 
and >80cm(men) but ≤90cm 
   9 
  Waist circumference >85cm (women) and ≤90cm 
(men) 
      12 
Family history of diabetes No Yes Yes No 0 
  Yes       4 
India Risk 
Score, 
(Ramachandran 
et al., 2005) 
Age (years) <30yrs Yes Yes Yes 0 
 30-44yrs    10 
 45-59    18 
  >59       19 
Family history of diabetes No Yes Yes No 0 
  Yes       7 
BMI (kg/m2) <25kg/m2 Yes Yes Yes 0 
  ≥25kg/m2       7 
 Waist circumference (cm) <85cm (men), <80cm (women) Yes Yes Yes 0 
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Model Variable  Variable definition in Model CRIBSA KZN Guinea Score  
   ≥85cm (men), ≥80cm (women)       5 
  Physical activity Sedentary and light physical activity Yes Yes No 4 
Brazil risk 
score 
(Pires de Sousa 
et al., 2009) 
Age (years) 35-44yrs Yes Yes Yes 0 
 45-54yrs    7 
  >55       12 
BMI (kg/m2) <25kg/m2 Yes Yes Yes 0 
 ≥25kg/m2 but >30 kg/m2    5 
  ≥30kg/m2       18 
Hypertension (Systolic 
BP≥140mmHg and or 
Diastolic BP ≥90 mmHg or 
use of hypertension 
medication) 
No Yes Yes Yes 0 
 Yes    6 
US Risk Score, 
(Bang et al., 
2009) 
Age (years) ≤40yrs Yes Yes Yes 0 
 40-49yrs    1 
 50-59yrs    2 
  ≥60yrs       3 
Sex Female Yes Yes Yes 0 
  Male       1 
Family history of diabetes No Yes Yes Yes 0 
  Yes       1 
History of hypertension No Yes Yes No 0 
  Yes       1 
Obesity (defined by both 
BMI (kg/m2) and Waist 
Circumference (inch) 
Not overweight or Obese (BMI<25 and Waist 
circumference <37in (men), <31.5in (women) 
Yes Yes Yes 0 
 Overweight (BMI≥25 but <30 or waist 
circumference ≥37in but <40(men), ≥31.5in but 
<35(women) 
   1 
  Obese (BMI≥30 but <40 or waist circumference    2 
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Model Variable  Variable definition in Model CRIBSA KZN Guinea Score  
≥40in but <50(men), ≥35in but <49(women) 
   Extremely Obese (BMI ≥40 or waist circumference 
≥50(men), ≥49in(women) 
      3 
 Physical activity No Yes Yes No 0 
    Yes       -1 
Oman Risk 
Score 
(Al-Lawati and 
Tuomilehto, 
2007) 
  
Age (years) 20-39yrs; Yes Yes Yes 0 
  40-59yrs;     7 
   ≥60yrs        9 
Waist Circumference (cm) Men< 94cm, Women <80cm; Yes Yes Yes 0 
   Men ≥94cm, Women ≥80cm       2 
Body Mass Index (kg/m2 < 25kg/m2 Yes Yes Yes 0 
  25-30kg/m2    2 
  ≥30kg/m2       3 
Family history of diabetes 0, no; 1 yes  Yes Yes No 8 
Current hypertension status 
(Systolic BP≥140mmHg 
and or Diastolic BP ≥90 
mmHg) 
0, no; 1 yes  Yes Yes Yes 3 
 
Key 
BMI = Body Mass Index
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7.3.2 New Model Performance in Validation Populations 
Performance of the newly developed risk score is presented below. The score had on 
overall performance in all the validation population with AUC ranging from 0.70 (95% 
CI 0.70 to 0.75) (Figure 7-5 ) in the Guinea validation population with lowest 
performance to 0.82 (95% CI 0.76 to 0.87) in the Cape Town study population (Figure 
7-1). Also the overall performance was better when diabetes was defined using fasting 
glucose than when using OGTT, AUC in CRIBSA data were 0.82 (95% CI 0.76 to 0.87) 
versus 0.75 (95% CI 0.56 to 0.82)  respectively see Figure 7-1 and Figure 7-2 below but 
the difference is not statistically significant. 
 
Figure 7-1 Model Performance in CRIBSA Data Diagnosis by Fasting Glucose 
 
Figure 7-2 Model Performance in CRIBSA Diabetes Diagnosis by OGTT 
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When the new score was validated in a rural black South African population in the KZN 
data the score performance in terms of the Area under the ROC curve ranged from 0.70 
(95% CI 0.62 to 0.78)  to 0.8 (95% CI 0.77 to 0.83) using OGTT and fasting glucose 
respectively signifying good ability to discriminate between cases and non-cases. 
 
Figure 7-3 Performance of the New Score in KZN Data, Diagnosis by Fasting Glucose 
 
Figure 7-4 Performance of the New Score in KZN Data, Diagnosis by OGTT 
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Figure 7-5 Performance of the New Score in Overall Guinea Validation Population 
 
7.3.3 Comparison of the Performance of the New Model with Existing Risk 
Scores 
The new score performed better when compared to the existing diabetes scores in the 
CRIBSA study population (Table 7-2). 
In the CRIBSA study validation , compared to the KZN validation the US score (Bang et 
al., 2009) had similar performance when fasting glucose is used for diagnosis in both the 
Area under the ROC curve 0.79 (95% CI 0.73 to 0.85) vs. 0.76 (95% CI 0.69 to 0.84) and 
a better combination of sensitivity (66.7%) and specificity (77%) vs. sensitivity (50%) 
and specificity (82.4%)  . The Rotterdam (Baan et al., 1999), Chinese (Gao et al., 2010) 
and the US score (Bang et al., 2009) displayed overall good combination of both 
sensitivity and specificity . The Indian scores (Chaturvedi et al., 2008, Ramachandran et 
al., 2005) had sensitivity of over 90% but had the lowest specificity of around 30%. When 
OGTT is used to define cases a similar pattern is observed in both AUC and in sensitivity 
and specificity with the US score (Bang et al., 2009) showing almost similar performance 
when compared to the new score developed in this study. 
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Table 7-2 Comparison of the Performance of the New Model with Existing Scores in CRIBSA 
Study Population 
 
Key 
FPG = Fasting Plasma Glucose, OGTT = Oral Glucose Tolerance Test, AUC = Area 
under the Curve, Std. Error = Standard Error of the AUC 
The cut off used for the scores were ≥ 7 for the new score, ≥ 14 for the Chinese score 
(Gao et al., 2010), ≥ 10 for the Oman score (Al-Lawati and Tuomilehto, 2007), ≥ 18 for 
the Brazil score (Pires de Sousa et al., 2009), ≥ 21 (Ramachandran et al., 2005) and ≥ 16 
(Chaturvedi et al., 2008) for the Indian scores, ≥ 5 for the US score (Bang et al., 2009) 
and ≥ 6 for the Rotterdam score (Baan et al., 1999). 
Score   AUC  Sensiti
vity 
(%) 
Speci
ficity 
(%) 
 
 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
FPG       
New score  
0.82 0.029 0.76 0.87 80.0 72.4 
Chinese score (Gao et al., 2010) 
0.75 0.035 0.69 0.82 83.3 60.0 
Oman score (Al-Lawati and 
Tuomilehto, 2007) 0.74 0.037 0.67 0.81 76.9 54.0 
Brazilian score (Pires de Sousa et al., 
2009) 0.72 0.038 0.65 0.79 80.0 45.9 
Indian score (Ramachandran et al., 
2005) 0.77 0.032 0.71 0.83 94.9 29.1 
Indian score (Chaturvedi et al., 
2008) 0.76 0.032 0.69 0.83 97.4 31.0 
US score (Bang et al., 2009) 
0.79 0.030 0.73 0.85 66.7 77.0 
Rotterdam score (Baan et al., 1999)  
0.73 0.039 0.65 0.81 62.5 70.3 
2hr OGTT       
New score 
0.75 0.041 0.56 0.82 68.9 71.2 
Chinese score (Baan et al., 1999) 
0.69 0.044 0.60 0.77 73.7 57.4 
Oman score (Al-Lawati and 
Tuomilehto, 2007) 0.70 0.040 0.62 0.77 72.7 53.9 
Brazil score (Pires de Sousa et al., 
2009) 0.72 0.040 0.64 0.80 78.4 45.7 
Indian score (Ramachandran et al., 
2005) 0.70 0.039 0.63 0.78 91.0 43.4 
Indian score (Chaturvedi et al., 
2008) 0.69 0.041 0.61 0.77 84.4 29.4 
US score (Bang et al., 2009) 
0.75 0.037 0.68 0.82 60.0 77.2 
Rotterdam score (Baan et al., 1999) 
0.70 0.042 0.62 0.78 64.4 70.3 
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Table 7-3 Comparison of the Performance of the New Model with Existing Scores in KZN 
Study Population 
 
Key 
FPG = Fasting Plasma Glucose, OGTT = Oral Glucose Tolerance Test, AUC = Area 
under the Curve, Std. Error = Standard Error of the AUC 
The cut off used for the scores were ≥ 7 for the new score, ≥ 14 for the Chinese score 
(Gao et al., 2010), ≥ 10 for the Oman score (Al-Lawati and Tuomilehto, 2007), ≥ 18 for 
the Brazil score (Pires de Sousa et al., 2009), ≥ 21 (Ramachandran et al., 2005) and ≥ 16 
(Chaturvedi et al., 2008) for the Indian scores, ≥ 5 for the US score (Bang et al., 2009) 
and ≥ 6 for the Rotterdam score (Baan et al., 1999). 
Score 
  AUC  
Sensi 
tivity 
Speci 
ficity 
  Std. 
Error 
Lower 
Bound 
Upper 
Bound 
(%) (%) 
FPG       
New score  0.80 0.035 0.77 0.83 90.5 65.0 
Chinese score 
(Gao et al., 2010) 
0.73 0.039 0.65 0.80 75.0 66.0 
Oman score (Al-Lawati and 
Tuomilehto, 2007) 
0.69 0.043 0.61 0.77 82.6 55.0 
Brazilian score (Pires de Sousa 
et al., 2009)  
0.64 0.042 0.56 0.72 54.5 57.6 
Indian score (Ramachandran et 
al., 2005) 
0.76 0.036 0.69 0.83 95.7 43.2 
India score (Chaturvedi et al., 
2008) 
0.76 0.039 0.69 0.84 95.8 39.8 
US score (Bang et al., 2009) 0.76 0.037 0.69 0.84 50 82.4 
Rotterdam score (Baan et al., 
1999) 
0.61 0.052 0.51 0.71 48 68.8 
2hr OGTT       
New score 0.70 0.040 0.62 0.78 67.9 64.0 
Chinese Score (Gao et al., 2010)  0.67 0.039 0.59 0.74 68.8 66.0 
Oman score (Al-Lawati and 
Tuomilehto, 2007) 
0.65 0.040 0.58 0.73 71.9 54.8 
Brazil score (Pires de Sousa et 
al., 2009) 
0.58 0.044 0.50 0.67 48.3 47.4 
Indian score (Ramachandran et 
al., 2005) 
0.68 0.040 0.60 0.76 78.1 42.6 
Indian score (Chaturvedi et al., 
2008) 
0.67 0.042 0.59 0.76 87.5 39.8 
US score (Bang et al., 2009) 0.70 0.036 0.64 0.77 37.5 82.3 
Rotterdam score (Baan et al., 
1999) 
0.58 0.048 0.48 0.67 39.4 68.7 
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As mentioned previously in this chapter, in the Guinea validation study only the Brazilian 
(Pires de Sousa et al., 2009) score could be validated due to lack of appropriate variables 
in the data sets, the results of which are stratified by sex categories because of enough 
events per variable. In this population the performance of the new risk score (AUC 0.69 
95% CI 0.64 to 0.75) was lower compared to when it was applied to the KZN (AUC 0.80 
95% CI 0.77 to 0.83) and CRIBSA study populations (AUC 0.82 95% CI 0.76 to 0.87). 
The score however had a non-significant better performance among females compared to 
males, AUC 0.7 (95% CI 0.63 to 0.77) vs. 0.65 (95% CI 0.57 to 0.73) respectively. The 
new score had much lower sensitivity among males (33%) compared to females (53%). 
The Brazilian score had poor performance in this population with especially low 
sensitivity ranging from 29% to 35% respectively but with good specificity of more than 
70%. 
Table 7-4 Performance of the New Risk Score in Comparison with Existing Scores in the 
Guinea Validation Population 
 
Key 
FPG = Fasting Plasma Glucose, AUC = Area under the Curve, Std. Error = Standard 
Error of the AUC 
The cut off used for the scores were ≥ 7 for the new score and ≥ 18 for the Brazil score 
(Pires de Sousa et al., 2009)  
Score   AUC  Sensitivity Specificity 
 
 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
(%) (%) 
FPG       
New score Overall 0.69 0.027 0.64 0.75 43.6 79.8 
New score Male   0.65 0.042 0.57 0.73 33.3 83.7 
New score Female 0.70 0.037 0.63 0.77 53.1 76.4 
Brazil score (Pires de Sousa 
et al., 2009) Overall  
0.62 0.027 0.57 0.67 31.9 77.8 
Brazil score (Pires de Sousa 
et al., 2009) Male  
0.58 0.041 0.50 0.66 28.8 78.2 
Brazil score (Pires de Sousa 
et al., 2009) Female  
0.66 0.035 0.59 0.73 34.7 77.4 
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7.4 Discussion 
This chapter was aimed at externally validating the derived new diabetes score in new 
populations and to compare its performance with existing scores. The existence of 
effective means for the prevention and control of diabetes have spurred the importance of 
diabetes risk scores as a public health tool to identify individuals at high risk of diabetes. 
In this study 7 existing risk scores are evaluated alongside the new score in various 
populations. All the existing risk scores were evaluated using the optimal cut off points as 
described in the original studies shown in Table 7-1.  
The performance of the newly derived risk score in the validation samples was 
comparable to the performance in derivation study population with Area under the ROC 
curve ranging from 0.70 to 0.82 despite using the point score rather than the regression 
equation which tends to lower performance if the former is used. This performance is 
good compared to score performance at validation (AUCs) reported in previously 
published scores where in some validation studies the score performance had wide 
uncertainty intervals. For example, the Rotterdam score (original performance AUC 0.68,  
95% CI 0.64 to 0.72) (Baan et al., 1999) performance ranged from AUC of 0.53 (95% CI 
0.48 to 0.71) in the Cameroonian and in the Oman populations (95% CI 0.53 to 0.54)  to 
0.70 (95% CI 0.67 to 0.73) when validated in the Australian, US 0.68 (95% CI 0.64 to 
0.71) and in the Danish 0.69 (95% CI 0.65 to 0.72) populations (Glumer et al., 2006). 
Another score that has reportedly been externally validated is the Indian diabetes score 
(original performance AUC 0.73 95% CI 0.70 to 0.76 ) (Ramachandran et al., 2005) with 
performances ranging from AUC of 0.63 (95% CI 0.60 to 0.65) in the Chinese population 
(Gao et al., 2010) to AUC of 0.70 (95% CI 0.66 to 0.74) in the Taiwanese population (Lin 
et al., 2009). The Danish score (original performance AUC 0.80 95% CI 0.76 to 0.83) 
shows significantly less performance at external validation in the Chinese population 
AUC 0.70 (95% CI 0.66 to 0.71) but comparable performance 0.75 (95% CI 0.71 to 0.78) 
in the Australian population.  
Of the scores validated in this study 3 scores have also been externally validated.  These 
include the Rotterdam (Baan et al., 1999), the Indian (Ramachandran et al., 2005) and the 
Oman (Al-Lawati and Tuomilehto, 2007) score. Compared to performance in the 
validation populations in this study, the Rotterdam score, for example, had an AUC of 
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0.68 (95% CI 0.64 to 0.72) in the original population with sensitivity and specificity of 
55% and 78% respectively, and at validation the score had a non-significant better 
performance in the CRIBSA study population with an AUC of 0.73 (95% CI 0.65 to 0.81) 
and sensitivity of 63% and specificity of 70%. Whilst in the KZN study population the 
performance was non-significantly lower with AUC of 0.61 (95% CI 0.51 to 0.71) and 
sensitivity and specificity of 48% and 69% respectively.  
The Oman risk score in this population in this validation study had an AUC of 0.74 (95% 
CI 0.67 to 0.81) and sensitivity and sensitivity of 77% and 54% in the CRIBSA study 
population and AUC of 0.70 (95% CI 0.61 to 0.77) and sensitivity and specificity of 83% 
and 55% respectively which is lower compared to the score performance in the original 
population (AUC 0.83 95% CI 0.82 to 0.84, sensitivity 79% and specificity 73%). The 
performance of the score has shown consistent results when this validation performance is 
compared to what was reported when the Oman score was validated in the Taiwanese 
population where the AUC was reported to be 0.72 (95% CI 0.69 to 0.75) (Lin et al., 
2009). 
The Indian risk score developed by Ramachandran et al had good performance when 
applied to both the CRIBSA (AUC 0.77 95% CI 0.71 to 0.83) and the KZN (AUC 0.76 
95% CI 0.69 to 0.83) study populations which is non-significantly  higher compared with 
the performance in the original population (AUC 0.73 95% CI 0.70 to 0.76) in terms of 
the ability to discriminate cases from non-cases measured as the Area under the ROC 
curve, but the score had varying performance in terms of sensitivity and specificity both 
in this study and other studies that had previously validated the score. In the original 
population this score had sensitivity and specificity of 77% and 60% respectively. At 
validation in the CRIBSA study population this score had sensitivity and specificity of 
97% and 29% respectively and in the KZN population the score had sensitivity and 
specificity of 96% and 43% respectively. These results are similar to what was reported 
by Gao (Gao et al., 2010).  When the score was applied to the Chinese population in this 
study the score had sensitivity of 96% but poor specificity of around 19%. 
Many risk scores show worse performance when applied to populations other than the 
original population where the score was developed. However, in this study we have 
shown contrary findings in that some of the scores, for example the Rotterdam and the 
Indian risk scores, had better discrimination statistics at validation although the 
differences did not reach statistical significance. This could be explained by the high 
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prevalence of the outcome in the validation population. For example, the CRIBSA study 
population (see chapter 6 on page 76) had a high diabetes prevalence of 12%, had higher 
mean BMI (29% kg/m
2
) and had higher prior history of diabetes (30%). To support this 
hypothesis the Rotterdam score had a lower performance in the KZN study population 
which had much lower diabetes prevalence (4.3%), lower mean BMI (25.5 kg/m
2
) and a 
lower prevalence of hypertension history (16%) compared to the original population.  
One reason for the consistent performance for example of the Oman risk score is the use 
of predictor variables that can be measured consistently across populations; this model 
incorporates only age, waist circumference, BMI, family history of diabetes and current 
hypertension status. Behavioral variables such as diet and physical activity measures may 
be difficult to be ascertained because they may be affected by cultural diversity and 
therefore affect the accuracy of the measurements.  This is reflected by the poor 
sensitivity and specificity at validation and requires adjustment of the cut-off point to 
improve performance as illustrated previously by Al Lawati and Colleagues when they 
validated different scores using both the optimal cut off in the original study and the 
adjusted cut off to fit the Kuwaitian population (Al-Lawati and Tuomilehto, 2007). Also 
because many scores incorporate anthropometry measures, whose cut offs are dependent 
on ethnicity risk scores derived in Whites and Asian, for example, they will have poor 
performance in estimating risk resulting in poor sensitivity and specificity e.g. the Indian 
and the Chinese risk scores (Chaturvedi et al., 2008, Mohan et al., 2005, Ramachandran et 
al., 2005, Gao et al., 2010). 
The relationship between sex and diabetes varies across settings with the risk in males 
being clearer in White populations and this could explain the poor performance of the risk 
scores (Bang et al., 2009, Baan et al., 1999) that incorporate sex as a predictor variable, 
especially in African settings where this relationship is unclear. 
The study is not without limitations, firstly not all the scores could be validated because 
of the lack of some of the predictor variables in the scores, and also the validation data 
sets had more women than men which could further affect the overall performance of the 
scores. Missing data in some of the data sets is another challenge which could potentially 
introduce bias. It should also be noted that the validation data sets used different methods 
for diabetes diagnosis which could have potentially affected the performance of the 
scores. 
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The validation of the different scores was done using the simplified point based risk 
scores presented by authors in the various studies instead of applying the original model; 
which normally lowers the model performance. But it should be noted that the results on 
performance of the original scores presented by the study authors were all calculated 
using the point scores. An attempt was made to contact the authors to make comparison 
between the performance of point based score and the original score, but information 
could not be obtained as most authors did not report the y – intercept from for their full 
models. 
It should be noted that the performance of the scores (sensitivity and specificity) is 
dependent upon the level of cut-off point as highlighted previously and also the 
prevalence of disease in a particular population, this could have affected the performance 
of the scores in the validation studies. The higher the prevalence of diabetes, the higher 
the probability of a positive test and the reverse is also true. The scores would probably 
have a different performance had the appropriate cut off point been applied, no attempt 
was made to modify the score to enhance the performance because it was beyond the 
scope of this study.  The main advantage of this study is that it had adequate sample size 
for validation for the number of variables in the validated scores. 
The results of the present study are significant in respect to the future direction of 
diabetes screening.  Combining more than one population in deriving the risk score could 
potentially lead to a risk score that can be broadly applied across different populations 
and also by using variables that are not ethnic or culturally specific the performance of 
the scores can be enhanced, this could potentially explain the good performance of the US 
score which was developed using multi-ethnic population (Bang et al., 2009). Secondly, 
this study affirms the previous recommendation that before the score is adapted for use in 
a given population it should be validated and adjusted accordingly to suit that particular 
population. Methods of updating the risk scores to a new population have been described 
(Steyerberg, 2009) and more efforts should be directed towards evaluating the existing 
scores and adapting them to local settings.  
More research is needed however in this area to validate the utility of such a score in 
different settings, and so more research is needed to elucidate the impact and cost 
effectiveness of using these risk scores as a public health tool towards prevention of 
diabetes and its complications.  
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There is also the need to study how the score would work in clinical practice before 
rolling out a screening program. An evaluation of the UK pilot diabetes screening 
revealed that there were a lot of unanticipated challenges from implementing the 
screening program in a non-trial setting. The findings showed inconsistency in 
implementing the screening protocol, lack of quality control, lack of adequate diagnostic 
testing and follow up after a positive test (Goyder, 2008) which affected the overall 
effectiveness of the intervention. 
Another interesting area of research is to look at the performance of scores derived to 
predict undiagnosed diabetes for prediction of future development of diabetes in disease 
free individuals. 
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Chapter 8. Validation of the Model in a Clinical Setting and 
Comparison of the New Model Performance to Existing Models 
8.1 Introduction 
Chapter 7 described the performance of the new risk score across different validation 
populations using data from studies in South Africa and Guinea different from the score 
derivation population. As previously established the performance of a score tends to be 
better in populations in which they were derived and it is important to validate the 
performance across new settings.  The aim of this chapter is to evaluate the performance 
of the newly developed score across a different context from the score derivation 
population. The data for deriving the score were obtained from diabetes population based 
surveys where subjects were chosen at random during community surveys, the sampling 
process of these studies is described in details in Chapter 5 above. This chapter explores 
the performance of the score in a pragmatic setting where there is no random selection of 
participants; enrolment was rather based an open invitation on fulfilling a certain 
selection criteria. The criterion for selection was that the participants had to be above the 
age of 34 years and living in Dar es Salaam. The decision to include only those above the 
age of 34 was to increase the proportion of individuals with diabetes given that the 
prevalence of diabetes is low in younger age groups as outlined in Chapter 2 pg. 13. 
This setting represents rather a different contextual setting form the score development. 
Apart from looking at the overall performance of the new score in comparison to other 
existing scores, this chapter looks at details the outcome of applying the score in terms of 
the characteristics of the populations by the outcomes of applying the new score to the 
populations.  
To explore the usefulness of applying the score to screen for undiagnosed diabetes in this 
setting, a detailed account of characteristics and a comparison of the study populations is 
made between different categories of risk score points and across different diagnostic 
categories; true positives, false positive, true negative and false negatives obtained by 
applying the new score at a pre specified cut off point. Also this chapter looks at the yield 
of applying the score at different cut points in terms of the numbers needed to screen to 
identify one case of diabetes and the subsequent number of people that have been  
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identified correctly into the respective categories whether positive or negative for the 
condition being screened. 
8.2 Methods 
8.2.1 Study Population 
Data used for validating the score is from screening individuals at district hospitals in Dar 
es Salaam Tanzania. People were invited to participate for diabetes screening to their 
local district hospitals in Dar es Salaam. Detailed accounts of the data collection methods 
and participants’ characteristics are provided in chapter five on Overview of Study 
Populations page 76. This population represents a different setting compared to the score 
derivation population and the South African and Guinea validation populations. In the 
clinical validation population individuals were not selected at random therefore likely to 
contain a more homogenous population with individuals who are more likely to be older 
and or at high risk, which could be a source of bias but represent a pragmatic setting if the 
derived score were to applied as a screening tool at a hospital setting. 
8.2.2 Assessment of Performance 
The ability of the new score to discriminate between those with and without diabetes was 
assessed using Area under the Receiver Characteristic Curves (AUCs) and calibration 
compared using box plots and calibration slopes (Steyerberg, 2009) . Calibration slopes 
were calculated as the differences in the mean predictions in those with and without the 
disease (Steyerberg, 2009). 
Clinical utility (diagnostic capacity) of the score was assessed using sensitivity, 
specificity and positive and negative predictive values (Herman et al., 1998). In addition 
participants’ characteristics across diagnostic groups (true positives, true negatives, false 
positives and false negatives) were compared using Kruskal-Wallis test (Hennekens and 
Buring, 1989) . To calculate sensitivity and specificity of the score for comparison with 
existing ones, the cut-off point for the new score was set at a score of ≥7. The yield of the 
new score was further assessed at various cut points by the numbers needed to screen to 
identify one case of diabetes and the percentage of subjects with diabetes that were 
identified. The number needed to screen was calculated as the ratio of total number of 
undiagnosed diabetes cases diagnosed and the total number needed to be screened with 
the confirmatory test.  
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8.2.3 Risk Scores for Validation 
In addition to the new model, all risk scores applied in chapter 8 on page 128, were also 
validated in this population to compare the performance of existing models and of the 
new model to this populations.  
8.3 Results 
8.3.1 Score Performance 
The performance of the new score when applied to the Tanzania validation data is shown 
in Figure 8-1, Figure 8-2 and Table 8-1 below. The new score had an overall performance 
(AUC) of around 0.67 (95% CI 0.63 to 0.70) (Figure 8-1) with higher performance in 
males (AUC 0.69 95% CI 0.62 to 7.60) than in females (AUC 0.64 95% CI 0.62 to 0.74) 
see Figure 8-2. This performance is slightly lower than what was found when the score 
was validated in the CRIBSA and KZN and Guinea data with AUC ranging from 0.70 
(95% CI 0.70 to 0.75) (Figure 7-5 ) in the Guinea validation population with lowest 
performance to 0.82 (95% CI 0.76 to 0.87) in the Cape Town study population (Figure 
7-1). Table 8-1  below shows the performance of the new risk score in comparison with 
existing scores (Pires de Sousa et al., 2009, Al-Lawati and Tuomilehto, 2007, Baan et al., 
1999, Bang et al., 2009, Chaturvedi et al., 2008, Gao et al., 2010, Ramachandran et al., 
2005) in this population. The overall performance of existing scores ranged from an AUC 
of 0.58 (95% CI 0.54 to 0.61) for the Brazilian (Pires de Sousa et al., 2009) and Oman 
AUC 0.58 (95% CI 0.54 to 0.61) (Al-Lawati and Tuomilehto, 2007) scores, and the 
highest performance was shown with the US (Bang et al., 2009) score which had an AUC 
of 0.64 (95 CI 0.60 to 0.67) . The Chinese score (Gao et al., 2010) and a relatively better 
combination of sensitivity (76%)  and specificity (45%) compared to the other existing 
scores. The Indian scores (Chaturvedi et al., 2008, Ramachandran et al., 2006) had high 
sensitivities ranging from 83% to 89% but very poor sensitivity ranging from 20% to 27% 
at the defined cut off points. The new score had moderately good sensitivity and 
specificity with sensitivity of 74% and specificity of 57%. Figure 8-2 shows the 
performance of the new score was better in males compared to females. In males the 
sensitivity and specificity of the new score was 70% and 65% respectively whilst in 
females it was 67% and 60% respectively. A similar pattern also emerged with all the 
existing scores when the analysis was done by sex, with all the scores having better 
performances in males compared to females in this population. The reason for the better 
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performance in men could be due to better correlation of the anthropometric measures 
(BMI and waist circumference) with diabetes risk in men compared to women. 
 
Figure 8-1 Performance of the New Score in the Tanzania Validation Population 
 
Figure 8-2 Performance of the New Score by Sex in the Tanzania Validation Population  
Key 
ROC = Receiver Operating Characteristic Curve 
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The calibration of the risk scores was assessed using calibration slopes, the higher the 
slope the better the distinction between those with and without the disease, with majority 
of cases without diabetes having scores below the cut-off point and those with diabetes 
having total scores above the cut- off point. In the derivation population the calibration 
was better in males with a calibration slope of 5 vs. a slope of 3 in females Figure 8-3, the 
findings also shows that the new score overestimated risk especially in women. In the 
validation population the calibration slopes were 5 for males and 4 for women slightly 
better than what was observed in the derivation population. 
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Table 8-1 Performance of the New Score Compared to Existing Scores in the Tanzania 
Validation Study  
 
Score AUC Sensiti
vity 
% 
Specifi
city 
% 
 Std. 
Err. 
Lower 
Bound 
Upper 
Bound 
OVERALL       
New score  0.67 0.03 0.63 0.70 74.3 57.1 
Chinese score (Gao et al., 2010)  0.63 0.03 0.59 0.66 75.9 45.4 
Oman score (Al-Lawati and Tuomilehto, 
2007)   
0.58 0.03 0.54 0.61 65.4 40.6 
Brazil score (Pires de Sousa et al., 2009)  0.58 0.03 0.54 0.61 60.4 48.4 
India Score (Ramachandran et al., 2005)  0.61 0.03 0.58 0.64 83.5 27.2 
India Score (Chaturvedi et al., 2008)  0.62 0.03 0.58 0.64 89.2 20.1 
Us Score (Bang et al., 2009)  0.64 0.03 0.60 0.67 32.0 84.4 
Rotterdam (Baan et al., 1999)  0.60 0.03 0.57 0.63 44.9 69.6 
MALE       
New score  0.69 0.03 0.62 7.60 70.0 65.0 
Chinese score (Gao et al., 2010)  0.66 0.04 0.58 0.73 89.6 39.8 
Oman score (Al-Lawati and Tuomilehto, 
2007)  
0.59 0.04 0.50 0.67 60.0 52.5 
Brazil score (Pires de Sousa et al., 2009)  0.62 0.04 0.53 0.71 54.5 58.1 
India Score (Ramachandran et al., 2005)  0.65 0.04 0.58 0.73 87.2 39.5 
India Score (Chaturvedi et al., 2008)  0.66 0.03 0.58 0.74 91.3 31.2 
Us Score (Bang et al., 2009)  0.66 0.04 0.57 0.74 38.3 80.8 
Rotterdam (Baan et al., 1999)  0.61 0.04 0.52 0.70 63.3 52.6 
FEMALE       
New score  0.64 0.03 0.54 0.74 67.0 60.2 
Chinese score (Gao et al., 2010)  0.58 0.04 0.50 0.66 64.3 47.7 
Oman score (Al-Lawati and Tuomilehto, 
2007)  
0.58 0.04 0.50 0.66 69.6 35.7 
Brazil score (Pires de Sousa et al., 2009)  0.58 0.04 0.50 0.66 66.0 44.3 
India Score (Ramachandran et al., 2005)  0.60 0.04 0.51 0.68 80.4 22.0 
India Score (Chaturvedi et al., 2008)  0.60 0.04 0.51 0.67 83.9 28.6 
Us Score (Bang et al., 2009)  0.61 0.04 0.52 0.69 26.8 85.9 
Rotterdam score (Baan et al., 1999) 0.54 0.04 0.47 0.62 29.3 76.6 
Key 
FPG = Fasting Plasma Glucose, OGTT = Oral Glucose Tolerance Test, AUC = Area 
under the Curve, Std. Error = Standard Error of the AUC 
The cut off used for the scores were ≥ 7 for the new score, ≥ 14 for the Chinese score 
(Gao et al., 2010), ≥ 10 for the Oman score (Al-Lawati and Tuomilehto, 2007), ≥ 18 for 
the Brazil score (Pires de Sousa et al., 2009), ≥ 21 (Ramachandran et al., 2005) and ≥ 16 
(Chaturvedi et al., 2008) for the Indian scores, ≥ 5 for the US score (Bang et al., 2009) 
and ≥ 6 for the Rotterdam score (Baan et al., 1999). 
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Figure 8-3 Calibration of the New Score in the Derivation Population 
 
Figure 8-4 Calibration of the New Score in the Clinic Validation Population by Sex 
Key 
Box plots showing score calibration in derivation and validation in the clinic study population, 
the higher the mean score above the red reference line for those with diabetes the better the 
discrimination, and the lower the mean score below the reference line for those without diabetes 
the better the calibration, these graphs are showing that in both cases calibration was better in 
males. 
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8.3.2 Yield and Characteristic of Study Participant across Diagnostic Categories 
The yield (number of people diagnosed) of the score or clinical utility of the score is 
summarized in Table 8-2 and  
Table 8-3 below. Table 8-2 shows the yield of the score across different diagnostic 
categories and summarizes the number that will need to be screened with a subsequent 
test and the numbers needed to screen to identify one case of diabetes and also the 
percentage of those with undiagnosed diabetes that are diagnosed when the risk score is 
used for diagnosis. 
At the recommended cut off point of ≥7  the score has sensitivity and specificity of 74% 
and 57% as mentioned previously and a positive predictive value of  16.4 (Table 8-2). 
Using this  cut off point ( ≥7 ) 46% of the participants will require a confirmatory test and 
the number needed to screen to identify one diabetes case is reduced to 8  from 20 in this 
population at the cost of missing one case out of every five. 
Results also show that increasing the cut off points increases the specificity at the expense 
of sensitivity and reduces significantly the number of cases of undiagnosed diabetes that 
would be picked, for example increasing the cut-off point from ≥7 to ≥ 9 reduces the 
percentage of diabetes cases identified from 74% to 59%. Figure 8-5 also shows that the 
proportion of participants with diabetes increased sharply from around 5% among those 
with total scores of 5 or less than 5 to more than 15% in those with total scores of more 
than 5. 
Table 8-3 summarizes the characteristics of patients across different diagnostic categories 
namely true positives, true negatives, false positives and false negatives. Results show 
that both the true positives and false positives are individuals at high risk with higher 
levels of cardiovascular risk profiles; are older, obese, have hypertension, and have high 
cholesterol levels compared to the true negatives and the false negatives. The individuals 
with undiagnosed diabetes that are missed by the score are younger, with lower mean 
blood pressure and are less obese. 
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Table 8-2 Yield of Using the Score to Screen for Undiagnosed Diabetes across Different Categories 
Total score Sensitivity (95% CI) Specificity (95% CI) LR+ PPV N (%) Screen Prevalence % Diagnosed NNs 
≥0 91.4 (84.4 to 96.0) 16.5 (14.2 to 19.1) 1.1 11.0 870 (84.0) 5.0% 91.0 20 
≥3 82.9 (74.3 to 89.5) 34.8 (31.8 to 38.0) 1.27 12.6 691(66.9 ) 4.3% 82.9 23 
≥5 78.1 (69.0 to 85.6) 46.1 (42.8 to 49.3) 1.45 14.1 582(56.4) 3.8% 78.1 21 
≥7 74.3(64.8 to 82.3) 57.1 (53.8 to 60.3) 1.73 16.4 476 (46.1) 12.4% 74.3 8 
≥9 59.0 (49.0 to 68.5) 69.3 (66.2 to 72.2) 1.92 17.9 347(33.7) 19.3% 59.0 5 
≥12 29.5 (21.0 to 39.2) 83.2 (80.6 to 85.5) 1.75 16.6 187( 18.0) 16.6% 29.5 6 
Key 
NNS= Number Needed to Screen 
CI = Confidence Interval 
LR+ = Likelihood ratio of a positive test 
PPV = Positive Predictive Value 
N= Number of people requiring a confirmatory test 
 
Table 8-3 Characteristics of Study Participants across Different Diagnostic Categories   
Variables 
Diagnosis  Category   
TP FP FN TN All P value 
Age (yrs.) 55.2 (10.3) 54.3(10.2) 44.3(8.9) 40.63 (10.7) 47.1(12.5) <0.001 
BMI (kg/m2) 29.3 (4.7) 30.15 (6.0) 22.93(5.1) 24.95(5.1) 27.2(6.0) <0.001 
Waist Circumference (cm) 103.8 (18.5) 101.8(10.6) 82.11(12.8) 85.8 (11.3) 93.2 (14.4) <0.001 
Systolic BP 147.3 (23.4) 149.4(26.0) 123.6(17.3) 122.0(18.0) 134.5 (25.6) <0.001 
Diastolic BP 87.0(13.9) 88.2 (13.2) 77.7 (11.9) 74.8(12.0) 81.0 (14.2) <0.001 
Total Cholesterol 6.1(2.0) 6.2(2.1) 5.6(1.5) 5.5(1.8) 5.8(1.9) <0.001 
HDL Cholesterol 1.4(0.7) 1.5(0.5) 1.5(0.6) 1.5(0.5) 1.5(0.5) 0.205 
Triglycerides 1.3(0.9) 1.2(0.9) 1.2(0.9) 0.9(0.7) 1.1(0.8) <0.001 
Key  
Values are means (standard deviation), P Value for differences between groups 
TP= True Positives, FP= False Positives, FN = False Negatives, True Negatives 
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Figure 8-5 Proportion with Diabetes across Risk Score Quartiles 
Key 
1= Total score of -9 to 2,  
2= Total score of 3 to 5,  
3= Total score of 6 to 10  
4= Total score 11 to 15 
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8.4 Discussion 
 This chapter dealt with the validation of the newly derived score in a pragmatic clinical 
(where the score would be applied for screening at a hospital) setting. The chapter 
specifically sought to determine the yield and the effectiveness of applying the score to 
screen for undiagnosed diabetes. 
The score performance in this population was lower than what was found in the previous 
chapters where the score was applied to populations of South African origin chapter 7. 
Ewout  2009 (Steyerberg, 2009) suggests that external validity of a risk prediction is 
affected by two main factors first is the validity of the regression coefficients which is 
affected by the differences in the relationship between the validation and the 
developmental study population, this could be due to true differences or differences in the 
definition of predictors and  the outcome and differences in the selection of patients. Also 
the differences could arise from a narrow selection of cases which he termed 
homogeneous case mix. The later theory explains better the drop of performance in this 
study due to the non-random selection of study and the nature of how the patients were 
recruited the participants that were recruited were somewhat homogenous with high 
levels of risk factors hence affected the discriminatory capacity of the score without 
affecting its calibration. This findings show that the performance of the score would 
actually be better in populations with more heterogeneous case mix for example in 
settings where the participants are selected at random which was the case for the south 
Africa and the Guinea validation populations. The better performance of the score in men 
compared to women could be due to the fact that waist circumference has better 
correlation with diabetes risk in men. 
In evaluating screening tests one of the important characteristic besides the discrimination 
and the calibration statistics is the yield of screening. The yield of screening is affected by 
the prevalence of the target disease in the background population. In settings where 
prevalence of the outcome is low screening everyone may not be worthwhile as the yield 
may be very low (Janssen et al., 2007, Leiter et al., 2001). The yield can be enhanced by 
targeting a group of individuals with high probability of the outcome. Risk scores and 
using other demographic characteristics can be used to identify individuals at high risk.  
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For example the Nationwide screening that was carried out in Brazil (Nucci et al., 2004, 
Toscano et al., 2008) identified one case of diabetes for every 64 people screened 
translating into a cost of 76 USD to identify one case of diabetes. The cost could have 
been significantly reduced if an initial screening test was used to identify high risk 
individuals. In settings where the prevalence of diabetes is high universal screening may 
be cost effective for example in Saudi Arabia one of the countries with highest prevalence 
of diabetes needed to screen 6 individuals to identify one case of diabetes in a community 
wide screening that was carried out (Al-Baghli et al., 2010). In this study applying the 
risk score reduced the number needed to screen from 20 to 8 which similar findings 
compared to what has been reported in other studies for example a study in Japan 
reported a reduction of the number needed to screen from about 16 to less than 7 when 
age, BMI, hypertension history was used to pre-screen individuals before going for a 
secondary test. 
This study has shown that screen detected high risk individuals are at higher levels of 
cardiovascular risk factors regardless of their diabetes status. These findings agree with 
what has been reported previously in other studies. A study in the Netherlands (Janssen et 
al., 2008) demonstrated that  high risk individuals free of diabetes  identified at screening 
had high levels of cardiovascular events and should not be re-assured but intervened upon 
to reduce their risk of  bad cardiovascular outcomes. Other studies also report similar 
findings, for example a study by Sandbaek et al (Sandbaek et al., 2008) showed that 
individuals with high risk score had significantly higher mortality compared to those 
within the lower risk score categories in the ADDITION study . In this study it was found 
that the individuals with diabetes who are missed by the score have lower cardiovascular 
risk profiles and a study previously demonstrated that this group of individuals was 
shown to have significantly lower risk of mortality compared to the true positives and the 
false positives (Spijkerman et al., 2002). 
The cost screening for diabetes is dependant over several factors including, the type of 
test used and the cut off points used for diagnosis, the test uptake, frequency of testing, 
and most importantly what happens to those diagnosed with diabetes or having 
prediabetes. Studies have previously reported that screening is more cost effective if a 
diabetes risk score or a form of risk stratification such as age and obesity is applied to 
stratify individuals at high risk who are then invited (Zhang et al., 2003, Mohan et al., 
2011). The type of glucose test used also affect the overall cost of screening, due to the 
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cost of individual test (HbA1c more costly compared to FBG or RBG) or the overall test 
uptake, with studies showing that OGTT screening strategies with OGTT were less cost 
effective if the OGTT uptake was low (Hoerger et al., 2004, Icks et al., 2004, Icks et al., 
2005, Janssen et al., 2007). Most studies have shown that diabetes screening is more cost 
effective if started above the age of 40 years and if repeated after every 3 to 5 years, 
frequent screening or screening those below the age of 40 are less likely to be cost 
effective because it leads to low yield due to resulting low prevalence (Kahn et al., 2010, 
Gillies et al., 2008). 
For a screening program for undiagnosed diabetes, the underlying assumption is that 
people with diabetes will be diagnosed early and referred for proper care. Studies looking 
at effectiveness of diabetes screening have shown that this is a key underlying factor that 
determines cost effectiveness (Gillies et al., 2008, Kahn et al., 2010, Li et al., 2010). 
Availability of organised care and follow up of cases identified through screening is 
likely to be a challenge if this risk score is to be applied in practice, as outlined in chapter 
three on page 32; diabetes screening in Sub-Saharan Africa will require further 
investment in strengthening the health care system. 
In conclusion screening for diabetes may be worthwhile but likely to be challenging 
especially Sub Saharan Africa. Studies have demonstrated that individuals that are 
labelled high risk by the risk scores tend to have higher risk of cardiovascular diseases 
and mortality and that it is worthwhile to intervene in this group of individuals regardless 
of their diabetes status. Use of diabetes risk scores also significantly reduces the overall 
cost of screening and increases the yield of the screening program.
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Chapter 9. Conclusion 
This study has given an account of the burden of diabetes in Africa and the opportunities 
for earlier identification of people at high risk of diabetes and its complications. It is 
evident that the prevalence of diabetes and its related complications are increasing in 
Africa and globally as a whole. Strategies are needed to ensure that the current trends in 
the increase in the burden of diabetes do not continue.  
This study was designed to develop and validate a diabetes screening tool for use in low 
resource settings in Africa, and also describes the performance of diabetes risk scores 
derived from other populations when applied to the African populations. The study 
pooled data from 3 African countries with the aim of developing a risk score that would 
be applicable across a wider African setting.  
The resulting score has age, waist circumference and prevalent and or history of 
hypertension as predictor variables. In this study when the existing scores were validated, 
it is worth noting that the scores did not differ much in their ability to discriminate 
between cases and non-cases based on the AUCs, but calibration was poor for all the 
scores. The following conclusions can be drawn from the present study; the performance 
of the new score developed in this study was better across all populations where it was 
validated in terms of both discrimination and calibration.  Also the score performance can 
be enhanced by re calibrating the score to the new populations where it is intended to be 
applied (Steyerberg, 2009). The present study confirms previous findings that risk scores 
may not apply universally as it has generally been demonstrated by previous studies, and 
in this study, that a risk score developed in one population performs poorly when applied 
to other populations of different ethnic background.  
Although there may be issues with age ascertainment and measuring waist circumference 
and blood pressure as discussed in chapter 6 on page 125, the risk score is simple enough 
for use by health workers, and can be used both at the health facility level and during 
community outreach programs. Majority of people would be aware of their age, but the 
challenge remains with those that have poor literacy and the elderly, but often their age is 
estimated using major life events such as the age of their children, major country events 
like independence etc. Health care workers can be trained on proper measurements of 
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waist circumference, and also blood pressure measurement form part of routine health 
check at the health facilities. 
At this stage when community wide screening for diabetes is not recommended, I see this 
risk score being useful in primary health care setting where services for diagnosis may be 
unavailable; hence it can be used to identify individuals at high risk of diabetes that can 
be referred to the next level of care for confirmatory diagnosis and further management. 
However it should be acknowledged that the effectiveness of the screening will be 
dependent on the availability of a proper resources infrastructure to support the screening 
program, which is discussed in detail in chapter 3, 6, 7 and 8. 
During implementation of such a screening program, there will be individuals that will be 
detected with prevalent diabetes which present opportunity for secondary prevention i.e. 
early treatment of hypertension, blood glucose control, treatment with lipid lowering 
agents etc. to prevent micro and macrovasular complications and also management of 
prevalent complications to prevent disability (tertiary prevention). Diabetes screening also 
identifies individuals at high risk of diabetes who may benefit from primary prevention 
programs, this particularly presents a challenge especially in Sub-Saharan Africa where 
there not yet systems or there may be little resources both technical know-how and 
budgetary available to implement such interventions. There will be need to engage with 
policy makers in order to ensure evidence based decision making in developing and 
implementing plans to strengthen care for diabetes and other cardiovascular diseases. 
The study was limited in several ways.  First the study used secondary data from previous 
diabetes studies.  Not all the variables were assessed the same way therefore some of the 
variables could not be used to derive the score.  Also the family history variable was 
lacking in some of the data sets therefore was not included as a predictor variable. Not all 
variables were present to enable validation of all existing scores and, as a result, some 
scores could not be validated. The diagnostic methods for diabetes varied across studies 
which could be a source of bias and makes it difficult to compare the various risk scores. 
In addition, a completed case analysis was undertaken to deal with missing data this could 
also potentially bias the findings of this study especially if the data was not missing at 
random. 
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Secondly, the data that were used to validate the clinical utility of the new score were 
based on a convenience sample so caution must be applied as the findings might not be 
transferable to the Tanzanian population.  
This study was focused on determining prevalent undiagnosed diabetes; more research is 
needed to validate the score across other African settings and also to study the feasibility 
of applying the score for opportunistic screening in a clinical setting and to investigate the 
issues related to who to screen, how should the score be applied, whether be filled by 
nurses or clinicians attending patients, issues related to acceptability by both the health 
workers and patients, resources needed and identify challenges of implementation as a 
whole and also the resources required to implement such as screening program.  
This type of evaluation could not be undertaken during the present study because of time 
and other resource limitations. Further research will also be needed to evaluate the 
process and also the outcome of screening in terms of reducing the unfavourable diabetes 
outcomes. This research has also thrown up many questions that need further 
investigations such as the need to explore the score’s capacity to predict incident diabetes 
and in predicting pre diabetes which are essential components in identifying individuals at 
high risk of diabetes targeted for primary prevention interventions.  
What this study adds is that I have developed the first ever diabetes risk score for Africa. 
This score performed better compared to other available risk scores developed from 
developed countries as discussed in detail in chapter 7 on page 128 . 
The policy implications of this study is that results of this support the idea that there is no 
universal score that is applicable to all but rather it is possible to have a risk score that 
cuts across different settings; instead of having a plethora of new scores efforts should be 
directed towards validating and adapting existing, simple risk scores that are relevant 
across different settings and; are using predictor variables that are not culturally specific 
and; those that can be consistently and accurately measured. The choice of the risk score 
to be used should be guided by the local needs. Before adapting a score for use, it should 
be validated and re calibrated if necessary to suit the local population.   
Diabetes screening to identify high risk individuals to be directed for proper interventions 
has to be organised in a systematic manner for it to be cost effective and countries need to 
develop their screening strategies based on resources available. Facts to support universal 
screening for diabetes are unclear but available evidence supports screening of 
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individuals at high risk of diabetes by opportunistic screening (chapter 3).  Diabetes risk 
scores are a could be a feasible approach as an initial screening tool to reduce the number 
of individuals that would require a confirmatory blood test which tend to be more 
expensive and unavailable, for example in rural African settings. 
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Appendix 
Appendix 1 Selected Publications, Presentations and Certificates of Attendance to 
Conferences and Seminars 
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Appendix 2  The Scoring System used for the QUADAS Tool to Assess Quality of 
Studies included in the Review of Diabetes Risk Scores  
QUADAS Item Y =Yes, N =No, U =Unclear 
1. Was the spectrum of patients’ 
representative of the patients who 
will receive the test in practice?  
Y- participants enrolled reflect those affected by the 
condition in practice 
N- participants enrolled does not reflect those affected 
by the condition in practice 
U-if the source or characteristics of participants is not 
adequately described 
2. Were selection criteria clearly 
described? 
 
Y-participant selection criteria adequately described 
N-patient selection criteria not clearly reported 
U- if insufficient information is given to permit 
judgement 
3. Is the reference standard likely 
to correctly classify the target 
condition?  
Y- if OGTT, FBG or HbA1c is used to as  reference 
standard 
N-if another test is used 
U- if insufficient information is given to permit 
judgement 
4. Did the whole sample or a 
random selection of the sample, 
receive verification using a 
reference standard of diagnosis? 
Y-if all participants received both index(risk score) 
and reference test 
N-if not all participants received both index and 
reference test 
U- if insufficient information is given to permit 
judgement 
5. Did patients receive the same 
reference standard regardless of 
the index test result? 
Y-if the same reference test was used in all participants 
N-if different reference tests are used depending on 
index test 
U- if insufficient information is given to permit 
judgement 
6. Was the reference standard 
independent of the index test (i.e. 
the index test did not form part of 
the reference standard)? 
Y-if OGTT , HbA1c or FBG is the reference test 
7. Was the execution of the index 
test described in sufficient detail 
to permit replication of the test? 
Y- if details of the process of derivation and validation 
of the score (the index tests) are provided 
N-if no details of  the index test 
U- if insufficient information is given to permit 
judgement 
8. Was the execution of the 
reference standard described in 
sufficient detail to permit its 
replication? 
Y- if details of execution of reference tests are 
provided 
N-if no details of execution of  the reference test 
U- if insufficient information is given to permit 
judgement 
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9. Were uninterruptable/ 
intermediate test results reported?  
Y-if the number of patients that have undergone the 
tests matches the number reported in results 
N- if the number of patients that have undergone the 
tests does not matches the number reported in results 
U-if insufficient information is given to permit 
judgement 
10. Were withdrawals from the 
study explained? 
 
Y-if there are no participants excluded from the 
analysis, or if the exclusions are adequately explained 
N-if there are unexplained exclusions from the study 
U-if insufficient information is given to permit 
judgement 
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Appendix 3 Patient Consent Forms (English and Swahili Versions) 
PATIENT CONSENT FORM 
 
Identification number: _____________________________ 
 
 
Title of project: DERIVATION AND VALIDATION OF A RISC SCORING SYSTEM 
FOR IDENTIFICATION OF UNDIAGNOSED DIABETES FOR TANZANIA AND 
OTHER AFRICAN POPULATIONS 
 
Name of researcher; Dr Mary Mayige   
 
I confirm that I have read and understood the information sheet for the above study. I have 
had the opportunity to consider the information, ask questions and have had these answered 
satisfactorily. 
 
I understand that my participation is voluntary and that am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected 
 
 
I agree to have my height and weight, waist and hip circumference measured and my Blood 
pressure checked and recorded 
 
I agree to complete a short questionnaire to check my risk for diabetes 
 
I agree to fasting blood glucose measurements 
 
I understand that the information collected in the study may be viewed by other members of 
the research team [in addition to those named] for the purposes of quality control and by 
Research Governance auditors. 
 
I agree to take part in this study 
 
 
Name of Patient  Date    Signature  
 
 
Researcher   Date    Signature 
 
_______________________________________________________________________ 
 
 
 173 
 
 
FOMU YA RIDHAA KUSHIRIKI KWENYE UTAFITI 
 
Namba ya utambulisho:______________________________ 
 
 
Jina la Utafiti: DERIVATION AND VALIDATION OF A RISC SCORING SYSTEM FOR 
IDENTIFICATION OF UNDIAGNOSED DIABETES FOR TANZANIA AND OTHER 
AFRICAN POPULATIONS 
 
Majina ya mtafiti; Dr Mary Mayige  
 
Nakubali kwamba nimesoma/nimesomewa na kuelewa maelezo yaliyotolewa kuhusu utafiti 
huu. Nimepata fursa ya kuchambua maelezo yaliyotolewa na kuuliza maswali. Nimeridhika 
na maelezo niliyopata. 
 
Naelewa kuwa ushiriki wangu ni wa hiari na nina haki ya kujitoa ushiriki kwenye utafiti huu 
muda wowote bila kupoteza haki zangu au upotevu wa faida yeyote ninayotakiwa kupata  
 
Nakubali kufanyiwa vipimo vilivyotajwa kama kupima urefu, upana wa kiuno, uzito na 
shinikizo la damu 
 
Nakubali kufanyiwa kipimo cha kiwango cha sukari kwenye damu 
 
Nakubali kujaza dodoso fupi ambalo lina maswali yanayolenga kutathmini uwezekano 
wangu wa kuwa na kisukari 
 
Naelewa kuwa taarifa zitakazochukuliwa kwenye utafiti huu zinaweza kuonwa na watu 
mbali mbali ambao wanahusika na utafiti huu [tofauti na waliotajwa hapo juu] kwa ajili ya 
kutatmini kiwango cha utafiti huu na waangalizi wa viwango vya tafiti. 
 
Nakubali kushiriki kwenye utafiti huu 
 
 
Jina la mgonjwa   Tarehe    Sahihi 
 
 
 
Jina la mtafiti    Tarehe    Sahihi 
_______________________________________________________________________ 
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Appendix 4 Patient Information Sheets (English and Swahili Versions) 
PARTICIPANT INFORMATION SHEET 
Introduction 
Greetings! This form contains information about the study on derivation and validation of a 
tool to detect undiagnosed diabetes. To be sure you understand the study we ask you to read 
this form (or have it read to you). The form may contain some words that you do not 
understand, please ask us to explain anything that you may not understand. 
Reason for the research 
This study is being conducted in order to develop a simple tool that can be used to detect 
undiagnosed diabetes in settings where blood glucose measurements may not be feasible or 
available 
General Information about the study 
We are inviting people like you between ages of 35 to 64 who are attending general 
outpatient clinics at the district hospital. That is the age where diabetes is common.  
Your part in the research 
If you agree to participate in this study: 
You will be asked to complete a questionnaire that is meant to assess your individual risk for 
diabetes.   Your height and weight, waist measurement and blood pressure will be checked.  
Identifying information will be collected from you during this interview, but all  information 
will be kept confidential 
You will also be given an appointment for a blood sugar test that involves the following; you 
will be required not to eat or drink anything 8 hours before the test, you will be given 
morning appointments for convenience and you will be provided with some refreshments 
after the test. The blood test will be a finger prick. You will be reimbursed your transport 
cost however this is restricted to public transportation 
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Confidentiality 
I assure you that all the information collected from you will be kept confidential. Only people 
working in this research study will have access to the information. We will be compiling a 
report, which will contain responses from several diabetic patients without any reference to 
individuals.  
Risks 
You will be asked questions about factors that are associated with the risk of diabetes. You 
may refuse to answer any particular question and may stop the interview at any time if you 
feel uncomfortable. Taking part will also take up some of your time.  You will have to return 
another day for the fasting glucose test 
Rights to Withdraw and Alternatives 
Taking part in this study is completely your choice. If you choose not to participate in the 
study or if you decide to stop participating in the study you will not get any harm. You can 
stop participating in this study at any time, even if you have already given your consent. 
Refusal to participate or withdrawal from the study will not involve penalty or loss of any 
benefits to which you are otherwise entitled.  
Benefits  
As a result of you taking part in the study we might identify a way if improving your 
healthcare, you will be given feedback on your health status and information how to reduce 
your risk of getting diabetes. Even if this is not the case the information that you give us will 
help us to ensure that good quality health care is provided to other people like you. The 
information collected will allow us to develop and refine a tool that predicts diabetes so it is 
more useful for populations like our own.  
In Case of Injury 
We do not anticipate that any harm will occur to you or your family as a result of 
participation in this study 
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Who to contact 
If you ever have questions about this study, you should contact the study Coordinator or the 
Principal Investigator, Rd. Mary .T. Mayige, National Institute for Medical Research, 
P.O.Box 538 Tukuyu. (Tel.0713255456). If you ever have questions about your rights as a 
participant, you may contact NIMR ethics review committee, P.O.Box 9653, Dar es Salaam, 
(Tel. 022 2121400) ,  and Dr Eugene Sobngwi, Newcastle University, Institute of Health and 
Society, Newcastle upon Tyne,NE2 4AX, United Kingdom who is the supervisor of this 
study (Tel. +44 (0)191 222 8897 ). 
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FOMU YA MAELEZO YA UTAFITI 
Utangulizi 
Habari! Fomu hii  ina maelezo juu ya utafiti unaohusu tathmini ya upimaji wa kisukari.  
Lengo la utafiti huu ni kuainisha jinsi ya kuwatambua wagonjwa wa kisukari bila kutumia 
kipimo cha damu. Kabla ya kuanza kushiriki tunaomba usome (au tukusomee) maelezo 
yaliyoko kwenye fomu hii. Fomu hii inaweza kuwa na maneno ambayo ni magumu kwako, 
kwa hiyo tafadhali usisite kuomba ufafanuzi kwa maneno ambayo hutayaelewa. 
Malengo ya Utafiti 
Utafiti huu una  lengo la kuanisha jinsi ya kuwatambua watu wenye tatizo la   kisukari bila 
kufanya kipimo cha sukari kwenye damu. Ugunduzi huu utasaidia kugundua wagonjwa 
wengi zaidi wa kisukari kwenye maeneo ambayo kipimo cha damu hakipatikani au hakiwezi 
kufanyika   
Taarifa kuhusu utafiti huu 
Tunakaribisha wagonjwa mbalimbali wenye umri kati ya miaka 35 na 64 wanaohudhuria 
cliniki mbalimbali katika hospitali za wilaya mkoani Dar es Salaam. Ugonjwa wa kisukari 
huwapata zaidi watu walio katika umri huu. 
Nini kitatokea iwapo utakubali kushiriki 
Ukikubali kushiriki katika utafiti huu yafuatayo yatatokea: 
1. Utaombwa kujaza dodoso ambalo lina maswali yanayolenga kutathmini uwezekano 
wako wa kuwa na kisukari. Pia utapimwa urefu na uzito, upana wa kiuno na shinikizo 
la damu 
2. Tutakusanya taarifa chache za utambulisho ambazo zitatunzwa kwa usiri. 
3. Pia utapangiwa siku ya kurudi kwa ajili ya kupima sukari kwenye damu. Kipimo hiki 
kitahitaji: usile au kunywa kitu chochote masaa nane kabla ya kutolewa damu, 
utapewa ahadi ya mapema asubuhi ili iwe rahisi kufanyiwa kipimo kabla ya  chai. 
Utatolewa damu kwenye kidole kwa ajili ya kupima wingi wa sukari. Baada ya 
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kuchukuliwa kipimo utapewa kitu kidogo cha kula . Pia utarudishiwa nauli ya dala 
dala uliyotumia kurudi hospitali kwa ajili ya kipimo. 
Usiri 
Tunapenda kukuhakikishia kwamba taarifa zote utakazotupatia zitakuwa ni siri, ni watu 
wanaofanya kazi katika utafiti huu tu ndio wanaweza kuziona taarifa hizi. Tutajumuisha 
ripoti ambayo itakua na majibu kutoka kwa wagonjwa  kadhaa bila kuweka taarifa zao za 
utambulisho.  
Madhara 
Utaulizwa maswali juu ya masuala ambayo yanaweza kukusababishiakupata kisukari. Baadhi 
ya maswali yanaweza kukukera kidogo.. Unao uwezo wa kukataa kujibu swali lolote na pia 
unaweza kusitisha ushiriki wako kwenye utafiti huu wakati wowote. Kushiriki kwenye utafiti 
huu kutatumia muda wako, kwa sababu utahitajika kurudi tena hospitali kwa ajili ya kipimo 
cha damu. 
Haki ya kujitoa  
Kushiriki katika utafiti huu ni hiyari yako. Unaweza kutokushiriki au kuamua kusitisha 
ushiriki wako bila kupata madhara yoyote. Unaweza kusitisha kushiriki katika utafiti huu 
muda wowote hata kama ulisharidhia kushiriki. Kukataa kushiiriki au kujitoa katika utafiti 
hakutaambatana na adhabu yoyote au upotevu wa faida yoyote unayotakiwa kupata.  
Faida 
Faida ya kushiriki kwako katika utafit huu ni pamoja na wewe binafsi kupata maelezo ya 
yatakayokusaidia kujua hali yako ya kiafya na jinsi ya kuweza kujikinga na matatizo 
yanayoweza kukusababishia kisukari au kujikinga na madhara zaidi yanayotokana na 
kisukari kwa wale watakaogundulika kuwa na kisukari. Vilevile hata kama wewe binafsi 
hutakuwa na tatizo la kisukari taarifa utakazotupatia kwakushiriki kwako zitasaidia 
kuboresha huduma kwa wagonjwa wa  kisukari na taarifa itakayotokana na utafiti huu 
itasaidia katika kugundua njia  ya kutambua wagonjwa wa kisukari kwenye jamii yetu bila 
kulazimika kuchukua vipimo vya damu. 
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Endapo Utadhurika 
Hatutegemei madhara yoyote kwako au kwa familia yako kwa kushiriki kwako katika utafiti 
huu. 
Watu wa kuwasiliana nao 
Kama una maswaIi zaidi kuhusu utafiti huu unaweza kuwasiliana na mratibu mkuu wa 
mradi, Dr. Mary .T. Mayige, Taasisi ya Utafiti wa Magonjwa ya Binadamu (NIMR), S.L.P 
538 Tukuyu (Simu. no. 0715255456). Kama utakuwa na maswali yoyote kuhusu haki zako 
kama mshiriki unaweza  kuwasiliana na  kamati ya taifa ya maadili ya  utafiti , S.L.P 9653 , 
Dar es Salaam (Simu namba: 0222121400) au Dr Eugene Sobngwi wa Chuo Kikuu cha 
Newcastle (Newcastle University), Institute of Health and Society, Newcastle upon 
Tyne,NE2 4AX, United Kingdom ambaye ni msimamizi wa utafiti huu (Simu nambari.  +44 
(0)191 222 8897) 
 180 
 
Appendix 5 Ethics 
 
 181 
 
 
 182 
 
Appendix 6 Field Manual 
 
 
 
 
Derivation and Validation of a Simple Tool for Detection 
of Undiagnosed Diabetes 
 
Field Manual 
 
 
 
Investigator:   Mary Mayige 
Supervisors: Dr Eugene Sobngwi 
      Prof Richard Walker 
      Dr Richard Mcnally 
 
 183 
 
 
Introduction  
Diabetes and its associated conditions is an increasing problem in the country and cause a 
great burden on the country’s health system. Many diabetes patients remain undiagnosed and 
as a result present to the hospitals at late stages of the disease. This study is being undertaken 
as part of a study to develop and test a simple tool for identifying undiagnosed diabetes in 
clinical and non clinical settings. The protocol has been developed to standardise data 
collection procedures and for training of research assistants and also to provide a 
documentation of the process of data collection. 
 
Methods and Design 
Aims and objectives 
The aim of this phase of the project is to; 
1. validate the risk score in a clinical setting 
2. evaluate the  yield and 
3. Comment on the cost of applying the tool in a clinical setting  
Study sample 
Inclusion criteria: Patients 35 to 64 years invited to participate in the study  at district 
hospitals from various areas of Dar es Salaam  
Exclusion criteria: Age <35 and >64 years 
Sample size   
The total estimated sample size is at least 1200. A sample of 200 with and 1000 without 
disease is needed to achieve a minimal standard error of the parameter estimate of tool 
performance. 
Data collection 
Assessment of diabetes risk 
- Selected patients are subjected to the risk score questionnaire which is derived from 
the first part of the study and a general diabetes questionnaire 
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 Physical measurements include
1
; 
- Weight; measured using a standard calibrated portable weighing scale while patient is 
barefoot and wearing light clothing 
- Height; measured while patient is barefoot using a standard stadiometer  
- Blood Pressure; measured using a standard electronic Blood Pressure machine 
- Waist and hip Circumference; measured using a flexible tape and categorised using 
WHO guidelines 
- Fasting blood glucose measurements; 
 
An appointment will be given for fasting blood glucose measurements, participants will be 
asked to fast for a minimum of 12 hours. Blood sample is taken by a finger prick, and 
analysed using a portable glucometer. Hyperglycaemia will be classified according to the 
standard WHO criteria. Patients will be reimbursed transport costs for the additional visits. 
Patients contact details should be taken to facilitate follow up for the fasting glucose 
measurements. The participants will be classified as a loss to follow up after at least three 
failed follow up attempts. 
Yield and the Cost of using the Score 
The yield of patients with undiagnosed diabetes will be compared to those diagnosed through 
the routine diagnostic pathway. Those classified as diabetic from the blood glucose 
measurements should be referred to the diabetic clinic. These patients will have to undergo 
further tests. These include a repeat fasting glucose to confirm diagnosis, eye exam 
(fundoscopy), urine protein using rapid tests(uristics) and further urine analysis if resources 
allow, foot examinations, ECG  and venous blood is taken for cholesterol , renal function 
tests (blood creatinine) and if possible glycated haemoglobin measurements. To document 
resources required to carry out the screening, all materials and time taken to complete the risk 
score and give feedback should be recorded for each of the participant. 
Research Assistants   
Research assistants are to be recruited from the sites to assist with patient recruitment, 
interviews, physical and laboratory examination .The research assistants will have specific 
roles which includes; registration and questionnaire administration, physical as well as 
                                                 
1
 According to the WHO STEPS Guidelines 
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laboratory measurements. These should preferably be nurses, medical assistants and 
laboratory technicians. Research assistants should be adequately trained before beginning the 
research activities. The team should be aware of infection prevention guidelines and 
procedures especially those involved with taking blood samples from patients, Refer to the 
National infection prevention and control guidelines for health care services in Tanzania.  
Setting  
The study sites include Ilala, Temeke and Mwananyamala District Hospital; it is the 
responsibility of the study PI to liaise with the hospital administration to obtain an 
appropriate setting/ room that will allow interviews and the clinical examination procedures 
to be carried out.  
Patient Recruitment Procedures 
Participants will be invited to participate from different areas of Dar es Salaam, invitations to 
participate will be sent out to different social gatherings e.g. churches and mosques, 
advertisement for study will also be placed at busy areas.  
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Summary of Patient Flow and Activities 
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Registration 
This should take place in a quiet place, with a table and chairs 
Greet the subject 
Determine eligibility based on the stated inclusion/ exclusion criteria 
Provide information about the study (refer to the study information leaflet) 
If the subject agrees to participate, take the participant through the informed consent form 
make sure they have understood what has been explained to them before asking them to sign 
the form 
Add the patient to the register and prepare for administering questionnaire 
 
Completing the Questionnaire 
Ask the participant to complete the study questionnaire  
Start with administering the Risk Score and do not forget to record start and finish time 
Follow with the survey Questionnaire, do not repeat the questions, fill in repeating questions 
with information from the risk score 
Questions should be asked in a standard manner using Kiswahili and record answers legibly 
using a pen in appropriate spaces provided. Do not leave any question blank. 
Follow the specific instructions for completing the different items in the questionnaire  
Direct the patient to the person responsible for physical measurements 
 
Physical Measurements 
The following physical measurement will be done; 
Taking Blood Pressure and Recording Heart Rate  
Measuring Height  
Measuring Weight  
Measuring Waist Circumference  
Measuring Hip Circumference  
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Physical Measure Unit of Measurement 
Systolic blood pressure(SBP) mmHg 
Diastolic blood pressure (DBP) mmHg 
Height Cm 
Weight Kg 
Body mass index (BMI) Kg/m
2 
Waist circumference Cm 
Hip circumference Cm 
Heart rate Beats/minute 
 
Sequence of tests 
The physical measurements should be taken from the participant in the following order: 
1. Blood pressure and heart rate 
2. Height 
3. Weight 
4. Waist circumference 
5. Hip circumference. 
Equipments required for tests:  
Please prepare the following the physical measurement station 
blood pressure monitor and appropriate cuff sizes= OMRON blood pressure machines 
will be provided 
height measuring board; 
weighing scales; 
tape measure; 
pen; 
chair or coat rack for participant's clothes; 
curtain or screen to provide privacy if no private area is available for taking 
measurement 
Measuring Blood Pressure and Heart Rate 
Equipment: OMRON digital blood pressure machine 
Preparing the patient: Ask the participant to sit quietly and rest for 15 minutes with his/her 
legs uncrossed.  If the subjects had been seated during and after questionnaire administration, 
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arrangements should be made to make sure that they move only a short distance to the blood 
pressure station so that blood pressure can be measured without having to wait for 15 
minutes. 
Measurements: See instructions below and Refer to the manufacturer’s instructions for 
measuring blood pressure. Three blood pressure measurements and pulse rate should be 
taken. During data analysis the mean of the second and third readings will be calculated.  
Make the patient rest for three minutes between each of the readings. 
record your Interviewer ID (if not already filled in) in the participant's instrument; 
after each of the three measurements, record the results in the participant's instrument; 
check that all readings are correctly filled in the instrument; 
inform the participant on the blood pressure readings only after the whole 
 
The instructions below apply to the use of an OMRON blood pressure monitor. 
Applying the OMRON cuff; follow the steps below to select an appropriate size and apply 
the cuff: 
1.  Place the left arm* of the participant on the table with the palm facing upward. 
2.  Remove or roll up clothing on the arm. 
3. Select the appropriate cuff size for the participant  
4. Position the cuff above the elbow aligning the mark ART on the cuff with the brachial 
artery. 
5.  Wrap the cuff snugly onto the arm and securely fasten with the Velcro. 
Note: The lower edge of the cuff should be placed 1.2 to 2.5 cm above the inner side of the 
elbow joint. 
6 Keep the level of the cuff at the same level as the heart during measurement. 
 
Taking the measurement with an OMRON 
Follow the instructions below to take the blood pressure measurement: 
1. Switch the monitor on and press START  
2. The monitor will start measuring when it detects the pulse and the "heart" symbol will 
begin to flash. The systolic and diastolic blood pressure readings should be displayed within 
a few moments 
 (systolic above and diastolic below). 
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3. Record the reading in the participant's instrument. 
4. Switch the monitor off, but leave the cuff in place. 
5 .Wait three minutes, then repeat steps 1-4 two more times. 
 
Measuring Height 
Equipment: Portable stadiometer 
Preparing the patient: Ask the participant to remove their: 
Footwear (shoes, slippers, sandals, etc) 
 Head gear (hat, cap, hair bows, comb, ribbons, etc). Note: If it would be insensitive to seek 
removal of a scarf or veil, the measurement may be taken over light fabric. 
Taking the measurement 
Follow the steps below to measure the height of a participant: 
Ask the participant to stand facing forward. 
Ask the participant to stand with: 
feet together 
heels against the wall 
knees straight. 
 
Ask the participant to look straight ahead and not tilt their head up. 
Make sure eyes are the same level as the ears. 
Lower the measuring plate gently down onto the head of the participant and ask the 
participant to breathe in and stand tall. 
Read the height in centimetres at the exact point. 
Ask the participant to step away. 
Record the height measurement in centimetres in the participant’s Instrument. Height should 
be recorded to the nearest centimetre 
Record your Technician ID code in the space provided in the participant’s instrument.  
Measuring Weight 
Equipment: Seca digital portable scale. The equipment should be checked and calibrated 
each day. 
Preparing the patient: Ask the participant to remove their footwear (shoes, slippers,sandals, 
etc) and socks. 
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Taking the measurement 
 Ask the participant to step onto scale with one foot on each side of the scale. 
Ask the participant to: 
stand still 
face forward 
place arms on the side and 
wait until asked to step off. 
Record the weight in kilograms on the participant’s instrument. Weight should be measured 
to the nearest 0.1 and rounding up if midway  
Measuring Waist Circumference  
Equipments:  To take waist circumference measurements you will need a: 
constant tension tape (for example, Figure Finder Tape Measure) 
pen 
chair or coat stand for participants to place their clothes. 
Privacy; A private area is necessary for this measurement. This could be a separate room, or 
an area that has been screened off from other people 
 
Preparing the participant:  
Measurement should be taken over light clothing; thick or bulky clothing must be removed. 
How to take the measurement: 
This measurement should be taken:at the end of a normal expiration; with the arms relaxed at 
the sides; at the midpoint between the lower margin of the last palpable rib and the top of the 
iliac crest (hip bone). 
 
 
Follow the steps below to measure the waist circumference of a participant: 
Standing to the side of the participant, locate the last palpable rib and the top of the hip bone. 
You may ask the participant to assist you in locating these points on their body. 
Ask the participant to wrap the tension tape around themselves and then position the tape at 
the midpoint of the last palpable rib and the top of the hip bone, making sure to wrap the tape 
over the same spot on the opposite side. 
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Note: Check that the tape is horizontal across the back and front of the participant and as 
parallel with the floor as possible. 
 Ask the participant to: 
stand with their feet together with weight evenly distributed across both feet;  
hold the arms in a relaxed position at the sides; 
breathe normally for a few breaths, then make a normal expiration. 
 Measure waist circumference and read the measurement at the level of the tape to the nearest 
0.1 cm, making sure to keep the measuring tape snug but not tight enough to cause 
compression of the skin. Record the measurement on the participant’s instrument. 
 
 
Guide for Measuring WC adapted from diabetes atlas (2006)
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Measuring Hip Circumference 
Equipments needed; constant tension tape (for example, Figure Finder Tape Measure), pen, 
a chair or coat stand for participant's to place their clothes. Privacy; A private area is 
necessary for this measurement. Hip measurements are taken immediately after waist 
circumferences. 
Preparing the participant 
Ideally this measurement should be taken without clothing, that is, directly over the skin but 
for cultural reasons in this study the measurement will be taken over light clothing. 
How to take the measurement 
This measurement should be taken: 
-with the arms relaxed at the sides 
-at the maximum circumference over the buttocks 
1. Stand to the side of the participant, and ask them to help wrap the tape around themselves 
2. Position the measuring tape around the maximum circumference of the buttocks. 
3.  Ask the participant to: 
-stand with their feet together with weight evenly distributed over both feet; 
-hold their arms relaxed at the sides. 
4.  Check that the tape position is horizontal all around the body and snug without 
constricting. 
5. Measure hip circumference and read the measurement at the level of the tape to the nearest 
0.1 cm. 
6. Record the measurement on the participant’s instrument. 
Note: Measure only once and record. 
After completing the physical measurements direct the patient to the biochemical 
measurement station, where the patient will be given a morning appointment for fasting 
blood glucose measurement.
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Biochemical Measurements 
Fasting Blood Glucose 
Equipment needed:  
blood glucose measuring device  (Hemoque 201) 
test strips 
lancet 
cotton balls 
sterile swabs 
gloves 
disposable container. 
 
Preparing the patient 
Patient should fast for at least 12 hours before the test. Ask the patient if they have been 
fasting for the past 12 hours. If the patient has not fasted correctly, explain to the patient the 
importance of fasting to the accuracy of the test and if they are willing give them another 
appointment to come back for the test. 
Measuring blood glucose 
Put on gloves  
Remove a test strip 
Rub and kneed a fingertip to help withdraw blood (rub the side of the participant's finger 
closest to the thumb) 
Wipe or swab the fingertip by using a sterile swab 
Lance the massaged place on the fingertip with lancing device.  
Allow a hanging blood drop to form without applying too much pressure 
 Carefully apply the drop of blood to the test field on top of the strip without touching the test 
field directly to the finger.  
Note: The test field must be completely covered with blood. If too little blood is applied, 
do not rub it in or apply a second drop, but repeat the measurement with a fresh test 
strip. 
Give the participant a cotton ball to press on the puncture.  
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Put the test strip into the machine  
Wait for the measurement to be displayed .The blood glucose results is usually displayed in 
mmol/L.  
 Record the results of the fasting blood sugar reading in the participant’s instrument.  
 
IMPORTANT SAFETY INFORMATION: 
Sharps should be handled with care; you should not recap used syringes.  
Dispose any sharps in the disposable container to avoid the risk of injuries. 
Avoid direct contact with body fluids. Gloves must be worn when drawing blood. Does 
not re use gloves between patients 
In case of blood spillage clean the surface immediately with JIK (sodium hypochlorite) 
solution; avoid direct skin contact with the disinfectant 
In case of accidental injury with blood contaminated sharps, wash injured site 
immediately with soap and water, and report to the immediate supervisor 
Report to the officer in charge of  Post Exposure Prophylaxis (PEP) for evaluation and 
reporting 
Label  blood containers before putting in the sample 
For more information on personal protection refer to the National infection prevention 
and control guidelines for health care services in Tanzania 
 
Additional Tests  
The additional tests include; 
Biochemical measurements; Lipid profile, Renal function tests, Urinalysis and HbA1c 
Electrocardiogram (ECG)    
Biochemical measurements 
The blood for biochemical measurements should be taken at the same seating, as soon as one 
obtains the results of the fasting blood glucose so that the patient does not have to fast again 
for the blood lipids measurement. You should clean hands with alcohol gel or clean with 
water before and after the procedure 
Note: Experienced laboratory technician will be sought to do the venepunctures and handle 
the specimens.  
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Blood samples 
Preparing the patient 
The patient should be seated for the procedure and should be informed of the purpose for 
collecting the blood samples 
Equipments needed; 
 Tourniquet 
Cotton balls 
Alcohol swabs, 
Disposable container 
Syringes 
Appropriate blood containers 
Procedure for taking blood samples 
Place a tourniquet around the upper part of the patients arm, and pull fairly tight  
Locate the vein in the anterior cubital fossae  
Wipe the area with an antiseptic wipe and wait for this to dry 
Insert a needle through the skin to the vein  
On successful venous entry release the tourniquet 
Extract blood via either a syringe with a needle, or vacuum tubes 
Collect a total of about 5mls of blood into the different tubes as shown below 
Remove the needle , apply a cotton swab and instruct the patient to apply pressure for one or 
two minutes 
Make sure the blood samples are labelled correctly and placed on the rack at the bleeding 
station 
The blood samples should then be sent to the laboratory. 
Test Amount of blood Collection tube 
Lipid profile and 
Renal Function tests 
3mls Plain  
HbA1c 2mls EDTA 
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IMPORTANT SAFETY INFORMATION: 
Sharps should be handled with care; you should not recap used syringes.  
Dispose any sharps in the disposable container to avoid the risk of injuries. 
Avoid direct contact with body fluids. Gloves must be worn when drawing blood. Does 
not re use gloves between patients 
In case of blood spillage clean the surface immediately with JIK (sodium hypochlorite) 
solution; avoid direct skin contact with the disinfectant 
In case of accidental injury with blood contaminated sharps, wash injured site 
immediately with soap and water, and report to the immediate supervisor 
Report to the officer in charge of  Post Exposure Prophylaxis (PEP) for evaluation and 
reporting 
Label  blood containers before putting in the sample 
For more information on personal protection refer to the National infection prevention 
and control guidelines for health care services in Tanzania 
 
Collection of urine sample 
Participants should also be given a labelled urine collection jar with a paper bag and asked to 
bring a morning sample of urine when they come back for the fasting blood glucose 
measurements. The samples should then be sent to the lab after receipt. 
Participants should be explained the procedure for collecting the urine (mid stream urine 
Sample) 
Assessment of Cardiovascular Complications 
ECG Testing
2,3
 
Equipments needed 
Liquid gel 
Cotton wool 
Examination bed 
Sticker labels 
ECG machine 
                                                 
2
 ECG made easy  
 
3 Model protocol for diabetes and other NCDs by Dowse and Zimmet (1992) 
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Preparing the patient 
The patient should lie relaxed on the examination bed/couch. Ensure adequate privacy. 
Explain the procedure to the patient and explain the reason for test. 
Procedure for ECG testing  
Ask the patient lies flat on a bed or table 
Apply a small amount of gel  to the skin where the electrodes are to be applied 
Attached to each extremity (four total) and to six pre-defined positions on the front of the 
chest (see fig below) Ask the patient to remain still throughout the test 
Take the ECG recording 
Place a sticker label containing patient’s name and study number on the ECG tracing 
Note: Position the chest electrodes as described below; 
Lead V1 - right sternal border, fourth intercostal space 
Lead V2 - left side of the sternum, fourth intercostal space 
Lead V3 - midway between leads V2 and V4 
Lead V4- mid-clavicular line in the fifth intercostal space 
Lead V5 - anterior axillary line in the fifth intercostal space 
Lead V6 is at the mid-axillary line, fifth intercostal space 
 
 
 
Positioning electrodes for the 12 lead ECG (Image adapted from 
davismedicalequipments.com) 
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Appendix 7 Study Questionnaires (English and Swahili versions) 
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Development and Validation of a Risk 
Score Tool for Diabetes in Tanzania 
and other African Populations 
 
Diabetes Survey Questionnaire 
2011 
 
 
 Investigator:  Mary Mayige 
Supervisors: Dr Eugene Sobngwi 
Prof Richard Walker 
Dr Richard Mcnally 
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General Information 
Location and Date Response Code 
1 Centre ID 
 
 
G1 
2 Interviewer ID 
 
└─┴─┴─┘ 
G2 
3 Date of completion of the interview 
 
└─┴─┘ └─┴─┘ └─┴─┴─┴─┘ 
dd             mm             year 
G3 
Participant Id Number     
                                                                                                                                 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘   
Consent and Name Response Code 
4 Consent has been read and obtained 
Yes 1 
G4 
No 2       If NO, END 
5 Time of  starting interview  (24 hour clock) 
  
└─┴─┘: └─┴─┘ 
   hrs                mins 
G5 
 
6 Time of completing interview (24 hour clock) 
  
└─┴─┘: └─┴─┘ 
    hrs                mins 
G6 
7 
Time of interview  
(24 hour clock) 
 
└─┴─┘: └─┴─┘ 
             hrs                mins 
G7 
8 Family Surname 
 
G8 
9 First Name  G9 
Additional Information  
10 Contact phone number where possible  G10 
11 Mention, Whose phone is it (circle the correct 
answer) 
Office phone    1 G11 
Home 2  
Neighbours’ 3  
Other 4  
Other(please specify) 
 
└─┴─┴─┴─┴─┴─┘ 
 
G11 
other 
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Demographic Information 
Question Response Code 
12 Sex (Record Male / Female as observed) 
Male 1 
DE1 
Female 2 
13 
What is your date of birth?     
 
 
 
└─┴─┘ └─┴─┘ └─┴─┴─┴─┘  
     dd              mm                year 
 
Don't Know 
DE2 
14 How old are you?  Years 
 
└─┴─┘ 
DE3 
15 
What is the highest level of education you 
have completed? 
 
 
 
 
No formal schooling 1 
 
DE4 
Less than primary  school 2 
Primary school completed 3 
Secondary school completed 4 
High school completed 5 
College/University completed 6 
Post graduate degree 7 
Refused 88 
16 What is your marital status? 
Never married 1 
DE5 
Currently married 2 
Separated 3 
Divorced 4 
Widowed 5 
Cohabitating 6 
Refused 88 
17 
Which of the following best describes your 
main work status over the past 12 months? 
 
 
 
 
 
 
 
 
 
Government employee 1 
DE6 
Non-government employee 2 
Self-employed 3 
Non-paid 4 
Student 5 
Homemaker 6 
Retired 7 
Unemployed (able to work) 8 
Unemployed (unable to work) 9 
Refused 88 
\ 
 
 
18 
Taking the past year, can you tell me what 
the average earnings of the household have 
been? 
(RECORD ONLY ONE, NOT ALL 3) 
 
Per week 
 
└─┴─┴─┴─┴─┴─┴─┘    Go to T1 
DE7a 
OR per 
month 
 
└─┴─┴─┴─┴─┴─┴─┘    Go to T1 
DE7b 
OR per 
year 
 
└─┴─┴─┴─┴─┴─┴─┘    Go to T1 
DE7c 
Refused 88 
DE7d 
 
 
More than 250,000,  500,000 2 
DE7e 
More than 500,000,  750,000 3 
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More than 750,000,  1,000,000 4 
More than 1,000,000 5 
Don't Know 77 
Behavioral Measurements 
Tobacco Use 
Now I am going to ask you some questions about various health behaviors. This includes things like smoking, drinking 
alcohol, eating fruits and vegetables and physical activity. Let's start with tobacco. 
Question Response Code 
20 
Do you currently smoke any tobacco 
products, such as cigarettes, cigars or pipes?  
(USE SHOWCARD) 
 
Yes 1 
T1 
No 2      If No,  go to T6 
21 
Do you currently smoke tobacco products 
daily?  
Yes 1 
T2 
No 2      If No,  go to T6      
22 
How old were you when you first started 
smoking daily? 
Age (years) 
└─┴─┘ If Known, go to T5a 
T3 
Don’t know  77 
23 
Do you remember how long ago it was? 
 
(RECORD ONLY 1, NOT ALL 3) 
 
Don’t know 77 
In Years 
└─┴─┘ If Known, go to T5a 
T4a 
OR       in 
Months └─┴─┘ If Known, go to T5a 
T4b 
 
OR        in 
Weeks └─┴─┘ 
T4c 
24 
On average, how many of the following do 
you smoke each day? 
 
 
(RECORD FOR EACH TYPE, USE 
SHOWCARD) 
 
Don’t Know  77 
Manufactured 
cigarettes 
└─┴─┘ T5a 
Hand-rolled 
cigarettes 
└─┴─┘ T5b 
Pipes full of 
tobacco 
└─┴─┘ T5c 
Cigars, cheroots, 
cigarillos 
└─┴─┘ T5d 
Other 
                   If Other, go to T5other, 
└─┴─┘  else go to T9 
T5e 
Other (please 
specify): 
└─┴─┴─┴─┴─┴─┘ 
                  Go to T9 
T5other 
25 In the past, did you ever smoke daily? 
Yes 1      
T6 
No 2     If No,  go to T9 
26 
How old were you when you stopped 
smoking daily? 
Age (years) 
└─┴─┘ If Known, go to T9 
T7 
Don’t Know  77 
27 
How long ago did you stop smoking daily? 
 
(RECORD ONLY 1, NOT ALL 3) 
 
Don’t Know  77 
Years ago └─┴─┘ If Known, go to T9 T8a 
OR     Months 
ago 
└─┴─┘ If Known, go to T9 T8b 
OR       Weeks 
ago 
└─┴─┘ 
T8c 
 
 
 
28 
Do you currently use any smokeless 
tobacco such as [snuff, chewing tobacco, 
betel]? (USE SHOWCARD) 
Yes 1 
T9 
 
No 2       If No, go to T12 
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29 
Do you currently use smokeless tobacco 
products daily?  
Yes 1  
T10 
No 2       If No, go to T12 
30 
In the past, did you ever use smokeless 
tobacco such as [snuff, chewing tobacco, or 
betel] daily? 
Yes 1   
T11 
No 2 
31 
During the past 7 days, on how many days 
did someone in your home smoke when you 
were present? 
Number of days 
└─┴─┘ 
T12 
Don't know 77 
32 
During the past 7 days, on how many days 
did someone smoke in closed areas in your 
workplace (in the building, in a work area 
or a specific office) when you were present? 
Number of days 
└─┴─┘ 
T13 
      Don't know 
or don't  
work in a closed 
area 77 
Alcohol Consumption 
The next questions ask about the consumption of alcohol. 
 
33 
Have you ever consumed an alcoholic drink such 
as beer, wine, spirits, fermented cider or local 
brew? 
(USE SHOWCARD OR SHOW EXAMPLES) 
Yes 1 
A1a 
No 2    If No, go to D1 
34 
Have you consumed an alcoholic drink within 
the past 12 months? 
Yes 1 
A1b 
No 2    If No, go to D1 
35 
During the past 12 months, how frequently have 
you had at least one alcoholic drink?   
 
(READ RESPONSES, USE SHOWCARD)  
 
Daily 1 
A2 
5-6 days per week 2 
1-4 days per week 3 
1-3 days per month 4 
Less than once a 
month 
5 
36 
Have you consumed an alcoholic drink within 
the past 30 days? 
Yes 1 
A3 
No 2     If No, go to D1 
37 
During the past 30 days, on how many occasions 
did you have at least one alcoholic drink? 
Number  
Don't know 77 
└─┴─┘ 
A4 
38 
During the past 30 days, when you drank 
alcohol, on average, how many standard 
alcoholic drinks did you have during one 
drinking occasion? 
(USE SHOWCARD) 
Number  
Don't know 77 
└─┴─┘ 
A5 
39 
During the past 30 days, what was the largest 
number of standard alcoholic drinks you had on 
a single occasion, counting all types of alcoholic 
drinks together? 
Largest number 
Don't Know 77 
└─┴─┘ 
A6 
41 
During each of the past 7 days, how many 
standard alcoholic drinks did you have each day?  
 
(USE SHOWCARD) 
 
 
Don't Know 77 
Monday └─┴─┘ A8a 
Tuesday └─┴─┘ A8b 
Wednesday └─┴─┘ A8c 
  Thursday └─┴─┘ A8d 
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Friday └─┴─┘ A8e 
Saturday └─┴─┘ A8f 
Sunday └─┴─┘ A8g 
Diet 
The next questions ask about the fruits and vegetables that you usually eat. I have a nutrition card here that shows you some 
examples of local fruits and vegetables. Each picture represents the size of a serving. As you answer these questions please 
think of a typical week in the last year. 
Question Response Code 
42 
In a typical week, on how many days do you eat 
fruit? 
(USE SHOWCARD) 
Number of days 
Don't Know 77 
└─┴─┘     
If Zero days, 
go to D3 
D1 
43 
How many servings of fruit do you eat on one of 
those days?  (USE SHOWCARD)  
Number of servings 
Don't Know 77 
└─┴─┘ 
D2 
44 
In a typical week, on how many days do you                 
eat vegetables? (USE SHOWCARD) 
Number of days 
Don't Know 77 
└─┴─┘     
If Zero days, 
go to D5 
D3 
45 
How many servings of vegetables do you eat on one 
of those days?  (USE SHOWCARD) 
Number of servings  
Don’t know 77 
└─┴─┘ 
D4 
46 
On average, how many meals per week do you eat 
that were not prepared at a home? By meal, I mean 
breakfast, lunch and dinner. 
Number 
Don’t know 77 
└─┴─┘ 
D5 
 Physical Activity 
 
Next I am going to ask you about the time you spend doing different types of physical activity in a typical week. Please 
answer these questions even if you do not consider yourself to be a physically active person.  
Think first about the time you spend doing work.  Think of work as the things that you have to do such as paid or unpaid 
work, study/training, household chores, harvesting food/crops, fishing or hunting for food, seeking employment.  In 
answering the following questions 'vigorous-intensity activities' are activities that require hard physical effort and cause 
large increases in breathing or heart rate, 'moderate-intensity activities' are activities that require moderate physical effort 
and cause small increases in breathing or heart rate. 
Question Response Code 
Work 
47 
Does your work involve vigorous-intensity activity 
that causes large increases in breathing or heart rate 
like lifting heavy loads, manual construction work, 
digging etc for at least 10 minutes continuously?  
(USE SHOWCARD) 
Yes 1 
P1 
No 2     If No, go to P 4 
48 
In a typical week, on how many days do you do 
vigorous-intensity activities as part of your work? 
Number of 
days 
└─┘ 
P2 
     
49 
How much time do you spend doing vigorous-
intensity activities at work on a typical day? 
Hours : 
minutes └─┴─┘: └─┴─┘ 
    hrs                mins 
P3 
(a-b) 
50 
Does your work involve moderate-intensity activity, 
that causes small increases in breathing or heart rate 
Yes 1 P4 
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such as brisk walking, carrying light loads, doing 
chores like cleaning, washing  or ironing clothes etc 
,for at least 10 minutes continuously?   
 (USE SHOWCARD) 
No 2      If No, go to P 7 
51 
In a typical week, on how many days do you do 
moderate-intensity activities as part of your work?  
Number of 
days 
└─┘ 
P5 
52 
How much time do you spend doing moderate-
intensity activities at work on a typical day? 
Hours : 
minutes └─┴─┘: └─┴─┘ 
    hrs                mins 
P6 
(a-b) 
Travel to and from places 
The next questions exclude the physical activities at work that you have already mentioned. 
Now I would like to ask you about the usual way you travel to and from places.  For example to work, for shopping, to 
market, to place of worship.  
53 
Do you walk or use a bicycle (pedal cycle) for at 
least 10 minutes continuously to get to and from 
places? 
Yes 1 
P7 
No 2      If No, go to P 10 
54 
In a typical week, on how many days do you walk or 
bicycle for at least 10 minutes continuously to get to 
and from places? 
Number of 
days 
└─┘ 
P8 
55 
How much time do you spend walking or bicycling 
for travel on a typical day?  
Hours : 
minutes └─┴─┘: └─┴─┘ 
     hrs               mins 
P9 
(a-b) 
Recreational activities 
 
 The next questions exclude the work and transport activities that you have already mentioned. 
Now I would like to ask you about sports, fitness and recreational activities (leisure) 
56 
Do you do any vigorous-intensity sports, fitness or 
recreational (leisure) activities that cause large 
increases in breathing or heart rate like running, 
playing football  etc, for at least 10 minutes 
continuously?  
(USE SHOWCARD) 
Yes   1 
P10 
No 2      If No, go  to P 13 
57 
In a typical week, on how many days do you do 
vigorous-intensity sports, fitness or recreational 
(leisure) activities? 
Number of 
days 
└─┘ 
P11 
58 
How much time do you spend doing  vigorous-
intensity sports, fitness or recreational activities on a 
typical day? 
Hours : 
minutes └─┴─┘: └─┴─┘ 
    hrs                mins 
P12 
(a-b) 
59 
Do you do any moderate-intensity sports, fitness or 
recreational (leisure) activities that cause a small 
increase in breathing or heart rate such as brisk 
walking, cycling, swimming, dancing etc  for at least 
10 minutes continuously? 
 (USE SHOWCARD) 
Yes   1 
P13 
No 2      If No, go to P16 
60 
In a typical week, on how many days do you do 
moderate-intensity sports, fitness or recreational 
(leisure) activities?  
Number of 
days  
└─┘ 
P14 
61 
How much time do you spend doing moderate-
intensity sports, fitness or recreational (leisure) 
activities on a typical day? 
Hours : 
minutes 
 
└─┴─┘: └─┴─┘ 
 
P15 
(a-b) 
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Sedentary behavior 
 
The following question is about sitting or reclining at work, at home, getting to and from places, or with friends including 
time spent sitting at a desk, sitting with friends, traveling in car, bus, train, reading, playing cards or watching television, but 
do not include time spent sleeping. 
 (USE SHOWCARD) 
62 
How much time do you usually spend sitting or 
reclining on a typical day? 
Hours : 
minutes └─┴─┘: └─┴─┘ 
                 
P16  
(a-b) 
Personal History 
History of  Raised Blood Pressure 
Question Response Code 
63 
Have you ever had your blood pressure measured by a doctor or 
other health worker? 
Yes 1 
H1 
No 2       If No, go to H6 
64 
Have you ever been told by a doctor or other health worker that you 
have raised blood pressure or hypertension? 
Yes 1 
H2a 
No 2       If No, go to H6 
65 Have you been told in the past 12 months? 
Yes 1 
H2b 
No 2  
66 Are you currently receiving any of the following treatments/advice for high blood pressure prescribed by a doctor or 
other health worker? 
 
Drugs (medication) that you have taken in the past two weeks 
Yes 1 
H3a 
No 2 
Advice to reduce salt intake 
Yes 1 
H3b 
No 2 
Advice or treatment to lose weight 
Yes 1 
H3c 
No 2 
Advice or treatment to stop smoking 
Yes 1 
H3d 
No 2 
Advice to start or do more exercise 
Yes 1 
H3e 
No 2 
67 
Have you ever seen a traditional healer for raised blood pressure or 
hypertension? 
Yes 1 
H4 
No 2 
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68 
Are you currently taking any herbal or traditional remedy for your raised blood 
pressure? 
Yes 1 H5 
 
 
 
 
 
No 2 
History of  Raised Blood Sugar 
Question Response Code 
69 
Have you ever had your blood sugar measured by a doctor or other health 
worker? 
Yes 1 
H6 
No 
2       If No, go to 
H8 
70 
Have you ever been told by a doctor or other health worker that you have raised 
blood sugar? 
Yes 1 
H7a 
No 
2       If No, go to 
H8 
71 Have you been told in the past 12 months? 
Yes 1 
H7b 
No 2  
 
 
 
 
Other past Illnesses 
 Previous history of stroke Yes 1  
72  No 2 H8 
  Don’t Know 777  
73 Previous history of heart disease Yes 1 H9 
  No 2  
  Don’t Know 777  
Family History of Cardiovascular Diseases (Do you have any first degree relative mother, father, child, sister or brother 
with any of the following) 
 Hypertension Yes 1  
74  No 2 H10 
  Don’t Know 777  
75 Diabetes Yes 1  
  No 2 H11 
  Don’t Know 777  
76 Stroke Yes 1  
  No 2 H12 
  Don’t Know 777  
77 Heart Disease Yes 1  
  No 2 H13 
  Don’t Know 777  
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Physical Measurements 
Height and Weight 
Question Response Code 
78 
 
Interviewer ID  
└─┴─┴─┘ 
M1 
79 Device IDs for height and weight 
Height └─┴─┘ M2a 
Weight └─┴─┘ M2b 
80 Height cm └─┴─┴─┘. 
└─┘ 
M3 
81 
Weight   
If too large for scale 666.6 
 kg 
└─┴─┴─┘.└─┘ 
M4 
82 For women: Are you pregnant? 
Yes 
1  If Yes, go to M 
8 M5 
No 2   
Waist and Hip 
83 Device ID for waist 
 
└─┴─┘ 
M6 
84 Waist circumference    cm 
└─┴─┴─┘.└─┘ 
M7 
 
85 Hip circumference   cm 
└─┴─┴─┘.└─┘ 
M8 
Blood Pressure 
86 Interviewer ID 
 
└─┴─┴─┘ 
M9 
87 Device ID for blood pressure  └─┴─┘ M10 
88 Cuff size used 
Small 1 
M11 Medium 2 
Large 3 
89 Reading 1 
                   
SBP  mmHg └─┴─┴─┘ 
M12a 
DBP mmHg 
└─┴─┴─┘ 
M12b 
90 Reading 2 
SBP  mmHg 
└─┴─┴─┘  
M13a 
DBP mmHg 
└─┴─┴─┘ 
M13b 
91 Reading 3 
SBP  mmHg 
└─┴─┴─┘ 
M14a 
DBP mmHg 
└─┴─┴─┘ 
M14b 
92 
During the past two weeks, have you been treated for raised blood 
pressure with drugs (medication) prescribed by a doctor or other 
health worker? 
Yes 1 
M15 
No 2 
93 
Heart Rate   
Reading 1 Beats/min └─┴─┴─┘ M16a 
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Reading 2 Beats/min └─┴─┴─┘ M16b 
Reading 3 Beats /min └─┴─┴─┘ M16c 
Biochemical Measurements 
Blood Glucose 
Question Response Code 
94 
During the past 12 hours have you had anything to eat or drink, other than 
water? 
Yes 1 
B1 
No 2 
95 Technician ID  
 
└─┴─┴─┘ 
B2 
96 Device ID  
 
└─┴─┘ 
B3 
97 Fasting blood glucose: mmol/l  
mmol/l └─┴─┘. └─┴─┘ 
B4 
 
 
 
 
 
Additional measurements for Participants  
Blood Lipids  
98 
During the past two weeks, have you been treated 
for raised cholesterol with drugs (medication) 
prescribed by a doctor or other health worker? 
 
Yes 1 
B5 
No 2    
99 HDL Cholesterol mmol/l └─┴─┘. └─┴─┘ B6 
100 LDL Cholesterol mmol/l └─┴─┘. └─┴─┘ B7 
101 Triglycerides mmol/l  mmol/l └─┴─┘. └─┴─┘ B8 
102 Total cholesterol: mmol/l mmol/l └─┴─┘. └─┴─┘ B9 
Renal Function Tests and Urinary Albumin excretion 
103 Serum Creatinine umol/l └─┴─┘. └─┴─┘ B10 
104 Urine Albumin mg/l └─┴─┘. └─┴─┘ B11 
105 Urine Creatinine umol/l └─┴─┘. └─┴─┘ B12 
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Taarifa za awali 
Mahali na Tarehe Jibu Code 
1 Alama ya kituo  
└─┴─┘ 
G1 
2 Utambulisho wa Mhojaji  
└─┴─┴─┘ 
G2 
3 Tarehe ya kukamilisha dodoso   
└─┴─┘ └─┴─┘ └─┴─┴─┴─┘ 
   tarehe      mwezi            mwaka 
 
G3 
                                                                    Namba ya Mhojiwa     
                                                                                                              └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘       
Ridhaa, Lugha ya mahojiano na Jina la Mhojiwa 
Jibu Code 
4 Mhojiwa amesomewa fomu ya Ridhaa na ridhaa 
imepatikana 
Ndio 1  
G4 
Hapana 2   Kama Hapana, 
MWISHO 
Hapana 2       Kama Hapana, 
MWISHO 
5 Muda wa kuanza mahojiano             
└─┴─┘:└─┴─┘ 
                masaa            
dakika 
G5 
6 Muda wa kumaliza mahojiano  └─┴─┘: └─┴─┘ 
 Masaa          dakika    
G6 
7 Muda wa mahojiano 
(masaa 24) 
 
              └─┴─┘: └─┴─┘ 
            masaa               dakika 
G7 
8 Jina la ukoo/ mwisho la mhojiwa  G8 
9 Jina la kwanza la mhojiwa  G9 
Maelezo ya ziada 
10 
Namba ya simu ya mhojiwa 
inapowezekana  
 
G10 
11 
Taja simu ni ya nani 
Kazini 1 
G11 
Nyumbani 2 
Jirani 3 
Nyingine 
(elezea) 
4 
 
Nyingine 
 
└─┴─┴─┴─┴─┴─┴─┘ 
G11 
other 
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Maelezo ya demografia 
Maswali Jibu Code 
12 Jinsi (Andika Mume/Mke kama 
inavyoonekana) 
Mume 1 
DE1 
Mke 2 
13 
Tarehe yako ya kuzaliwa ni ipi?     
    
Sijui 77 777 7777 
 
└─┴─┘ └─┴─┘ └─┴─┴─┴─  Kama inafahamika, nenda 
C4 
    tarehe        mwezi       mwaka 
DE2 
14 Una miaka mingapi? Miaka 
 
└─┴─┘ 
DE3 
15 Ni kiwango gani cha elimu cha juu zaidi 
ulichofikia? 
 
 
 
Sijasoma 1 
DE4 
Sikumaliza elimu ya msingi 2 
Nimemaliza elimu ya msingi 3 
Nimemaliza elimu ya 
sekondari 
4 
Nimemaliza elimu ya juu ya 
sekondari 
5 
Nimemaliza Chuo/Chuo Kikuu 6 
Elimu baada ya shahada ya 
kwanza(uzamili/uzamivu) 
 
 
7 
Amekataa kujibu 88 
16 Hali ya Ndoa Sijawahi kuoa/ kuolewa   1 
 
DE5 
Nimeoa/ nimeolewa 2 
Tumetengana 3 
Mtalaka 4 
  Mjane 5 
  Tunaishi pamoja bila ndoa 6 
  
Amekataa kujibu 88  
17 Ni ipi kati ya haya yafuatayo yanaelezea 
vizuri kazi ambayo umekuwa ukifanya 
katika miezi 12 iliyopita? 
 
 
Mtumishi wa Serikali 1 
DE6 
 
 
 
 
 
 
 
 
 
 
 
 
Mtumishi asiye wa Serikali 2 
Nimejiajiri mwenyewe 3 
Kazi/shughuli bila malipo 4 
Mwanafunzi 5 
Shughuli za nyumbani 6 
Mstaafu 7 
Sina kazi (ana uwezo wa 
kufanya kazi) 
 
8 
Sina kazi (hana uwezo wa 
kufanya kazi) 
9 
Amekataa kujibu 
88 
 
      18 Katika mwaka mmoja uliopita, naomba 
unitajie wastani wa mapato ya kaya yako ni 
kiasi gani? 
 
(JIBU MOJA TU) 
Kwa juma 
└─┴─┴─┴─┴─┴─┴─┘    Nanda 
swali T1 
DE7a 
AU Kwa mwezi 
└─┴─┴─┴─┴─┴─┴─┘    Nenda 
swali T1 
DE7b 
AU Kwa mwaka 
└─┴─┴─┴─┴─┴─┴─┘    Nenda 
swali T1 
DE7c 
Amekataa kujibu 88 
DE7d 
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19 Ikiwa hufahamu ni kiasi gani , unaweza 
kutoa makisio/makadirio ya jumla ya 
mapato ya kaya yako kwa mwaka (kwa 
shilingi za kitanzania) ikiwa nitakusomea 
majibu yafuatayo? Je ni, 
 
  
(MSOMEE MAJIBU YOTE)   
 250,000  1 
DE8 
Zaidi ya 250,000  500,000 2 
Zaidi ya 500,000  750,000 3 
Zaidi ya 750,000  1,000,000 4 
 Zaidi ya 1,000,000 
, 
5 
Sifahamu 7 
Amekataa kujibu 88 
Kipimo cha mwenendo wa tabia 
Utumiaji wa Tumbaku 
Sasa nitakuuliza maswali yanayohusiana na tabia/mazoea mbalimbali yanayohusu afya. Haya yanahusisha masuala ya uvutaji 
sigara/tumbaku, unywaji wa pombe, ulaji wa matunda ma mbogamboga na mazoezi ya mwili. Tuanze na sigara/tumbaku. 
Maswali Jibu Code 
20 Je, kwa sasa unavuta aina yoyote ya tumbaku 
kama vile sigara, kiko, sigara ya kusokota n.k? 
Ndio 1 
T1 
Hapana 
2  Kama Hapana,  nenda 
T6 
21 
Kama Ndio,  
Kwa sasa unavuta sigara au tumbaku kila siku? 
Ndio 1 
T2 
Hapana 
2   Kama Hapana,  nenda 
T6  
22 Ulikuwa na umri gani ulipoanza kuvuta sigara 
kila siku kwa mara ya kwanza? 
Umri (miaka) └─┴─┴─┘Kama 
inafahamika, nenda T5a 
T3 
Sikumbuki  777 
23 
Unakumbuka ni muda gani uliopita? 
 
 
(JIBU MOJA TU) 
 
Sikumbuki  77 
Kwa miaka 
└─┴─┴─┘ Kama 
inafahamika, nenda T5a 
T4a 
 
 
 
 
AU       kwa miezi  └─┴─┴─┘ Kama 
inafahamika, nenda T5a 
T4b 
 
AU    kwa majuma 
└─┴─┴─┘ T4c 
 
24 Kwa wastani, unavuta kiasi gani kwa siku cha 
kila moja ya aina zifuatazo za tumbaku? 
Sigara zinazotengenezwa 
viwandani 
└─┴─┴─┘ T5a 
  
 
Sigara /tumbaku za kusokota 
kwa mikono 
└─┴─┴─┘ T5b 
  
(JAZA KWA KILA MOJA) 
Kiko kilichojazwa 
tumbaku/sigara 
└─┴─┴─┘ T5c 
  
Sikumbuki  77 
Biri(Cigars) └─┴─┴─┘ T5d 
  
Aina nyingine  
└─┴─┴─┘Kama aina 
nyingine, nenda T5 other 
T5e 
  Aina nyingine (zitaje 
tafadhali): 
└─┴─┴─┴─┴─┴─┴─┘ T5 other 
25 
Hapo zamani, ulishawahi kuvuta 
sigara/tumbaku kila siku? 
Ndio 1 
T6 Hapana 2      Kama Hapana, nenda 
T9 
26 Kama Ndio, ulikuwa na miaka mingapi 
ulipoacha kuvuta sigara/tumbaku kila siku? 
 
 
Umri (miaka)  
└─┴─┴─┘    Kama 
inafahamika, nenda T9 
T7 
Sikumbuki  77 
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27 Ni muda gani umepita tangu ulipoacha kuvuta 
sigara/tumbaku kila siku? 
 
 
(JIBU MOJA TU) 
 
Sikumbuki  77 
Miaka 
└─┴─┴─┘   Kama 
inafahamika, nenda T9 
T8a 
AU         Miezi 
└─┴─┘         Kama 
inafahamika, nenda T9 
T8b 
AU    Majuma └─┴─┘ T8c 
28 Kwa sasa unatumia aina yoyote ya tumbaku 
isiyo ya kuvuta kama vile ugoro, ‘kuber’ n.k.? 
Ndio 1 
T9 Hapana 2      Kama Hapana, nenda 
T12 
29 
Kwa sasa, unatumia tumbaku isiyo ya 
kuvuta kila siku? 
Ndio 1 
T10 Hapana 2      Kama Hapana, nenda 
T12 
30 Hapo zamani, ulishawahi kutumia aina yoyote 
ya tumbaku isiyo ya kuvuta kama vile ugoro, 
‘kuber’ n.k. kila siku? 
Ndio 1 T11 
Hapana 2  
31 Ndani ya siku saba zilizopita, ni siku ngapi mtu 
mnayeishi naye ndani ya nyumba amevuta 
sigara ukiwepo? 
Siku 
 
 
└─┴─┘ 
 
Sijui 77 
T12 
32 Ndani ya siku saba zilizopita, ni siku ngapi mtu 
amevuta sigara kwenye eneo lisilo la wazi 
kazini ukiwepo? 
Siku 
 
 
└─┴─┘Sijui au nafanya kazi 
kwenye eneo la wazi 77 
T13 
Utumiaji wa Pombe/Vileo 
Maswali yafuatayo yanauliza kuhusu utumiaji wa pombe/Vileo 
Maswali Jibu Code 
33 Je, umewahi kutumia kinywaji chenye kilevi (kama 
vile bia, mvinyo, pombe kali au pombe ya kienyeji) 
katika miezi 12 iliyopita? 
(TUMIA kadi ya kielelezo AU TOA MIFANO) 
Ndio 
 
1 
A1a 
Hapana 
2    Kama 
Hapana, nenda 
D1 
34 Je umekunywa kinywaji chenye kilevi ndani ya miezi 
12 iliyopita? 
Ndio 
 
1 
A1b 
Hapana 
2    Kama 
Hapana, nenda 
D1 
35 Katika miezi 12 iliyopita, ni mara ngapi umekunywa 
angalau kinywaji kimoja chenye kilevi? 
( MSOMEE MAJIBU, TUMIA kadi ya kielelezo) 
Kila siku 1 
A2 
Siku 5-6 kwa juma 2 
Siku 1-4 kwa juma 3 
Siku 1-3 kwa mwezi 4 
Chini ya mara 1 kwa 
mwezi 
5 
36 Umetumia kinywaji chenye kilevi (kama vile bia, 
mvinyo, pombe kali au pombe ya kienyeji) katika siku 
30 zilizopita? 
 
 (TUMIA kadi ya kielelezo AU TOA MIFANO) 
Ndio 1 
A3 
Hapana 
2      Kama 
Hapana, nenda  
D1 
37 Katika siku 30 zilizopita, ni mara ngapi umekunywa 
angalau kinywaji kimoja chenye kilevi? 
 
Mara 
 
└─┴─┘ 
Sijui 77 
A4 
38 Katika siku 30 zilizopita, ulipokunywa kinywaji chenye 
kilevi, kwa makisio ulikunywa vinywaji vingapi 
(standard drinks) kwa mkupuo 
(TUMIA KADI YA KIELELEZO) 
Mara 
 
└─┴─┘ 
Sijui 77 
A5 
39 Katika siku 30 zilizopita , ulipokunywa kinywaji Idadi kubwa zaidi ya └─┴─┘ A6 
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chenye kilevi , ni kiasi gani kikubwa ulichokunywa 
(standard drink) siku uliyokunywa zaidi kwenye 
mkupuo mmoja ukijumlisha vinywaji vyote?  
vinywaji                                Sijui 77 
40 Katika siku 30 zilizopita, ni mara ngapi umekunywa 
Kinywaji chenye kilevi (standard drink); 
Kwa wanaume: 5 au zaidi  
Kwa wanawake: 4 au zaidi ; kwenye mkupuo mmoja? 
 
Mara 
 
└─┴─┘ 
Sijui 77 
A7 
41 
 
 
 
Katika siku 7 zilizopita, umekunywa vinywaji vingapi 
(standard drinks) vyenye kilevi katika kila siku ya 
wiki? 
 
(JAZA KWA KILA SIKU, TUMIA kadi ya kielelezo) 
 
 
Sifahamu 77 
Jumatatu └─┴─┘ A8a 
Jumanne └─┴─┘ A8b 
Jumatano └─┴─┘ A8c 
Alhamisi └─┴─┘ A8d 
Ijumaa └─┴─┘ A8e 
Jumamosi └─┴─┘ A8f 
Jumapili └─┴─┘ 
A8g 
  Lishe 
Maswali yafuatayo yanauliza kuhusu matunda na mbogamboga ambazo unakula mara kwa mara. Hapa nina kadi ya maelezo ya 
lishe yenye mifano ya matunda na mbogamboga zinazopatikana katika maeneo yako. Kila picha inawakilisha kipimo kimoja. 
Unapojibu maswali haya tafadhali fikiria wiki moja ya kawaida katika mwaka uliopita. 
Maswali Jibu Code 
42 Kwa kawaida ni siku ngapi ndani ya wiki moja 
unakula matunda? (TUMIA SHOWCARD) 
Idadi ya siku └─┴─┘     
Kama siku 
0, nenda  
D3 
D1 
Sifahamu 77 
43 Unakula matunda kipimo gani katika moja ya siku 
hizo? (TUMIA SHOWCARD) 
Idadi ya vipimo 
Sifahamu 77 
└─┴─┘ D2 
44 Kwa kawaida ni siku ngapi ndani ya wiki moja 
unakula mbogamboga? (TUMIA SHOWCARD) 
Idadi ya siku 
Sifahamu 77 
 
└─┴─┘     
Kama siku 
0, nenda  
D5 
D3 
45 Unakula mbogamboga kipimo gani katika moja ya 
siku hizo? (TUMIA SHOWCARD) 
Idadi ya Vipimo 
└─┴─┘ D4 
Sifahamu 77 
46 Kwa wastani huwa unakula milo mingapi kwa wiki 
ambayo haijaandaliwa nyumbani? Mlo hapa ni 
kifungua kinywa, mlo wa mchana na ule wa jioni 
Idadi ya milo 
 
Sifahamu 77 
└─┴─┘ D5 
Mazoezi ya viungo  
Sasa nitaendelea kukuuliza kuhusu muda unaotumia kufanya shughuli mbalimbali zinazohusu mazoezi ya viungo katika wiki moja 
ya kawaida. Tafadhali ujibu maswali haya hata kama unadhani wewe si mtu wa kufanya mazoezi mara kwa mara. 
Kwanza tafakari kuhusu muda unaotumia kufanya kazi. Tunaposema kazi tunamaanisha shughuli zozote unazofanya zikiwemo 
zinazokuingizia kipato na zisizokuingizia kipato, mfano kuvua samaki, masomo, shughuli za nyumbani, kilimo,  kuvuna mazao, 
kutafuta kazi n.k. Katika kujibu maswali haya 'shughuli za kutumia nguvu – kasi sana ni shughuli ambazo zinahitaji nguvu nyingi 
na husababisha ongezeko kubwa katika kupumua au mapigo ya moyo, shughuli za kutumia nguvu-kasi kiasi ‘ ni shughuli 
zinazohitaji nguvu ya kiasi na husababisha ongezeko dogo katika kupumua na mapigo ya moyo  
Maswali Jibu Code 
Mazoezi wakati wa kazi  
47 Je, kazi yako inahusisha shughuli za kutumia nguvu 
ambazo zinaongeza kasi ya kupumua na mapigo ya 
moyo kama vile kubeba mizigo mizito, kumwaga 
zege, kupiga kokoto, kuchota maji, kusomba 
mazao, kilimo au kazi za ujenzi kwa angalau 
dakika 10 mfululizo? 
(TUMIA  SHOWCARD) 
Ndio 1 P1 
Hapana 
2     Kama 
Hapana, 
nenda  P 4 
 
48 Katika wiki ya kawaida, ni kwa siku ngapi 
unafanya shughuli hizo za kutumia nguvu nyingi 
Idadi ya siku 
 
└─┘ P2 
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katika kazi yako? 
49 Unatumia muda gani kufanya shughuli za nguvu 
katika siku moja ya kazi? 
 
 └─┴─┘: └─┴─┘ 
Masaa        Dakika 
  P3 
50 Kazi yako inahusisha shughuli za kutumia nguvu 
kiasi ambazo zinaongeza kidogo kasi ya kupumua 
na mapigo ya moyo kama vile kutembea kwa 
haraka, kubeba mizigo isiyo mizito, kudeki, 
kufagia, kuosha vyombo, kufua, kupika, kupiga 
pasi, kuvuna mazao kwa angalau dakika 10 
mfululizo? 
 (TUMIA SHOWCARD) 
Ndio 1  
Hapana 
2      Kama 
Hapana, 
nenda  P 7 
P4 
51 Katika wiki ya kawaida, ni kwa siku ngapi 
unafanya shughuli hizo za kutumia nguvu kiasi 
katika kazi yako? 
Idadi ya siku └─┘ P5 
52 Unatumia muda gani kufanya shughuli za nguvu 
kiasi katika siku moja ya kazi? 
    
└─┴─┘└─┴─┘ 
    Masaa : dakika 
 P6  
(a-b   
Safari ya kwenda na kurudi toke sehemu moja hadi nyingine 
Maswali yafuatayo hayahusishi shughuli unazofanya wakati wa kazi ambazo umeshazitaja.  
Sasa ningependa kukuuliza kuhusu aina ya usafiri unaotumia kwenda sehemu mbalimbali kama vile sokoni, shambani, kanisani, 
msikitini n.k. 
53 Una kawaida ya kutembea kwa miguu au kwa 
kutumia baiskeli kwa angalau dakika 10 mfululizo 
wakati unapokwenda mahali fulani? 
Ndio 1 
P7 
 
Hapana 
2      Kama 
Hapana, 
nenda P 10 
54 Katika wiki ya kawaida, unatumia siku ngapi 
kutembea kwa miguu au kwa kutumia baiskeli kwa 
angalau dakika 10 mfululizo wakati unapokwenda 
mahali fulani? 
Idadi ya siku 
└─┘ 
P8 
55 Unatumia muda gani kutembea kwa miguu au kwa 
kutumia baiskeli katika siku moja ya kawaida? 
 
└─┴─┘:└─┴─┘ 
Masaa : dakika 
P9 
Mazoezi wakati wa mapumziko 
Sasa nitakuuliza maswali yahusuyo shughuli mbalimbali unazofanya wakati wako wa mapumziko, kwa mfano mazoezi ya viungo, 
michezo mbalimbali n.k. Usijumuishe shughuli unazofanya wakati wa kazi au kusafiri ambazo umeshajitaja hapo awali. 
56 Una kawaida ya kushiriki katika shughuli za 
michezo au mazoezi ambazo zinaongeza kwa kiasi 
kikubwa kasi ya kupumua au mapigo ya moyo 
kama vile kukimbia, kuruka kichura, kuinama na 
kuinuka, kuruka viunzi, kucheza nmpira kwa 
angalau dakika 10 mfululizo?  
 (TUMIA SHOWCARD) 
Ndio   1 P 10 
Hapana 
2      Kama 
Hapana, 
nenda  P13 
 
57 Katika wiki ya kawaida, unatumia siku ngapi 
kufanya shughuli hizo za michezo au mazoezi? 
Idadi ya siku             └─┘ P 11 
58 Katika siku ya kawaida, unatumia muda gani 
kufanya shughuli hizo za michezo au mazoezi? 
 
└─┴─┘: └─┴─┘ 
Masaa : dakika 
P 12 
59 Una kawaida ya kushiriki katika shughuli za 
michezo au mazoezi ambazo zinaongeza kwa kiasi 
kidogo kasi ya kupumua au mapigo ya moyo kama 
vile kuendesha, baiskeli, kutembea, kuogelea, 
kuimba kwa vitendo kwa angalau dakika 10 
mfululizo?  
 (TUMIA SHOWCARD) 
  
1 Ndiyo   
2 Hapana 
P13 
Kama Hapana, nenda P16 
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60 Katika wiki ya kawaida, unatumia siku ngapi 
kufanya shughuli hizo za michezo au mazoezi?     Idadi ya siku        
  └─┘ 
P 14 
61 Katika siku ya kawaida, unatumia muda gani 
kufanya shughuli hizo za michezo au mazoezi? └─┴─┘: └─┴─┘ 
Masaa     : dakika 
 
    
P15 
Tabia ya kukaa pasipo kujishughulisha 
Swali lifuatalo linahusu muda uliotumia kukaa au kujinyoosha/kujiegemeza kujilaza wakati wa kazi, katika usafiri, kukaa na 
marafiki, kuangalia televisheni n.k. lakini bila kujumuisha muda uliotumia kulala. (TUMIA SHOWCARD) 
  
62 Kwa kawaida unatumia muda gani kukaa au kujinyoosha 
kujilaza katika siku moja mfano ukiwa unaangalia TV, 
unasikiliza redio, unasoma gazeti au vitabu nk 
? 
└─┴─┘: └─┴─┘ 
Masaa : dakika 
P16  
(a-b) 
Historia ya Mhojiwa 
Historia ya Ongezeko la Shinikizo la Damu 
Maswali Jibu Code 
63 
Je umeshawahi kupimwa na daktari au mtaalam wa afya?  
Ndiyo 1 
H1 
 Hapana 
2       kama 
hapana, nenda 
H6 
64 
Je umeshawahi kuambiwa na daktari au mtaalam wa afya kuwa una 
shinikizo la damu, au presha yako iko juu kuliko kawaida? 
Ndiyo 1 
H2a 
 Hapana 
2       kama 
hapana, nenda 
H6 
65 Je umeambiwa hivyo ndani ya miezi 12 iliyopita? 
Ndiyo 1 
H2b 
Hapana 2  
66 
Kwa sasa unapata matibabu au ushauri kwa ajili ya ongezeko la shinikizo la damu kutoka kwa daktari au mtaalamu 
mwingine wa afya? 
 Dawa au matibabu ambayo umetumia katika wiki 2 zilizopita Ndio 1 H3a 
  Hapana 2  
 Masharti maalum ya chakula Ndio 1 H3b 
  Hapana 2  
 Ushauri au matibabu ya kupunguza uzito Ndio 1 H3c 
  Hapana 2  
 Ushauri au matibabu ya kuacha kuvuta sigara Ndio 1 H3d 
  Hapana 2  
 Ushauri wa kuanza mazoezi au kufanya mazoezi zaidi Ndio 1 H3e 
  Hapana 2  
67 Je umeshawahi kupata ushauri au kutibiwa na mganga Ndio 1 H4 
  Hapana 2  
68 
Kwa sasa unatumia aina yoyote ya mitishamba kwa ajili ya shinikizo 
la damu Ndio 1 H5 
  Hapana 2  
Historia ya Kisukari 
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Maswali Jibu Code 
69 Umewahi kupimwa kiwango cha sukari katika damu? Ndio 1  
Hapana 2 H6 
70 Katika miezi 12 iliyopita, umewahi kuambiwa na daktari au 
mtaalamu mwingine wa afya kuwa una ugonjwa wa kisukari? 
Ndio 1  
Hapana 2 H7a 
71 Je umeambiwa hivyo ndani ya miezi 12? Ndio 1  
Hapana 2 H7b 
Magonjwa mengine 
 Historia ya Ugonjwa wa kiharusi Ndio 1  
72  
Hapa
na 
2 H8 
  Sijui 777  
73 Previous history of heart disease 
Ndio 1 
H9 
Hapa
na 
2 
Sijui 777 
Historia ya magonjwa sugu kwenye familia (Je kuna ndugu yeyote wa karibu; baba, mama, dada, kaka, au mtoto wako 
anayeugua au aliyewahi kuugua magonjwa yafuatayo?) 
74 
Shinikizo la damu Ndio 1 
H10  
Hapa
na 
2 
 Sijui 777 
75 
Kisukari Ndio 1 
H11  
Hapa
na 
2 
 Sijui 777 
76 Kiharusi 
Ndio 1 
H12 
Hapa
na 
2 
Sijui 777 
77 
Ugonjwa wa moyo Ndio 1 
H13  
Hapa
na 
2 
 Sijui 777 
Vipimo vya mwili visivyohusisha kutoa damu 
Urefu na Uzito Jibu Code 
78 Utambulisho wa Mhojaji  
└─┴─┴─┘ 
      
M1 
79 Utambulisho wa vifaa vya kupimia Urefu na Uzito 
Urefu └─┴─┘ M2a 
  Uzito └─┴─┘ M2b 
80 Urefu 
 
kwa Sentimeta(sm) └─┴─┴─┘. └─┘ 
M3 
81 Uzito   
Ikiwa uzito umezidi  uwezo wa mizani andika 666.6 
kwa Kilogramu (kg) └─┴─┴─┘.└─┘ 
 
 
M4 
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82 (Kwa Wanawake) Wewe ni mjamzito? 
 Ndio 
1   Kama Ndio, nenda M 8 
M5 
Hapana 
2    
Kiuno na mzunguko wa nyonga 
83 Utambulisho wa kifaa cha kupimia kiuno  └─┴─┘ M6 
84 Mzunguko wa Kiuno 
 
cm 
└─┴─┴─┘.└─┘ 
M7 
85 
Mzunguko wa Nyonga  cm └─┴─┴─┘.└─┘ 
M8 
 
Shinikizo la Damu 
86 
Utambulisho wa Mhojaji  
└─┴─┴─┘ M9 
87 Utambulisho wa kifaa cha kupimia BP  └─┴─┘ M10 
88 
Ukubwa wa cuff itakayotumika Ndogo 
1 
M11 Ya kati 2 
Kubwa 3 
89 Kipimo cha 1 SBP  mmHg └─┴─┴─┘ M12a 
  DBP mmHg └─┴─┴─┘ M12b 
90 Kipimo cha 2 SBP mmHg  └─┴─┴─┘  M13a 
 
 
 
DBP mmHg └─┴─┴─┘ M13b 
91 Kipimo cha 3 SBP  mmHg └─┴─┴─┘ M14a 
  DBP mmHg └─┴─┴─┘ M14b 
92 
Katika wiki 2 zilizopita, umetumia dawa yoyote ya 
ongezeko la shinikizo la damu kama ulivyoandikiwa na 
daktari au mtaalamu mwingine wa afya? 
Ndio 1 
M14 
Hapana 2 
93 
Mapigo ya moyo 
Kipimo cha 1 └─┴─┴─┘ M16b 
Kipimo cha 2 └─┴─┴─┘ M16b 
Kipimo cha 3 └─┴─┴─┘ M16c 
Vipimo vya mwili vinavyohusisha kutoa damu 
Sukari katika Damu Jibu Code 
94 
Ndani ya masaa 12 yaliyopita, umekula au kunywa kitu 
chochote zaidi ya maji? 
Ndio 1 
B1 
Hapana 2 
95 
Utambulisho wa Mpimaji  
└─┴─┴─┘ B2 
96 
Utambulisho wa kifaa cha kupimia  
└─┴─┘ B3 
97 Kiwango cha sukari katika damu kabla ya kula 
mmol/l 
└─┴─┘. └─┴─┘ B4 
 
 221 
 
 
 
 
 
 
 
 
Vipimo vya Ziada  
Lehemu (Blood Lipids) 
98 
Ndani ya wiki mbili je umekunywa dawa yeyote ya kupewa na daktari kwa 
ajili ya kushusha kiwango cha lehemu (cholesterol)  
Ndiyo 1 
B5 
Hapana 2    
99 HDL Cholesterol mmol/l └─┴─┘. └─┴─┘ B6 
100 LDL Cholesterol mmol/l └─┴─┘. └─┴─┘ B7 
101 Triglycerides mmol/l  mmol/l └─┴─┘. └─┴─┘ B8 
102 Total cholesterol: mmol/l mmol/l └─┴─┘. └─┴─┘ B9 
(Vipimo vya Figo) Renal Function Tests and Urinary Albumin excretion 
103 Serum Creatinine umol/l └─┴─┘. └─┴─┘ B10 
104 Urine Albumin mg/l └─┴─┘. └─┴─┘ B11 
105 Urine Creatinine umol/l └─┴─┘. └─┴─┘ B12 
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